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Summary
Summary
In comparison to other cancers, advanced prostate cancer is resistant to chemotherapy. 
There is a need to understand the mechanisms which are responsible for this 
resistance and find better treatments for this disease or methods to increase the 
efficacy of cuixent treatments.
Cancer cells often evade apoptosis. Cyclooxygenase-2 (COX-2) is an enzyme 
reported to be elevated in prostate cancer, and has oncogenic properties, including 
apoptosis attenuation. Because of this, COX-2 inhibition could be beneficial for both 
prevention and treatment of cancer.
This study showed that COX-2 protein was not detected in LNCaP, PC-3 or DU145 
cells. To assess the effect COX-2 has on the apoptotic sensitivity of prostate cancer 
cells, we transfected two cell lines (stable transfection in LNCaP, transient in PC-3) 
with the human COX-2 gene or empty control vector. We measured the effect on cell 
viability of COX-2 after treatment with a diverse set of agents e.g. etoposide, 
carboplatin, Fas, TRAIL, celecoxib and sulindac, using the MTT assay. We observed 
COX-2 dependent resistance to cai'boplatin, etoposide and celecoxib in LNCaP but 
not PC-3.
Carboplatin mediated reduction in cell viability was due to an S phase block and 
induction of apoptosis. COX-2 transfection in LNCaP cells attenuated both the cell 
cycle block and apoptosis. There was reduced p53 and p27^ ^^  ^ induction following 
carboplatin treatment in LNCaP-COX-2, compared to LNCaP-Neo. COX-2 
transfection caused elevated cellular levels of anti-apoptotic proteins Bcl-2, B c1-xl  
and survivin.
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Celecoxib could not reverse the resistance seen in LNCaP-COX-2 to carboplatin, and 
PGE2 could not increase the resistance in LNCaP-Neo cells, suggesting that COX-2 
mediates an apoptotic resistance which is COX-2 enzymatic activity independent. 
Other mechanisms were sought to reverse the carboplatin resistance. PI3K inhibitors 
wortmannin and LY294002 partially reversed the LNCaP-COX-2 resistance. These 
data suggests that COX-2 acts on the PI3K signalling pathway to mediate resistance in 
LNCaP. This was confirmed by Western blot findings of elevated levels of P-Akt^ '^^ ^^  ^
in LNCaP-COX-2 compaied with LNCaP-Neo. Celecoxib decreased levels of P- 
Aktser473 ^ niaiiner similai* to PI3K inhibitors, indicating that the PI3K inhibitors and 
celecoxib act in different ways on PI3K signalling. Because complete reversal of 
resistance does not occur with PI3K inhibition, COX-2 must be acting on other 
pathways also. However, unlike the PI3K inhibitors, celecoxib could not reverse 
resistance to carboplatin.
Wortmannin and LY294002 decreased levels of Bcl-2, B c1-x l , survivin and, 
suiprisingly, COX-2 protein. In contrast, celecoxib had little effect on Bcl-2 and 
increased COX-2 levels. Cyclin B1 levels were higher in LNCaP-COX-2 than 
LNCaP-Neo.
Gene microaixay analysis confiimed the up-regulation of survivin in LNCaP-COX-2 
and also showed elevation of cyclin I and fatty acid synthase and down-regulation of 
glutathione-S-transferase in LNCaP-COX-2.
In conclusion, stable COX-2 transfection causes a selective resistance to cytotoxic 
agents which is mediated via activation of the PI3K pathway and attenuation of p53 
induction in LNCaP. COX-2 also causes the up-regulation of a number of anti- 
apoptotic factors and PI3K inhibition results in down-regulation of these proteins.
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CHAPTER 1
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Chapter 1 Introduction
Chapter 1 Introduction
1.1 Prostate Cancer
1.1.1 Incidence and Mortality
Prostate cancer is the sixth most common cancer in the world and the third most 
common in men. However, it is the most common non-dermatological cancer in men 
in Europe and North America (reviewed by Gronberg 2003), suipassing lung and 
colon carcinomas, comprising 32% of all cancers (Yoshimura et al. 2000). In the UK 
there are 30000 new cases annually, which constitutes 20% of all male cancers. 10000 
men die from the disease annually in the UK, a figure which represents 12% of cancer 
related deaths in males (figures taken from Cancer Research UK website, April 2005). 
40000 Americans die annually from prostate cancer, a figure which represents 15% of 
all cancer related deaths, making it the second leading cause of cancer deaths in males 
(reviewed by Denmeade et al. 1996). Annual mortality is declining however, and this 
could be due to better detection, more effective treatment and increased public 
awareness.
Prostate cancer poses one of the greatest health risks to men over 50, and in the US 
approximately 230,000 men will be diagnosed with the disease, a number which is 
growing annually. 60% of these diagnoses will be pathologically advanced, with no 
hope of cure (Steiner et al 2001). Only palliative care can be given for advanced 
disease. Once a prostate cancer patient progresses to an androgen independent state 
(Chapter 1.1.4), the disease is usually fatal. Men diagnosed with cancer confined to 
the prostate can benefit from surgery or radiation therapy, but there is no curative 
treatment for metastatic prostate cancer (reviewed by Nelson et al 2001).
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Three quarters of diagnosed prostate cancers may not result in fatality, largely due to 
old age and the indolent nature of the cancer (reviewed by Horwich et al. 2002). Less 
than 0.1% of all diagnosed patients are less than 50 years of age, whereas 85% are 
diagnosed after the age of 65. Worldwide, the mean age of diagnosis is 72-74. Most 
men older than 85 have histological prostate cancer at autopsy. As the population 
ages, the impact of prostate cancer will increase, especially as the incidence of people 
dying from illnesses such as cardiovascular disease has decreased (reviewed by 
Tindall & Scardino 2001).
1.1.2 Prostate Physiology
The function of the prostate gland is to produce seminal fluid. The gland is made up 
of epithelial glands in a fibromuscular stroma. The epithelia has three cell types: 
basal, luminal secretory and neuroendocrine cells. A subset of basal cells may be stem 
cells for luminal cells. It is the epithelial cells which eventually give rise to cancer. 
Luminal cells secrete components of prostatic fluid, prostate specific antigen (PSA) 
and prostatic acid phosphatase (PAP), in an androgen dependent manner and express 
the androgen receptor. The fibromusculai’ stroma contains fibroblasts, smooth muscle 
cells, endothelial cells, dendritic cells, nerves and infiltrating cells such as masts and 
lymphocytes (reviewed by Feldman & Feldman 2001).
All cells are thought to originate from a putative stem cell population in the basal 
layer (reviewed by De Mulder et al. 2002). Tissue stem cells are thought to reside in 
the basal layer, where most cell division (renewal) occurs. Luminal secretory cells 
derive from these basal cells and perform androgen regulated differentiated functions 
such as PSA production and secretion (reviewed by De Marzo et al. 2001). 
Neuroendocrine cells and chromogrannin A are often found in prostatic
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adenocarcinoma and are implicated in tumour growth and invasiveness (reviewed by 
Hoosein 1998).
Growth and development of the prostate gland requires presence of sex hormones and 
it is the androgens which are the most important in this regard. Androgens stimulate 
proliferation and inhibit apoptosis (reviewed by Denmeade et al. 1996), The 
androgens are synthesised primarily in the Leydig cells of the testes under control of 
the hypothalamus-pituitary axis but also by conversion of adrenal steroids. An 
important step in androgen mediated action is testosterone conversion to 
dihydrotesterone (DHT) by 5a-reductase within target cells (Castagnetta et al. 1994). 
90% of testosterone is converted to DHT by 5a-reductase.
The action of androgens is effected by binding to its receptor, the androgen receptor, 
which has DNA binding and transcriptional activity upon ligand binding. The 
androgen receptor gene is located on the X chromosome. DHT has higher affinity for 
the androgen receptor than testosterone, it is a 100-fold more potent androgen. The 
androgen receptor in the basal state is bound to heat shock protein which prevents 
DNA binding. Testosterone is bound to sex hoimone binding globulin (SHBG) in 
blood with only a small fraction free in blood (reviewed by Feldman & Feldman 
2001). Upon ligand binding the receptor dimerises and binds to androgen response 
elements (ARE) in promoter regions of target genes. Testosterone stimulates growth 
of prostate cancer, partly by modulating activity of local growth factors. Cancer cells 
are known to produce epidennal growth factor (EGF), transfoiming growth factor 
(TGF-a, cachetin), basic fibroblast growth factor (bFGF) and nerve growth factor 
(NGF) (reviewed by Limonta et a l 1994).
As well as controlling growth rate, androgens induce enzymes involved in lipogenesis 
such as fatty acid synthase and cholesterol synthesising enzymes. Fatty acid synthase
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is over-expressed in a number of cancers including prostate cancer and is associated 
with a poor prognosis (Swinnen & Verhoeven 1998).
There is continuous epithelial prostate cell turnover in the normal adult prostate. In 
androgen maintained rat prostate, a low cell proliferation rate of approximately 1-2% 
per day is balanced by an equally low apoptotic rate. In the normal prostate 
epithelium, cell proliferation balances with cell death, hence neither involution nor 
overgi'owth occur (reviewed by Denmeade et al. 1996). Cancer growth is detennined 
by the balance of this cell proliferation and cell death relationship. Tumour regression 
will only occur if the proliferation rate is less than the cell death rate. Any cancer can 
be seen as a disruption in homeostasis such that there is a net accumulation of atypical 
cells. Prostate cancer can be caused by uncontrolled cell proliferation, defective cell 
death (apoptosis), or a combination of both. Historically, cancer research has focused 
on cell proliferation, but recently much attention has been directed towards the role of 
apoptosis in cancer (reviewed by Riss 2001).
Upon castration or other androgen withdrawal methods e.g. anti-androgen treatment 
or luteinizing hormone release hormone (LHRH) analogues, serum testosterone levels 
drop and the prostate involutes due to a loss of prostate epithelial cells but not basal or 
stromal cells, as only the epithelial cells are androgen dependent and undergo 
apoptosis. Androgen withdrawal triggers apoptosis in normal prostate glandular 
epithelia and androgen dependent prostate cancer cells. However, androgen 
independent cells do not apoptose with androgen ablation, but the death cascade can 
be activated if sufficient cellular damage accrues (reviewed by Denmeade et al. 
1996).
Following castration, within 24 hours there is a rapid drop in serum testosterone, 
cellular DHT, and changes in the androgen receptor, but apoptosis continues
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approximately 2 weeks post castration, implying that reduction in androgen receptor 
occupancy by DHT is not sufficient alone to activate apoptosis. Thus, some other 
survival factors whose levels drop to a critical level, and are DHT-regulated, initiate 
apoptosis. Early events in androgen withdrawal are decreased glandulai* cell 
proliferation and cell atrophy. At this stage, events are reversible with exogenous 
androgen administration. Next there is change in nuclear chromatin structure after 
continued androgen withdrawal. There is an increase in intracellulai' calcium and it is 
thought that up-regulation of TGF-pl mRNA may play a role in this. Endonucleases 
are enzymatically activated. Proteases degrade nuclear laminins after nuclear 
fragmentation, membrane blebbing and cellular fragmentation into apoptotic bodies 
occur. Apoptotic bodies aie then phagocytosed by macrophages or neighbouring 
epithelial cells (reviewed by Denmeade et al. 1996).
Castration of rats and measurement on apoptotic rate show 1.2% glandular cells die 
pre-castration. 2-5 days after castration 17-21% die by apoptosis. These results show 
that glandular cell death is due to apoptosis and not necrosis. There is also a 
significant decrease in the percentage of cells entering cell cycle S phase following 
castration. There is thought to be no involvement of p53 in androgen ablation induced 
apoptosis (reviewed by Denmeade et al 1996).
If androgen dependent prostate cancer cells are present in métastasés, then the 
métastasés will also be sensitive to androgenic stimulation. Most men with metastatic 
prostate cancer initially respond well with androgen ablation therapy. However due to 
the presence of androgen independent cells, which are unaffected by androgen 
ablation, prostate cancer cells will continue to proliferate (see Chapter 1.1.5). Daily 
rates of cell proliferation and cell death have been determined for normal, pre­
malign ant and cancerous prostate cells, and métastasés in lymph node, soft tissue and
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bone. Data shows that noimal prostate glandular epithelial cells have extremely low 
proliferation and death rates in the rat. Localised prostate cancer cells arise from no 
further increase in proliferation but a decrease in rates of cell death (reviewed by 
Denmeade et al 1996).
In the elderly male the prostate gland is often affected by benign prostatic hyperplasia 
(BPH), a non-malignant enlargement of the prostate, or by malignant disease 
(Chaudry et al. 1991). Before the onset of malignant disease, pre-malignant 
precursors ai*e thought to develop first. Proliferation of epithelial cells involved in 
prostate cancer predominantly occurs in the peripheral zone, but can also rarely occur 
in the transition zone (reviewed by Agarwal 2000).
Low and high giade prostatic intraepithélial neoplasia (LGPESf and HGPIN) are 
prostatic lesions. HGPIN is thought to be a precursor lesion for prostate cancer. It is 
not certain yet if inteimediate lesions exist. In HGPIN and prostate cancer, stem cell 
features appear in the secretory compartment also. Thus cells have moiphological 
features of both stem and secretory cells (reviewed by De Mai'zo et al. 2001).
Prostatic epithelium could be a target for carcinogenesis because of chronic 
inflammation, with reactive oxygen species (ROS) released by inflammatory cells 
causing genomic damage. Inflammation may also be influenced by diet. Indeed, the 
activated macrophage is the hallmai'k of chronic inflammation and can be associated 
with carcinogenesis. Proliferative inflammatory atrophy (PIA) is another lesion 
thought to be a precursor for prostate cancer. It is also known as post atrophic 
hypeiplasia, and is often associated with inflammation (Zha et al 2001). Early 
inactivation of glutathione S-tiansferase (GST) is thought to play a role in PIA 
development as it is usually accompanied by chronic inflammation (reviewed by De
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Mai’zo et al 2001). PIA is different from diffuse hoimonal atrophy because it is not 
related to androgen withdrawal and is not associated with elevated levels of apoptosis. 
Inactivation of GST may serve as an initiating lesion for prostatic carcinogenesis and 
normal prostate cells may be susceptible to neoplastic progression mediated by dietary 
components as a result of GST deficiency. GST can inactivate carcinogens by 
conjugating them to reduced glutathione. GST can be inactivated by hypermethylation 
of residues near its regulatory sequences and such inactivation has also been reported 
in tumour suppressor genes such as Rb and pl6 in other cancers. This increased 
méthylation could occur as a result of increased DNA methyl transferase (DNMT) 
expression, which is reported in a number of cancer tissues. The model proposes that 
chronic inflammation (perhaps from infection) triggers the appearance of PIA lesions, 
which express high levels of GST and other protective enzymes, and the subsequent 
loss of GST function results in increased genome damage by the diet over decades. A 
possible therapeutic intervention is inhibition of DNMT (reviewed by Nelson et al 
2001). The putative role of GST in prostate cancer development is shown in Figure 
1 . 1 .
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Figure 1.1 Proposed model for prostate carcinogenesis. A potential mechanism for 
the development of advanced prostatic disease, emphasising the importance of GST 
inactivation (Taken from Nelson et al. 2001).
This section described the non-pathological function and physiology of the prostate 
gland and the role that androgens and the androgen receptor play in growth and 
development of the gland. It also described the advent of pre-malignant lesions. Some 
of the molecular mechanisms which are involved in prostate carcinogenesis will be 
covered more fully in later sections.
1.1.3 Risk Factors and Chemopreventlon
1.1.3.1 Risk Factors for prostate cancer
Prostate cancer is a multi-factorial disease involving both genetic and environmental 
risk factors such as age, race, family history, geography, androgenic status and diet 
(reviewed by Fleshner & Kucuk 2001). Risk factors or markers for the disease that 
could be used to identify suitable populations for chemoprevention are age greater
Chapter 1 Introduction
than 50 years, familial history of prostate cancer, high serum testosterone, a high fat 
diet, prostatitis and pre-malignant lesions (reviewed by Kelloff et al 2001).
Age is the greatest risk factor for prostate cancer. By age of 80, more than 70% of all 
men have prostate cancer. In the US this equates to more than 20 million men with the 
disease. Age dependent appearance of prostate cancer appears not to be influenced by 
race or geography.
There is a 70-fold difference in incidence between ethnic populations; it is lowest in 
China and Japan, and highest in Afiican-Ameiicans (Figure 1.2). The incidence is 
rising in both high and low risk populations. In the US this could be due to better 
screening. However, death rates are significantly lower in Japan than the US, 
suggesting that diet has a major impact not on the initial development of prostate 
cancer but on its progression from a local neoplasia to metastatic cancer (Myers & 
Ghosh 1999). Mortality rates of breast and prostate cancer are also much lower in 
Asian countries compared to the US, and upon migration to US these rates increase. 
As Asian countries adopt Western diets, the incidence of prostate and breast cancer 
has started to rise. Further, eaiiy events in carcinogenesis and BPH appear to be the 
same in US and Asia, suggesting that promotion and not initiation may be the 
difference in the two geographical regions (reviewed by Coffey 2001).
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Figure 1.2 Global prostate cancer incidence. Global age standardised incidence 
rates per 100 000 for prostate cancer (Taken from Gronberg 2003).
Populations that consume large amounts of animal fat are considered to have an 
increased risk of prostate cancer. The disease is associated with a Western lifestyle, in 
particular a high fat and meat diet. Animal fats and meat are rich source of 
arachidonic acid, a desaturated product of dietary linoleic acid and a polyunsaturated 
fatty acid. Arachidonic acid is the most prevalent component of membrane 
phospholipids, and is converted to biologically active eicosanoids, which are known 
to be involved in carcinogenic processes. For example, PGE] promotes colon 
carcinoma cell growth and 12-HETE (a 12-lipooxygenase [LOX] product) promotes
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cancer cell motility and invasion (Myers & Ghosh 1999). The cooking of red meat at 
high temperatures causes heterocyclic formation and these are known carcinogens. 
Low disease incidence in Asia is thought to be due to consumption of phyto- 
oestrogens such as soybeans and flavanoids. These could have several effects: an anti­
estrogenic effect via the estrogen receptor and reducing circulating androgens by 
increasing sex hormone binding globulin (reviewed by Gronberg 2003). For example, 
the phytoestrogens genistein, daidzein and coumestrol have been shown to have 
growth inhibitory properties in androgen-dependent (LNCaP) and -independent 
prostate cancer cell lines (PC-3) (Mitchell et al. 2000).
Chaudry et al (1991) were the first to show differences in fatty acid consumption in 
patients with benign and malignant prostatic disease. Lower levels of arachidonic acid 
were found in areas of malignancy and these tissues had a greater capacity for 
eicosanoid synthesis. Animal but not plant products contain arachidonic acid and an 
initial epidemiological link between high animal fat intake and prostate cancer 
postulated the importance of the eicosanoids. However, it has been difficult to make 
the link between dietary fat and prostate cancer, as the specific fatty acids people 
consume over the many years the disease develops are difficult to ascertain (reviewed 
by Myers et al 2001).
As explained above, growth and development of the prostate gland requires the 
presence of sex hoimones, the androgens. Studies have shown that circulating 
testosterone in youth, which is higher in blacks than whites, could account for 
observed differences in incidence rates. Also important is 5a-reductase activity and 
Japanese men have the lowest worldwide (Steiner et al. 2001). Thus, both testosterone 
biosynthesis and metabolism can contribute to prostate cancer.
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Ross et al. (1998) propose a genetic model for prostate cancer involving testosterone 
metabolism involving polymorphism in four groups of genes showing inter-racial 
allelic variation. The groups are those involved in testosterone biosynthesis, 
conversion of testosterone into DHT, the androgen receptor gene and those genes 
involved in testosterone metabolism. High fat diets also thought to be associated with 
high levels of androgens further implicate dietary fat in prostate cancer (reviewed by 
Fleshner & Kucuk 2001).
Mortality rates for prostate cancer are high in North America and North Western 
Europe but appear to be lower in Africa and central and South America, it is 
postulated that UV radiation could have a protective effect. It has also been 
hypothesised that vitamin D deficiency increases prostate cancer risk (Walczak et ah
2001). Vitamin D is produced by UV iiTadiation in the skin or can be obtained from 
the diet. Increased age leads to decreased serum vitamin D levels as the 
photoproduction efficiency decreases with age. Melanin content, and therefore skin 
pigmentation, also effects vitamin D production as melanin absorbs UV radiation. 
Japanese men also consume fish oil in their diet, which contains large amounts of 
vitamin D and this may contribute to the lower mortality observed for prostate cancer 
in Japanese men.
1.1.3.2 Chemoprevention of Prostate Cancer
It is important to prevent prostate cancer in the first place as no effective curative 
treatment is cunently available for advanced disease. Many classes of cancer 
chemopreventive agents are being evaluated. Chemoprevention of malignant disease 
involves inhibiting the conversion of precancerous lesions to malignant caicinomas in 
the hope that it will lead to a reduction in cancer incidence.
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Because of the contribution of environmental factors to prostate cancer progression, 
there is an opportunity to modulate or manipulate them to reduce mortality from the 
disease. The major environmental risk factor is diet and this could be easily modified 
to prevent carcinogenesis (reviewed by Nelson et al 2001). Prostate cancer is also a 
realistic tai'get for chemoprevention because of its long latency, as it is thought to take 
20-40 years to develop. Cunent promising chemopreventive agents include anti­
androgens and anti-oestrogens, steroid aromatase inhibitors, retinoids, vitamins D, E 
and analogues, lycopene, differentiation agents, apoptosis inducers and anti­
inflammatories such as NS AIDs (the non-steroidal ant-inflammatory drugs) (reviewed 
by Kelloff et al 2001).
1.1.3.2.1 Flavanoids
Progression of prostate cancer initiation to clinical cancer could be controlled as 
mortality is low in Japan and other Asian countries. This could be explained on the 
basis of dietary habits, as food which is rich in flavanoids, isoflavones (genistein) and 
flavanones (silymarin), present in yellow-green vegetables, fruits, soybeans and green 
tea, are shown to inhibit disease progression. These compounds have anticancer 
activity such as inhibiting TGFa mediated EGFR activation in prostate cancer cell 
lines (reviewed by Agarwal 2000).
1.1.3.2.2 Anti^oxidants
Oxidative damage induced by ROS could play a pari in prostate carcinogenesis, by 
damaging biomolecules such as DNA, proteins and lipids. The diet is important in this 
respect because fats are a substrate for oxidative stress. Thus, it is not suiprising that
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antioxidants such as vitamin E and selenium are associated with reduced prostate 
cancer incidence. Also, as inactivation of GST may be an important step in prostate 
carcinogenesis (Fleshner & Kucuk 2001), supplemental vitamin E can have protective 
effect on oxidative damage and can inhibit tumour progression in nude mice. 
Glutathione peroxidase, an enzyme which protects cells against oxidative damage, is 
selenium dependent, but the mechanism of action of selenium is unknown. Selenium 
and vitamin E cancer prevention trial (SELECT) is a double blind placebo controlled, 
multinational study being conducted from 2001 for men with noimal digital rectal 
examination and normal PSA. The trial is due to end in 2013 and the primary 
endpoint is prostate cancer incidence (reviewed by Gronberg 2003).
Antioxidants such as p-carotene, a-tocopherol and ascorbic acid have also been shown 
to have chemopreventive activity in experimental animal models, a-tocopherol may 
reduce incidence of the disease but an increase in cerebral haemorrhage is also 
observed (reviewed by Vainio 1999). Lycopene is a carotenoid present in tomatoes 
and other fruits, and is a potent antioxidant also associated with a decreased risk of 
prostate cancer (Fleshner & Kucuk 2001).
1,13.23 Anti-inflammatories
Inflammation is often linked to cai'cinogenesis and in this respect COX-2 is a key 
inflammatory enzyme (see Chapter 1.2). Prostaglandins, the products of COX-2 
enzymatic activity, have multiple caicinogenic effects. Thus, down-regulation or 
inhibition of COX-2 could play an important role in cancer prevention. Because 
COX-2 is over-expressed at an early stage in some cancers, it is a potential target for 
chemopreventive agents (reviewed by Vainio 1999). Inhibition of prostaglandin 
synthesis can inhibit tumourigenesis, as can use of anti-inflammatory steroids such as
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glucocorticoids. Vitamin E and glucocorticoids inhibit PLA2 activity, resulting in 
decreased amount of arachidonic acid available for metabolism to inflammatory 
prostaglandins (reviewed by Vainio 1999). The mechanisms by which COX-2 
inhibitors may provide chemopreventive and anti-tumour activity will be discussed in 
greater detail in Chapter 1.2.7.1.
1,13.2,4 Anti-estrogens
Oestrogens can also cause inflammation in the prostate, as can a soy-free diet; 
chemicals present in soya include genistein and isoflavanoids, which are anti­
inflammatory, although their mechanism of action is unknown. They could act as anti- 
oestrogens, anti-oxidants or tyrosine kinase inhibitors (reviewed by Coffey 2001). 
Oestrogens have been implicated in the initiation of prostate cancer. The prostate 
contains oestrogen receptors in both the stroma and epithelium. They have DNA and 
ligand binding domains and bind oestradiol with equal affinity. Oestrogens can induce 
BPH only in the presence of androgens; they appear to increase the sensitivity of the 
prostate to androgens by up-regulating the androgen receptor. They stimulate cellular 
proliferation upon ER binding by inducing production of local stimulatory peptide 
growth factors such as TGFa, insulin growth factor (IGF) and EGF and inhibiting 
expression of local growth inhibitory factors such as TGFp. Thus, selective estrogen 
receptor modulators (SERMs) would be expected to decrease stimulatory and increase 
inhibitory growth factors, inactivating local oestrogen regulated genes. Because 
androgen levels are unaffected, SERMs do not affect libido and sexual function. Thus, 
they are attractive as potential chemopreventive agents. Japanese men have the lowest 
serum oestrone and oestradiol levels and the lowest risk for developing the disease 
(Chapter 1.1.3.1) (Steiner et ah 2001).
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To summarise. Chapter 1.1.3 described the various risk factors for prostate cancer and 
how the major environmental risk, diet, can be decreased by intervention measures. 
Chemoprevention is quite different in principle to disease treatment (Chapter 1.1.5) 
although both strategies may seek to disrupt similar signalling pathways. The 
potential role of NSAIDs and COX-2 inhibitors was briefly discussed, and as COX-2 
is central to this research project these agents will be discussed in greater detail 
throughout this work. Further, inflammatory events are linked to prostate cancer 
development and COX-2 is a key mediator of inflammation, implicating COX-2 in the 
carcinogenic process.
1.1.4 Androgen Independent Prostate Cancer (AlPC)
Prostate tumour growth is initially androgen dependent. Thus, the therapeutic option 
of slowing tumour growth by stopping androgen production exists -  this is the 
principle behind androgen deprivation therapy (Chapter 1.1.5). However, most 
advanced tumours eventually become resistant to the effects of androgen ablation and 
may grow even in the absence of androgens -  they become androgen independent. 
After androgen ablation therapy, tumour cells adapt by using growth factors other 
than androgens. During the development of this process prostate cancer cells acquire 
the ability to survive and then proliferate in an androgen depleted environment. 
Several possible pathways for the development of androgen independent prostate 
cancer (AIPC) exist and genetic modification underlies its development. The 
mechanism by which prostate cancer cells survive androgen ablation and become 
androgen independent is not clear, but several possible routes exist (reviewed by 
Denmeade et al. 1996).
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GST is expressed in the normal prostate but is lost in 90% of cancers via méthylation 
of its promoter. As this protein is involved in detoxification of potential carcinogens it 
renders prostate cells susceptible to mutations. There will then be increased chance of 
‘multiple hits’ of mutations which lead to androgen independence and malignancy. 
Some studies show that mutations exist even prior to androgen blockade, in untreated 
metastatic tumours. More mutations aie seen in the androgen receptor in metastatic 
disease compaied to primary prostate cancer. It is possible that androgen blockade 
may select for cells in which anti-andi'ogen acts as an agonist rather than antagonist.
In a review by Feldman & Feldman (2001) five separate mechanisms of AIPC 
development are described. In the first mechanism, the hypersensitive pathway, 
prostate cancer cells need much lower levels of androgen for survival i.e. have 
increased sensitivity to andi*ogens, but are still dependent on androgen. In this 
scenario, androgen receptor amplification will allow enhanced ligand occupancy even 
with reduced ligand. Indeed, 30% of tumours have an amplified androgen receptor 
gene. Furthermore, 5a-reductase activity or levels could be enhanced. To support this, 
it is known that after ablation testosterone levels fall by 95% but DHT levels fall by 
only 60%.
The second mechanism, termed the ‘promiscuous pathway’, concerns androgen 
receptor mutations. These mutations result in gain of receptor function. Non-classical 
ligands can then bind and activate the receptor e.g. other steroid hormones. LNCaP, a 
commonly used prostate cancer cell line, has a mutation in the ligand binding domain 
which allows it to be stimulated by other steroid hoimones and flutamide, the 
androgen antagonist. It has also been reported that in LNCaP, estrogen mediated cell 
growth is via specific estrogen receptors (Castegnetta et al. 1995). Co-activators and 
co-repressors also act on the receptor. Over-expression of co-activators or loss of co­
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repressors is a possible mechanism of enhancing receptor activity. For example, over­
expression and amplification of the p i60 co-regulator has been reported in human 
prostate cancers (reviewed by Scher et al. 2004).
A third mechanism, the outlaw pathway refers to steroid receptors activated by ligand 
independent means. IGF, keratinocyte growth factor (KGF) and EGF can also activate 
the androgen receptor in absence of androgen. Over-expression of HER2/ neu can 
activate androgen receptor dependent genes in the absence of androgen receptor 
ligand but not in absence of the receptor itself. Tyrosine kinase activation of these 
growth factor receptors activates mitogen activated protein kinase (MAPK) and 
phosphatidyl 3-kinase (PI3K) signalling, which phosphorylate and activate the 
androgen receptor.
In the fourth pathway there is no involvement of andi'ogens or its receptor, but the 
principle is the same, namely cells can provide a substitute survival signal and could 
be selected by therapy. In the normal prostate, Bcl-2 (B cell lymphoma) is expressed 
by basal epithelial cells, neuroendocrine cells but not glandulai’ epithelial cells and 
these Bcl-2 negative cells are the major androgen dependent cell type within the 
prostate gland and they are also the cells of origin of most human prostate 
adenocarcinoma (reviewed by Kyprianou et al. 2000).
There is increased Bcl-2 expression in prostate cancer cells and hormone refractory 
prostate cancer and an association between Bcl-2 expression and progression to 
androgen independence exists. However, Bcl-2 is not expressed in all androgen 
independent metastatic tumours, suggesting that there could be multiple pathways for 
progression to an androgen independent phenotype in prostate cancer. Mutations in 
p53, which triggers apoptosis in response to injury or DNA damage, may also be a
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factor, as p53 is associated with progression of prostate cancer from localised to 
metastatic androgen independent phenotype (reviewed by Denmeade et al. 1996).
The fifth pathway postulates that a population of androgen independent cells exists 
even before therapy is given, so called ‘lurker’ cells, i.e. putative stem cells, which 
therefore have the properties of cancerous cells. There could also be increased 
bioavailability of androgens within the tumour itself (despite castration levels in the 
blood) via sequestration with steroid hormone binding globulin and increased 
expression of enzymes involved in steroid synthesis e.g. squalene epoxidase 
(reviewed by Scher et al. 2004).
Androgen independent cells in the tumour population could suppress the proliferation 
of androgen sensitive cells and gain growth advantage as a result, this could be due to 
androgen independent cells secreting interleukin-1 (EL-1), inhibiting growth of 
androgen sensitive cells. Exogenous IL-1 has no effect on androgen independent PC-3 
or DU145 cells, suggesting that they have lost sensitivity to IL-1 growth inhibitory 
effects (reviewed by Hoosein 1998).
We have seen in this section that prostate cancer cells may acquire an androgen 
independent phenotype, which mediates their resistance to apoptosis not only 
following androgen deprivation but also to chemotherapy and radiotherapy (which is 
discussed in the next section). Changes in expression of apoptotic and cell cycle 
regulatory proteins underlie this phenotype. A central theme in this thesis is the 
potential role of COX-2 in modulating apoptotic proteins and mediating resistance to 
chemotherapy, although COX-2 is yet to be implicated in the development of 
androgen independence.
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1.1.6 Treatment Options
In prostate cancer, cell proliferation exceeds cell death, producing continuous tumour 
growth. One goal of prostate cancer therapy is to coixect this imbalance. Androgen 
independent cells can still undergo apoptosis by means other than androgen ablation; 
this is a target for therapeutic intervention. As discussed in Chapter 1.1.4, androgen 
withdrawal therapy may select for androgen independent, Bcl-2 expressing cells in the 
tumour population (reviewed by Kyprianou et ah 2000). Advanced prostate cancer is 
incurable and only palliative treatment is given.
1.1.5.1 Early Localised Disease
There are broadly three management options for patients with early, localised disease. 
Firstly, active surveillance involves not administering a curative treatment. Many 
patients with either localised or locally advanced disease will not die from it, 
especially patients with well differentiated tumours. Conservative patient management 
is reasonable in individuals over 70 years, a Gleason score less than or equal to 6, 
PSA less than 10 ng/mL and PSA doubling time greater than 10 years (reviewed by 
Horwich et ah 2002). Secondly, there is the option of radical prostatectomy, the 
surgical removal of the gland. But there is a high risk of impotence with this 
procedure although a low risk of incontinence. Thirdly, the patient can undergo 
radiotherapy, either with either external beam radiotherapy (EBRT) or the 
implantation of radioactive seeds (brachytherapy). It is thought that seeds offer lower 
toxicity, but can be used only for small tumours with good prognosis. For EBRT and 
brachytherapy possible side-effects are cystitis and dysuria. Hormonal ablation 
therapy can improve radiotherapy results (reviewed by Horwich et al. 2002).
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1.1.5.2 Androgen Deprivation Therapy
Inhibiting testosterone function is an important aspect of prostate cancer therapy due 
to its effect on cell proliferation and division. There are a number of methods 
available to either reduce circulating androgens or inhibiting their function. These 
include orchidectomy, androgen receptor antagonists, LHRH analogues and 5a- 
reductase inhibitors. Androgen ablation therapy is not always successful as metastatic 
prostate cancer in patients could have both androgen dependent and independent cells 
and this therapeutic strategy will be ineffective for pre-existing andiogen independent 
cells (reviewed by Tapia-Vieyra & Mas-Olivia 2001).
Orchidectomy, the surgical removal of testes, is now largely replaced by 
phaimacological means of depleting androgens. Also, there are side effects with this 
therapy which make them unattractive for prostate cancer prevention; loss of libido, 
muscle mass, bone mass and impotence. Thus other ways have been developed to 
perturb androgen metabolism with fewer side effects.
Anti-androgens have been approved to treat prostate cancer. 5a-reductase is the 
enzyme which mediates intracellular metabolism of testosterone to DHT. Inhibition of 
this enzyme is a good target for prostate cancer prevention as men with genetic 
deficiency for type II 5a-reductase have never been reported to develop clinical 
prostate cancer. Inliibitors of 5a-reductase, aie being tested to treat benign and 
malignant prostate disease, breast cancer, osteoporosis and alopecia. Agents such as 
finasteride have been shown to cause regression of the hyperplastic prostate and 
inhibit prostate growth, with a decrease in serum PSA levels (Trump et a l 2001).
Two sources of androgens are the testes which produce 95% of all androgens and 
adrenal glands, which produce dehydroandrosterone, dehydroandrosterone sulphate
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and androstenedione. Both sources are under control of the anterior lobe of the 
pituitary, which releases leutinizing hormone (LH). LH release from the pituitary is 
under control of LHRH (the releasing hormone), released by the hypothalamus. 
Hypothalamic LHRH is degraded in the pituitary; therefore circulatory levels are low. 
Serum testosterone acts as a negative feedback for LHRH release (reviewed by Droz 
et al. 2002).
LHRH analogues or agonists suppress LH release. Maximal androgen blockade 
combines an LHRH agonist with androgen receptor antagonist. Oestrogen treatment 
for prostate cancer was terminated with the advent of LHRH agonists (Corey et al.
2002). LHRH agonists are useful therapeutic agents in treating advanced prostate 
cancer, as they suppress androgen production. They also exert an anti-proliferative 
effect on the tumour directly by decreasing EGFR levels (reviewed by Motta et al. 
1996). Thus, LHRH agonists inhibit tumour growth by suppressing pituitary-testicular 
axis activity. LHRH agonists produce an initial LH flare which can be suppressed 
with a short course of anti-androgens. Intermittent androgen blockade may delay the 
development of hormone refractory disease and reduce side-effects. Control and 
regulation of LHRH action is illustrated in Figure 1.3. This figure also illustrates the 
mechanism by which LHRH agonists mediate their therapeutic activity along the 
hypothalamic-pituitary-prostatic axis.
23
Chapter 1 Introduction
LHRHO
LHRHagonists
T
Hypothalamus
Progesterone, oestrogen.' androgen receptor ^__binding and signalling
AR inhibitors 
A  f .......  LHRH antagonists
(Prolongedexposure)
l_HRH receptor
Pituitary
lhV
I
w
Castration 
L —I Testosterone
l_H receptor
Testis
Aminoglutethimide,ketocanazole
: ^  AndrogenAdrenalglarxJs Cholesterol 
r  “
Testosterone T
5a-Reductaseinhbrtors TARWncSr>g i andactivation of target genes
Prostate Anti-androgens
Figure 1.3 Control of androgen production by the hypothalamus-pituitary axis.
LHRH and LH release is under control of the hypothalamus-pituitary axis (Taken 
from Denmeade & Isaacs 2002).
1.1.5.3 Chemotherapy for Advanced Disease
One problem of early prostate cancer treatment is the frequency of indolent tumours, 
which renders chemotherapeutic treatments less effective than in other cancers. 
Agents that are cytostatic or cytotoxic only affect cells that are proliferating. More
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than 90% of prostatic cancer cells in a patient may not be actively proliferating and 
therefore will be resistant to cytotoxic chemotherapy (reviewed by Tapia-Vieyra & 
Mas-Olivia 2001). No chemotherapy has been demonstrated to improve survival in 
relapsed disease patients. Evidence is also lacking that chemotherapy prolongs 
survival in hormone refractory patients. No curative combination treatment for 
metastatic prostate cancer exists (reviewed by Droz et al. 2002). Thus, there is a need 
for cytotoxic therapy to kill androgen independent cells that does not require cell 
proliferation to be a mechanism of action.
Categories of agents tried as first line therapy include alkylating (cyclophosphamide), 
platinum-containing (cisplatin, carboplatin), pyrimidines (5-fluoro-uracil), anti-folates 
(methotrexate), intercalating (doxorubicin), anti-mitotic (etoposide, vinblastine), 
polyamine inhibitors and immunologic agents. Cyclophosphamide has suipassed 
doxorubicin as the standard cytotoxic agent for advanced prostate cancer (reviewed by 
Yagoda & Petrylak 1993). Estramustine, a conjugate of oestradiol and nitrogen 
mustard, is frequently used alone or in combination with docetaxol, vinblastine or 
etoposide (reviewed by Lai*a & Myers 1999).
Mitoxantrone has palliative effects but little effect on survival, but it is the recognised 
standard chemotherapy for advanced prostate cancer in the US. Docetaxel is attractive 
as it has wide-spectrum activity and synergism is shown with other agents. However, 
combinations may not be synergistic or even additive for prostate cancer cells; they 
could be antagonistic (Budman et al. 2002).
Bone is the most frequent site of metastasis and has major consequences in terms of 
pain and nerve compression, which affects treatment options. Hormone deprivation is 
the prefeiTed treatment at this stage. Symptoms are either local or diffuse. For pain, 
radiotherapy or radiopharmaceuticals are used. Patients with hoimone suppression can
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develop osteoporosis, with combination of both osteoblastic and osteolytic métastasés 
occurring (reviewed by Droz et al. 2002).
Trial regimens experimented for prostate cancer include prednisone, hydrocortisone, 
taxanes such as paclitaxel and vinblastine. Endpoints in such trials are typically 
suiwival, progression free survival, PSA response and quality of life. Due to absence 
of reliable biochemical and biological tumour markers for the disease, subjective 
analysis such as quality of life, weight changes and analgesic use for response criteria 
has had to be included (reviewed by De Mulder et al. 2002).
There are no consensus guidelines for second line therapies. Options include 
endocrine manipulation, chemotherapy alone or combined, or radiotherapy. The 
purpose of second line therapy is not to prolong life but to improve quality of life. For 
these patients quality of life is of greater importance than actual length of survival 
(reviewed by Mahler & Dennis 1992).
We have seen in this section the need for better treatment options for prostate cancer, 
particularly advanced, metastatic, androgen independent disease, which has no cure. 
COX-2 inhibitors, agents which foiTn a central part in this cunent study, have not 
been discussed here because they do not forai part of therapy for prostate cancer yet 
although their utility is cunently being assessed. The anti-cancerous effects will be 
discussed in greater detail regularly throughout this thesis.
1.2 Cydooxygenase-2 (COX-2)
1.2.1 Biochemistry
Cyclooxygenase (COX) is the rate limiting enzyme in the conversion of arachidonic 
acid to the eicosanoids. COX is bound to the endoplasmic reticulum (ER), but is also
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found associated with the nuclear membrane, but not plasma or mitochondrial 
membranes of fibroblasts, as determined by immunocytochemical studies (reviewed 
by Needleman et al. 1986). The enzyme is found in virtually every cell; only 
subsequent arachidonic acid metabolism to biologically active prostanoids varies in 
different cells. The molecular weight (Mw) of the purified enzyme is approximately 
72 kDa and it requires a haem molecule for maximal catalytic activity. COX is 
associated with lipid membranes; hence lipids derived from the membrane gain access 
to the COX active site without leaving their site of origin. A variety of 
polyunsaturated fatty acids (PUFAs) aie substrates for COX. The rate of oxygenation 
depends upon the number of cw-double bonds and number of carbons in the FA. The 
most common COX substrate in vivo is arachidonic acid (reviewed by Smith & 
Mamett 1991).
There are three phases of prostanoid formation: (i) hoimone mediated aiachidonic 
acid release from cellular phosphoglycerides by lipases (ii) sequential conversion of 
arachidonic acid to prostaglandin endoperoxides PGG2 then PGH2 by COX (iii) either 
isomérisation or reduction of PGH2 to biologically active derivatives PGD2, PGE2 , 
prostacyclin (PGI2), PGF2a and TxA2. After their synthesis, they exit the cell via 
facilitated diffusion (reviewed by Smith et al 1996).
Lipase systems which are activated when cell surface receptors interact with 
appropriate stimuli are PLA2 (which acts on phosphatidyl ethanolamine/ 
phosphatidylcholine) and PLC and DAG lipase (which act on phosphatidyl inositol 
derivatives). Arachidonic acid is often mobilised by both pathways in stimulated cells. 
PLD is a third form of phospholipase. Arachidonic acid used for prostanoid formation 
is derived primarily from membrane phospholipids, but may also come from 
cholesterol esters, phospholipids of LDL or the triglyceride pool. A number of PLA2
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isoforms exist: type I is secretory and pancreatic. Type II is secretory and from 
platelets and the liver. Three types of cytosolic PLA2 have also been characterised 
(reviewed by Smith 1992).
The COX enzyme contains 2 moieties: a COX moiety which converts arachidonic 
acid to PGG2 (the oxygenation reaction) and an endoperoxidase moiety which 
converts PGG2 to PGH2 (the cyclisation reaction). PGG2 and PGH2 are cyclic 
endoperoxides. Because PGH2 is the end product of COX, COX is also known as 
prostaglandin endoperoxide synthase (PES) or PGH synthase.
The first reaction is the synthesis of PGH2 by COX, after membrane phospholipids aie 
released by phospholipases. COX exhibits both a ôw-oxygenase or cyclooxygenase 
activity, catalysing PGG2 formation and a peroxidase activity, catalysing a 2 electron 
reduction of PGG2 to PGH2. COX and peroxidase activities of the enzyme are on 
spatially distinct sites of the enzyme and both activities require haem. Treatment with 
aspirin or indomethacin competitively inhibit arachidonic acid binding, blocking COX 
activity but not the peroxidase activity. Similarly, mutants of COX exist that have 
COX activity but not peroxidase activity. For example, Tyr-385 is essential for COX 
activity; replacement with Phe-385 by site-directed mutagenesis produces an enzyme 
with no detectable COX activity (Smith et al. 1996). There are two major differences 
between COX-catalysed and spontaneous oxidation of arachidonic acid; firstly, the 
increased rate and secondly the stereochemical control, as only 1 of 64 isomers 
predominates, i.e. PGH2 . A mechanism must exist whereby COX produces a single 
stereoisomer of PGG2 from arachidonic acid. Due to their unstable nature and short 
half-life, continued synthesis of prostanoids is needed to facilitate their diverse 
biological effects (Ristimaki et al. 1994).
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PGH2 is then converted by cell specific synthases to give products such as 
prostaglandins and thromboxanes. Most of the synthases that further metabolise PGH2 
are also present on the endoplasmic reticulum -  these are PGD, PGE, PGP, PGI and 
TxA synthases. Most prostaglandin forming cells produce only a single prostaglandin 
product because of the predominance of a single PGH2 metabolising enzyme e.g. 
platelets contain TxA synthase and normally form TXA2 but not other prostanoids, 
whereas endothelial cells produce mainly PGI2 . Thus, the particular prostaglandins 
produced depend upon the enzymatic machinery present on the ER in a particular cell 
type (reviewed by Dubois et al. 1998). Foimation of PGp2a from PGH2 involves a 2 
electron reduction, whilst all other products aie formed from non-redox isomérisation 
reactions. Figure 1.4 illustrates the enzymatic reactions involved in the conversion of 
arachidonic acid to two biologically active prostanoids, TxA2 and PGI2 .
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Figure 1.4 The COX pathway schematic. The enzymes involved in the conversion 
of arachidonic acid to two biologically active prostanoids (TxA; and PGI2). 
Arachidonic acid, upon release from phospholipids via phospholipases is converted 
first to PGG; (the COX reaction) then to PGH; (the peroxidase reaction). PGH; is the 
substrate for cell specific synthases, which catalyse the formation of the biologically 
active prostanoids.
The COX enzyme is inactivated by an autocatalytic mechanism; the product PGG; 
activates it (positive feedback) i.e. little PGG; results in little COX activity. However, 
since PGG; is converted to PGH; continually in normal tissue, there is little COX 
activity normally. Only at very high PGG; concentrations is there activation of COX; 
thus there is a PGG; window for normal COX function. It is thought that PGE; also 
activates COX2 expression i.e. a positive feedback loop exists where the product 
further downstream activates the initial rate limiting enzyme responsible for its
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synthesis. Oxygen levels are not limiting, except in anoxic tissue. Arachidonic acid 
concentration in the tissue is well above the Km level of COX for arachidonic acid. 
COX has a requirement for a hydroperoxide activator. If these levels are reduced 
COX activity can be inhibited. It is not certain what the hydroperoxide activator is. 
Many cells also contain reduced glutathione (GSH) and GSH peroxidase that also 
inhibit COX activity (reviewed by Smith & Mamett 1991).
During the two reactions of the COX enzymes, free radicals are generated which can 
oxidise xenobiotics to form mutagens. PGH; can also break down to 
malondialdehyde, a mutagen (Kirschenbaum et al. 2000). The peroxidase activity of 
COX, in particular can generate radicals in the cell, which could be mutagenic or 
carcinogenic. The peroxidase component of COX can oxidise a wide range of 
chemical carcinogens. The peroxy radicals foimed during arachidonic acid 
metabolism can cause epoxidation of carcinogens to more reactive forms.
1.2.2 COX isoforms
Prior to 1991, only one 1 COX isoform was identified, but two COX isofoims are 
now known to exist and they differ in teims of their expression, prostaglandin 
synthesis site, C-teiminus 18 amino acids, aspirin acétylation site, chromosome 
location and protein, gene and mRNA sizes. COX-1 and -2 are structurally similai* but 
are encoded for by two different genes; conserved regions between them include the 
active site (Tyr-371), glycosylation sites and transmembrane regions (reviewed by 
Badawi 2000).
Human COX-2 is very similar in structure to sheep COX-1, with enzymatic residues 
being conserved in the two enzymes. COX-1 and COX-2 genes have 61% sequence 
homology; COX-1 is located on chromosome 9, COX-2 on chromosome 1 (reviewed
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by Fosslien 2000). The murine COX-1 gene is 22.5 kb in length and the COX-2 gene 
is 8 kb. The locations of the intron/ exon boundaries aie the same for both but the 
non-coding introns in the genes are much smaller for murine COX-2 than COX-1 
(reviewed by Smith 1992).
Residue 523 (isoleucine in COX-1; valine in COX-2) is the only difference in the 
active site lining between the two isoforms, which means that the COX-2 binding site 
is larger and therefore results in biochemical differences between the two enzymes: 
COX-2 oxygenates a wider array of fatty acid substrates than COX-1 (reviewed by 
Taketo, 1998a).
COX-1 has 599 amino acids, COX-2 has 604. Although the Mw of both COX 
isoforms is approximately 72 IcDa, as determined by SDS-PAGE, the Mw calculated 
from the primaiy sequence is approximately 65.5 kDa. The difference is probably due 
to the attachment of a number of oligosacchaiides per enzyme. The enzyme exists as a 
homodimer in detergent solution, but it is not known if the enzyme can function as a 
monomer. It is not certain how COX is associated with cellular membranes because it 
does not have extensive hydrophobic domains -  one possibility is that the enzyme is 
membrane associated through a specific anchor protein (reviewed by Smith et al. 
1991).
In cultured cells, COX-1 is typically expressed at constant levels throughout the cell 
cycle -  hence it is known as the constitutive isozyme. COX-1 forms prostanoids that 
act locally through G protein coupled receptors (GPCRs) outside the cell to mediate 
‘housekeeping’ functions in response to circulating hormones relating to renal, gastric 
and platelet functions.
The rapid induction of COX-2 mRNA parallels the expression of c-fos and it is thus 
classified as an early immediate or early response gene. That is, it is a gene which is
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activated in cellular stimulation by mitogens, hormones, growth factors or phorbol 
esters. COX-2 was onginally identified as a gene product inducible by v-src in 
chicken fibroblasts and a phorbol ester early gene product in murine 3T3 cells 
(reviewed by Smith 1992). COX-2 is likely to have 2 roles: COX-2 co-localised with 
COX-1 in the ER could augment the actions of COX-1. COX-2 in the nuclear 
membrane forms prostanoids that act through nuclear targets associated with cell 
differentiation and replication (reviewed by Smith et al. 1996).
1.2.3 Functions of the Cyclooxygenases
Prostaglandins act via prostanoid receptors to modulate second messenger levels. 
They aie impermeable to the cell membrane. Prostanoids have both autocrine and 
paracrine functions and when they exit the cell, interact with receptors on either the 
parent cell or neighbouring cells (reviewed by Smith & Mamett 1991). Prostanoids 
can be thought of as local hormones foimed in response to circulating hormones.
Two classes of prostaglandin receptor transduce signal upon ligand binding; GPCR 
and nuclear peroxisome proliferator activator receptors (PPAR) which act directly as a 
transcription factor upon ligand binding.
The GPCRs are teimed TP, IP, EPl/2/3/4, FP and DP for TxAz, PGI, PGE, PGF, and 
PGD respectively. Functionally, these receptors can be put into 3 categories: relaxant 
(increase in cAMP), contractile (increase in Ca^^) and inhibitory (decrease in cAMP). 
Table 1.1 summarises the functions and organ expression of the GPCR prostaglandin 
receptors.
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PG and 
receptor
GPCR Effect Organs Physiological
Functions
PGEz EPl Unknown Î C a" via
intracellular
stores
Kidney,
lung,
stomach
Vaiious, organ 
dependent
EP2 Gs t  cAMP Abundant Various, organ 
dependent
EP3 Gi 1 cAMP Kidney, 
brain, GI 
tract
Valions, organ 
dependent
EP4 Gs t  cAMP Abundant Various, organ 
dependent
PGI2 IP Î cAMP and Vascular Vasodilation, inhibit
PI
metabolism
endothelium platelets
PGF2 FP Corpus
luteum
Uterine contiaction 
and ovulation
PGD2 DP Small
intestine
Allergic reactions
TxAz TP Gi q s t  cAMP Platelets Blood clotting
Table 1.1 Functions and expression of the GPCR family of prostaglandin 
receptors. The table summaiises 5 major prostaglandins, the receptors that mediate 
their biological function, the G protein associated with them and the major organs in 
the body where these receptors are located.
Prostaglandins not only play a central role in inflammation but are also induced in 
physiological functions such as blood clotting, ovulation, bone metabolism, nerve 
growth and development, wound healing, Iddney function, blood vessel tone and 
immune responses (reviewed by DuBois et ah 1998 and summailsed in Table 1,1). 
COX-2 is nonnally undetectable in most tissues. It is inducible by a number of 
inflammatory agents and is concerned with prostaglandin production in inflammatory 
sites, and in cell proliferation and differentiation (reviewed below). COX-2 is 
dramatically up-regulated when there is increased cell replication or differentiation 
(see Chapter 1.2.4).
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Initially, COX-2 was thought of as an inflammatory, inducible enzyme, however it 
appears to have significance in other disease states. COX-2 as well as COX-1 is found 
in the kidney, however interaction between the two are not clear. COX-2 null mice 
show severe disruption of kidney development. COX-2 appears to be involved in 
regulating brain function and neural development. Prostaglandins cause rhythmic 
contraction of the utems and thus help induce labour (reviewed by Narumiya et al. 
1999). The LH surge also produces prostaglandins and this is accompanied with 
COX-2 mediated ovulation. COX-2 is also involved in embryo implantation in the 
uterine endometrium. COX-2 null mice show multiple failures in reproductive 
function, including ovulation, fertilization and implantation, confirming the 
importance of prostaglandins in these processes (reviewed by Fosslien 2000). 
Prostaglandins stimulate both bone resorbing cells (osteoclasts) and bone fonning 
cells (osteoblasts) and thus, in the context of bone metabolism, its effects appear 
contradictory (reviewed by DuBois et al. 1998).
Animal models of inflammatory aithritis suggest that increased expression of COX-2 
is responsible for the increased prostaglandin production seen in inflamed tissues. 
Synovial fluid taken from patients with rheumatoid arthritis has COX-2 over­
expression (reviewed by DuBois et al. 1998). COX-2 is central to the inflammatory 
process and COX-2 inhibition can aiiive at the same therapeutic endpoints as less 
specific inhibitors that also tai'get COX-1. Prostaglandins sensitise pain receptors to 
lower levels of stimulus. Thus, COX action causes hyperalgesia -  an effect countered 
by pain relieving NSAIDs and COX-2 inhibitors, COX-2 inhibitors effectively 
suppress pain without gastrointestinal lesions. Inflammatory mediators and microglia 
result in chronic inflammation that causes neural damage. COX-2 expression in 
neurones also leads to apoptosis (reviewed by DuBois et al. 1998). The roles that
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COX-2 plays in carcinogenesis are described in Chapter 1.2.5. Figure 1.5 shows the 
differential expression, function and regulation of COX-1 and COX-2.
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Figure 1.5 Differential expression, induction and functions of COX-1 and COX-
2. The 2 isoforms of COX are expressed in different tissues, are regulated differently 
and are involved in different functions (Taken from Hussain et al. 2003).
1.2.4 Induction and Regulation of COX-2
There is little similarity between regions regulating gene expression of COX-1 and 
COX-2. COX-2 is a highly inducible gene product expressed in response to processes 
such as growth (Tjandrinawata et al. 1997), differentiation and inflammation. It can 
be induced by hormones (Shimada et al. 2000), growth factors, cytokines (Xu et al. 
1999), inflammatory factors (Bradbury et al. 2004) and stresses such as UV light
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(Tang et al. 2001), radiation, oxidative stress (Adderley et al. 1999), heat and 
hyperosmolai'ity. The promoter and enhancer regions regulating COX-2 reflect this. 
The 5' flanking region of the COX-2 gene has a TATA box; the COX-1 gene does 
not, and this enables p53 regulation of COX-2. COX-2 does not seem to be expressed 
in most unstimulated tissues, but is rapidly induced in response to these stimuli. Thus, 
although COX-1 and COX-2 catalyse the same reaction, they are regulated 
independently (reviewed by DuBois et al. 1998).
COX-2 expression is regulated primarily at the transcriptional level, with activation of 
transcription factors acting on sites such as SP-1, AP-1, AP-2, CRE, NE-IL6 (CCAAT 
enhancer binding protein or C/EBP), or NFKB within the COX-2 promoter but also at 
the post-transcriptional level by mRNA stability. This induction occurs in a cell type 
and stimulus dependent fashion. Compounds which inhibit AP-1 mediated COX-2 
transcription include: retinoic acid, PPAR agonists and agents that target HER-2/neu, 
EGFR, protein kinase C (PKC), PI3K, MAPK (reviewed by Subbaramaiah & 
Dannenberg 2003). If COX-2 promoter activity is elevated it is either due to an over­
expressed or overactive transcription factor, or a negative regulator of COX-2 
transcription is lost or mutated (McGinty et al. 2000).
COX-2 expression also conelates with activity of signalling pathways such as the 
MAPK family (the extracellular regulated kinases [ERK,] p38 and stress activated 
protein kinases/ c-Jun N terminal kinases [SAPK/ INK]) and PI3K. COX-2 
transcription can also occur via PKC and ras/ MAPK mediated signalling. PKC can 
activate Raf-1, which regulates MAPK activity. The ERK pathway is activated 
primaiily by mitogens of the RTK family and utilised by a number of different 
extracellulai- stimuli, such as cytokines and growth factors that lead to cell growth and 
differentiation. SAPK/JNK and p38 MAPK are preferentially activated by
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inflammatory cytokines (IL-lp and tumour necrosis factor a (TNFa)) and stress 
processes, and these two pathways are implicated in the inflammatory process. Their 
activation leads to growth inhibition and apoptosis. INK phosphorylates c-Jun on its 
N-terminal activating domain, leading to c-Jun and c-fos heterodimers and 
transcriptional activity of genes via AP-1 and CRE sites. ERK is thought to activate 
NF-IL6 by phosphorylation NF-IL6. Activation of ERK 1/2 not only stimulates COX- 
2 transcription but also stabilises COX-2 mRNA, COX-2 mRNA is unstable with a 
half-life of only minutes (Jang et al. 2004). COX-2 mRNA at the 3' untranslated 
region contains AU enriched elements, which confer instability. But binding of HuR, 
an mRNA binding protein increases mRNA stability (Subbaramaiah & Dannenberg
2003). Some of the signalling pathways, transcription factors and gene regulatory 
elements are shown in Figure 1,6.
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Figure 1.6 Regulation of the COX-2 gene in cancer. Some important ligands, 
receptors, signalling pathways and transcription factors involved in COX-2 gene 
induction and regulation (Taken from Subbaramaiah & Dannenberg 2003).
COX activity is also increased in some transformed cells. Subbaramaiah et aï. ( 1996) 
investigated the effects of transformation (both viral and Ras oncogene) on COX-2 
expression and prostaglandin biosynthesis in mammary epithelial cells. They showed
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that cellular transformation was associated with increased COX-2 expression and 
increased PGE2 production.
Because hypoxia induces human umbilical vasculai' endothelial cells (HUVEC) to 
increase prostacyclin production, Schmedtje et ah (1997) investigated if COX-2 was 
induced by hypoxia and demonstrated that it was induced by NF-kB p65, one of the 
NF-kB transcription factor family. NF-kB typically dimerises with p50 and p65 
subunits, enters the nucleus and binds to DNA consensus sites in COX-2 promoter 
region and initiates transcription. Hypoxia increased the levels of COX-2 mRNA and 
protein in HUVEC cells.
Microtubule interfering agents (MIAs) are widely used to treat cancer. These agents 
work by interfering with microtubule assembly, impaiiing mitosis and disrupting the 
cytoskeleton. Subbaramaiah et al. (2000) showed that paclitaxel, vinblastine and 
colchicine also stimulate expression of the COX-2 gene and increase PGE2 production 
in human mammaiy epithelial cells, mediated by ERKs 1 and 2 and p38 MAPKs and 
AP-1. Inhibitors of MAPK and p38 blocked MIA induced COX-2 induction. It is 
possible that MIA mediated COX-2 induction can decrease efficacy of these 
compounds. Because of COX-2 inducing activities of MIAs, COX-2 inhibitors may 
need to be given to enhance anti-tumour activities.
Wadleigh & Herschman (1999) showed that there is a requirement for CRE (cis- 
acting or cAMP response element) and NFIL6 sites and the c-Jun transcription factor 
in the COX-2 promoter for COX-2 induction by serum, bFGF, PDGF, PGE2 or TNFa 
plus IL-lp in a murine osteoblast line. Dominant negative forms of JN and MEKK 
blocked COX-2 induction but c-Jun over-expression enhanced COX-2 expression by 
the above stimuli. CRE transcription is usually mediated by CREB or members of the
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ATP family but c-Jun can also activate COX-2 expression via the CRE site. Mutation 
of both NFIL6 reduced COX-2 promoter activity by all inducers.
Subbaramaiah et aL (1999) investigated the effects of p53 on COX-2 expression. 
Mouse embryo fibroblasts which expressed p53 showed 10-fold decrease in PGE2 
compared to those cells expressing mutant p53, and COX-2 protein and mRNA levels 
were suppressed and this effect was due to decreased COX-2 transcription and 
activity of COX-2 promoter was significantly reduced. The region of the COX-2 
promoter that responds to p53, found using murine COX-2 promoter deletion 
constructs, was the first 40 base pairs of the 5’ transcription start site. These results 
could be important in understanding why COX-2 levels are undetectable in noimal 
cells but expressed in many tumours, which are frequently p5S defective. Thus, p53 
represses COX-2 transcription, and mutant p5S may contribute to increased COX-2 
expression seen in malignant tissue. p53 suppresses cellular growth and 
transformation and can induce apoptosis (Chapter 5). Inactivation of p53 can lead to 
deregulation of the cell cycle, DNA replication, selective growth advantage and 
tumour formation. p53 acts on a number of target genes via paiticular consensus 
sequences (Chapter 5).
Xu et al. (1999) investigated the effects of aspirin and sodium salicylate on COX-2 
expression in human umbilical vein endothelial cells and foreskin fibroblasts. Both 
compounds inhibited COX-2 mRNA and protein induced by IL-lp. Salicyclic acid is 
foimed from aspirin in the blood, but does not have inhibitory activity against purified 
COX-1 or COX-2, and fails to inhibit prostaglandin synthesis in intact cells. Thus, 
one possible mechanism is that it inhibits COX-2 gene transcription. Sodium 
salicylate had no effect on COX-2 mRNA degradation. The mechanism could involve 
inhibition of NF-kB or AP-1 mediated gene transcription.
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In this section, experimental evidence for the role of various stimuli, signalling 
pathways, transcription factors and DNA promoter regions involved in induction and 
regulation of COX-2 transcription in a number of non-cancerous cell types has been 
discussed. The same mechanisms may or may not be responsible for regulating COX- 
2 transcription in cancer cells. Interactions between COX-2, p53 and PI3K will be 
explored in Chapters 4 and 5, respectively.
1.2.5 Effects of COX-2 in Cancer
Cancers are known to form more prostaglandins than the normal tissues from which 
they arise (Chapter 1.2.6). As COX-2 and not COX-1 is reported to be elevated in 
many cancers (Chapter 1.2.6), COX-2 is likely to be responsible for the 
overproduction of prostaglandins in malignant tissue (Subburamaiah et ah 1996). 
Experimental and epidemiological evidence provide strong clues for the involvement 
of COX-2 and prostaglandins in the multistage carcinogenic process, in both early 
(initiation) and later (promotion) stages of tumour progression (discussed here).
The role of COX-2 in cancer was suggested by the observation that patients taking 
NSAIDs had a reduced risk of colon cancer. Epidemiological studies show that there 
is a lower rate of colorectal adenomas and carcinomas in subjects who have taken 
NSAIDs over a period of time, suggestive of a pathogenic role for COX in colonic 
tumourigenesis (Sheehan et al. 1999). As NSAIDs have inhibitory effect on 
carcinogenesis, this further implicates prostaglandin synthesis in cancer development 
(Badawi 2000).
It is known that when oncogenes are introduced into the cell, COX2 protein and 
mRNA is expressed (Subbaramaiah et al. 1996), suggesting that COX2 may be an 
important factor for carcinogenesis. Studies reviewed here show that COX-2
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transfected or induced in a variety of cell types causes pro-carcinogenic phenotypes. 
These include increased cell proliferation, resistance to apoptosis, pro-angiogenic 
effects, inflammatory effects, enhanced metastatic capability and changes in the cell 
cycle.
1.2.5.1 Increased Cell Proliferation
Tjandrinawata et al. (1997) showed that exogenous dmPGEz caused increased cell 
growth and PGE2 production, COX-2 mRNA and DNA content in PC-3 and LNCaP 
cells. The NSAID flurbiprofen reduced COX-2 mRNA levels.
Munkarah et al. (2002) showed that ovaiian epithelial cancer cells treated with 
dmPGE2 resulted in increases in COX-2, Bcl-2 and Bax mRNA. This was associated 
with increased proliferation flow cytometry and reduced apoptosis, as assessed by 
TUNEL.
Kawamori et al (2003) used the AOM colon carcinogenesis model to assess the 
effects of exogenous PGE2 in rats over 25 weeks on proliferation and apoptosis. PGE2 
was associated with increased multiplicity and tumour volume.
Kinoshita et al. (1999) showed that COX-1 and COX-2 transfection into a colon 
carcinoma line doubled the growth rate and elevated EGFR levels. Indomethacin 
inhibited this increased growth, EGFR induction and DNA synthesis. Also, PGE2 has 
been shown to induce COX-2 activity by activating tyrosine kinase activity of EGFR. 
Using knock out mice for prostanoid receptors or EP antagonists in the diet in the 
AOM mouse colon carcinogen model. Mutoh et al. (2002) assessed aberrant crypt 
foci formation. EP4 knock out mice developed 50% fewer tumours and there were 
fewer tumours in mice fed the EP4 antagonist.
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Chen & Hughes-Fulford (2000) showed that administration of arachidonic acid 
stimulated c-fos mRNA within minutes and PGE2 production remained elevated for 
hours in PC-3, although increased growth was not demonstrated. Flurbiprofen 
lowered both c-fos and PGE2 levels. Use of a PKA inhibitor confiimed its role in this 
induction.
COX-2 has also been showed to be an anti-proliferative. Zahner et ah (2002) showed 
that COX-2 transfection into rat mesangial cells caused reduced cell proliferation and 
this was associated with elevated p53, p21^^^^ and p27^^^\ NS398 could not prevent 
the COX-2 induced anti-proliferative effect or change in cell cycle check proteins. 
Thus, COX-2 was shown to have the opposite effects to other studies reviewed here, 
namely an anti-proliferative and therefore anti-cancerous effect.
1.2.5.2 Resistance To Apoptosis
Subbarayan et al (2001) showed that TNF-a caused an increase in COX-2 mRNA 
over 4 hours in LNCaP, DU145 and PC-3 cells, although no increase in LNCaP PGEg 
was detected, and this was associated with reduced apoptosis as assessed by PI 
staining.
Tsujii & Dubois (1995) transfected COX-2 into rat epithelial cells and observed 
altered ECM adhesion and resistance to butyrate induced apoptosis, increased Bcl-2 
levels, decreased expression of E-cadherin and the TGFp2 receptor, which is 
important in transducing signals modulating apoptosis. Sulindac sulphide, an NSAID, 
was able to reverse the inhibition of apoptosis and the increased ECM adhesion.
Lin et al (2001) transfected COX-2 into lung adenocai*cinoma cells and demonstrated 
resistance to vinblastine induced apoptosis. Myeloid cell leukaemia-1 (Mcl-l) protein 
levels but not Bcl-2, B cI-xl  or Bax were elevated due to transfection. Use of anti­
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sense Mcl-l vector restored normal apoptotic sensitivity, confirming the role of Mcl-l 
in this resistance.
Nzeako et al (2002) showed that in cholangiocarcinoma cells either transfecting or 
inducing COX-2 with a cytokine cocktail (TNFa, IL-ip, IFN-y) inhibited Fas (but not 
TNF-a or tumour necrosis factor related apoptosis inducing ligand [TRAIL]) 
mediated apoptosis. NS398 inhibited COX-2 mediated Fas resistance to apoptosis and 
PGE2 restored the resistance. Mcl-I but not other anti-apoptotic markers was up- 
regulated by COX-2 expression.
Tang et a l (2002) transfected COX-2 into colorectal HCT-115 cells and assessed the 
effect on TRAIL induced apoptosis. COX-2 cells had lower DR5 mRNA and elevated 
Bcl-2 mRNA and less caspase-3, -8 and -9 activation. Sulindac sulphide pre-treatment 
restored DR5 levels and also reduced cell viability when combined with TRAIL 
synergistically.
Sun et al. (2002) used colon carcinoma HCT-115 cells, which do not express COX-2 
or PGE2 . After COX-2 transfection they observed a reduction in apoptotic response to 
NS398, sulindac sulphide and 5-FU. Bcl-2 mRNA levels were increased and there 
was reduced caspase-3 and -9 activation. Lower doses of NS398 reduced PGE2 levels 
but did not reverse COX-2 mediated apoptotic resistance.
Jabbour et al. (2002) induced COX-2 in bladder epithelial cells with IL-la to assess 
its effect on camptothecin induced apoptosis. NS398 abolished PGE2 production 
caused by increased COX-2. PGE2 abolished camptothecin induced apoptosis and this 
was likely to have been mediated through cAMP since forskolin (a potent AC 
activator) had the same effect.
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Shimada et al. (2000) showed that COX-2 induction by hepatocyte growth factor 
(HGF) caused a resistance to ceramide induced apoptosis in gastiic epithelial cells, 
and this resistance was inhibited by 20 pM NS398.
Han et al. (2002) used various cancer cells to demonstrate that p53 can induce COX-2 
via the Ras/ Raf/ MAPK pathway and this reduced apoptosis in COX-2 expressing 
cells. This effect appears contrary to the role of p53, which is to induce and not inhibit 
apoptosis. The authors propose that this is to counter the pro-apoptotic effects of p53. 
Ishaque et al. (2003) performed adenoviral transfer of the COX-2 gene into rat 
mesangial cells to assess the effects on TNF-a and VP-16 mediated apoptosis. They 
also induced COX-2 with IL-lp. This conferred protection against apoptosis to TNF-a 
only, but not VP-16. NS398 restored TNF-a mediated apoptosis and PGE2 and PGI2 
protected against TNF-a mediated apoptosis.
McGinty et al. (2000) showed that COX-2 induced by DPTG in pheochromocytoma 
cells resisted apoptosis caused by NGF withdrawal. Pre-administration with NS398 
reversed this resistance. Caspase-3 activity was reduced due to COX-2 and PGE2 
treatment in control cells also decreased caspase-3 activity.
Krysan et al. (2004) transfected COX-2 into non-small cell lung cancer cells 
(NSCLC) cells in both sense and antisense directions. There was enhanced survivin 
protein levels in the COX-2 over-expressing cells and PGE2 had the same effect. The 
COX-2 inhibitor SC-58236 administered prior to staurosporine increased apoptosis. 
Survivin levels (but not other inhibitor of apoptosis [lAPs]) proteins were reduced 
with antisense COX-2 transfection. They found that survivin ubiquitination was 
reduced in COX-2 sense levels, stabilising survivin levels.
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1.2.5.3 Angiogenesis
COX-2 is thought to be involved in hypoxia induced tumour angiogeiiesis. PGE2 is 
reported to stimulate angiogenesis. Hypoxia is one of the most potent stimulators of 
vascular endothelial growth factor (VEGF). Concomitant up-regulation of COX-2 is 
seen with VEGF in the PC-3 ML subline. Use of NS398 suppressed cobalt chloride 
induced VEGF expression, but administration of PGE2 restored ability of cobalt 
chloride to induce VEGF (Kirschenbaum et aL 2001).
Masfener et aL (2000) showed in an in vivo study using the Lewis lung carcinoma 
model, dose dependent dietary celecoxib reduced primary tumour growth and 
decreased number and size of lung métastasés. COX-2 was detected in the 
neovasculature. In another corneal angiogenesis model, the same group demonstrated 
that celecoxib suppressed corneal blood foimation, implicating COX-2 in the 
angiogenic process.
Fujita et aL (2002) transfected COX-2 into LNCaP cells and observed greater growth 
rates and laiger tumour volumes in these cells versus mock transfectant when 
introduced into SCID mice. Also, the COX-2 transfectant produced higher levels of 
the angiogenic factor VEGF.
1.2.5.4 Inflammation and oxidative damage
COX-2 activity can generate free radicals (Chapter 1,2.1), and if detoxifying enzymes 
such as GST are down-regulated or deactivated, then damage to biomolecules and 
DNA in particular can occur. During the two reactions of the COX enzymes, free 
radicals are generated which can oxidise xenobiotics to form mutagens (Chapter 
1.2.1). PGH2 can also break down to the mutagen malondialdehyde.
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Inflammatory cytokines such as TNF-a, IL-la and IL-lp, induce COX-2 enzyme 
expression, which increase synthesis of pro-inflammatory prostaglandins (reviewed 
by Fosslien 2000).
Cellulai* proliferation in the prostate could also be associated with chronic 
inflammation (Chapter 1.1.2). Development of some cancers have inflammatory 
involvement. In prostate, these lesions are highly proliferative and exhibit reduced 
apoptosis. The anti-death gene Bcl-2 is over-expressed in these lesions and there is 
decreased expression of the cell cycle regulatory gene p27^^^\ Luminal cells induced 
to express COX-2 by inflammation have an increased expression of Bcl-2 and a 
decreased expression of p27^*^  ^ (Chapter 5). There is increased COX-2 expression in 
most PIN cells (Chapter 1.2.6). TNF-a and IL-6 induce COX-2 expression and PGE2 
secretion in these cells.
1.2.5.5 Invasion and Metastasis
Attiga et ah (2000) assessed effects of PLA2 , COX and LOX inhibitors on the ability 
of PC-3 and DU145 cells to invade through a reconstituted basement membrane and 
on cell survival, motility and secretion of matrix metalloproteinases (MMPs). 
Ibuprofen and NS398 inhibited cell invasiveness and this was reversed with PGE2, 
although PGE2 alone did not induce invasiveness itself. NS398 treatment resulted in 
reduction in MMP2 and MMP9 levels.
Tsuji et al. (1997) transfected COX-2 into Caco-2 colorectal cells to assess the effect 
on invasive potential. MMP2 levels were increased after transfection and sulindac 
sulphide inhibited PGE2 production and reversed the ability of the COX-2 transfectant 
to invade a membrane.
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Nithipatikom et al. (2002) showed that COX-2 levels were 3 times higher in PC-3 
high invasive cells compared to PC-3 low invasive cells and PGE2 levels were 2.5 
times higher. Indomethacin and NS398 inhibited PGE2 production and the ability to 
invade through a basement membrane. However, PGE2 alone did not induce invasion, 
it only enhanced it, and PGE2 reversed the ability of NS398 to inhibit invasion. 
Vadlamudi et al. (1999) showed that neu differentiation factor binding to HER2/3 led 
to an increase in COX-2 protein and mRNA levels and c-myc levels. NDF promoted 
ECM survival and cell invasion and this was inhibited with NS398, which also 
inhibited PGE2 production.
1.2.5.6 Cell Cycle
DuBois et al (1996) showed that transfection of COX-2 into rat epithelial cells 
delayed Gi progiession and this was associated with a reduction in cyclin D and 
CDK4 expression. These cells grow slower because G; duration increased from 8 to 
24 hours. These findings oppose the work reviewed in section 1.2.5.1, which 
describes an enhanced growth effect of COX-2 in other cell types. One consequence 
of this Gi delay is to increase the time abnormal cells with mutations to accrue i.e. for 
enhanced tumourigenesis to occur.
Trifan et al. (1999) showed that COX-2 transfection into various cells produced a Gq/ 
Gi block and reduction in cells in the S phase. NS398 could not reverse this effect and 
COX-2 mutants which are catalytically defective could also induce this cell cycle 
airest, suggesting a prostaglandin independent mechanism. Why COX-2 should 
produce anti-proliferative effects in these cells is not certain, but it could be a cell- 
type or context specific effect.
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In this section we have described the reported oncogenic effects of COX-2 in various 
cell types after experimental approaches such as transfection, enzyme induction and 
administration of the main prostaglandin normally expressed in the experimental cell 
system.
1.2.6 COX-2 Levels In Prostate Cancer
COX-2 has been reported to be elevated in many cancers, including prostate, 
compared to the non-cancerous tissues from which they arise. A consensus has not 
been reached on which cell types over-express COX-2, what the magnitude of over­
expression is and at which stage of the carcinogenic process the enzyme becomes 
elevated. Contradictory data exists in the literature concerning the relevance of COX- 
2 protein and mRNA levels in non-cancerous and cancerous regions of the prostate. 
Studies show that levels of prostaglandins in many tumours are higher than 
suiTOunding normal tissue, and the major prostaglandin is PGEg (reviewed below). 
This will be discussed below.
Kirschenbaum et aL (2000) showed that COX-2 was expressed in the smooth muscle 
cells of both noimal and cancerous prostates. In non-cancerous epithelia, COX-2 was 
expressed only in the basal cell layer and smooth muscle. In prostatic inflammation, 
COX-2 is induced in luminal epithelial cells by lymphocytes (reviewed by 
Kirschenbaum et aL 2001).
Kirschenbaum et aL (2000) also investigated the differential expression of COX-1 and 
COX-2 in prostate cancer, BPH and precancerous lesions, using 
immunohistochemistry. They found highest COX-2 expression in the smooth muscle 
of the prostate. COX-2 was also expressed in most basal epithelial cells and in luminal
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cells of higher grade PIN. COX-1 was also up-regulated in prostate cancer, but not to 
the same extent as COX-2.
Gupta et al. (2000) used pair matched benign and prostate cancerous tissue from the 
same patients to minimise inter-individual variation and showed there was 
significantly greater COX-2 mRNA and protein in cancerous tissue compared to 
benign tissue. Immunohistochemical analysis showed that there was mild staining in 
benign tissue and strong staining in tumour and stromal cells, with staining in stroma 
greater than that in tumour cells in 2 of 12 tissues.
Lee et al. (2001) performed a study to assess COX-2 expression in 22 BPH and 18 
prostate cancer samples using immunohistochemistry. The intensity of staining for 
COX-2 coiTelated with tumour grading as assessed by Gleason score. In most prostate 
cancer tissues, strong COX-2 expression was detected in glandular epithelial cells and 
weaker staining was found in the stroma. There was weak COX-2 staining in adjacent 
normal tissue. A much smaller percentage of positivity was observed for COX-2 in 
BPH tissue.
Madaan et al. (2000) assessed COX-1 and COX-2 distribution and expression in 82 
prostate cancer and 30 BPH samples using immunohistochemistry and 
immunoblotting. COX-1 was constitutively expressed in the fibromuscular stroma of 
all samples, with only a weak luminal expression. There was no COX-2 expression in 
the stroma of BPH specimens. They detected slightly greater COX-1 expression in 
tumour cells compared to BPH. Immunoblotting showed four times more COX-2 in 
prostate cancer than BPH but no difference for COX-1. There was also elevated 
COX-2 expression with increasing Gleason score. COX-2 expression in BPH was 
predominantly in luminal glandular epithelial cells, and in neoplastic epithelial cells 
for prostate cancer samples.
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Edwards et al. (2004) used 89 prostate cancer (all staged T1-T4 at diagnosis) and 28 
BPH samples. HER2 is over-amplified in ovarian and breast tumours and is associated 
with poor prognosis, but it is uncertain if HER2 is amplified in prostate cancer or if it 
is coiTelated with high Gleason score or poor prognosis. They performed IHC for 
COX-2 and HER2 and fluorescent in situ hybiidisation (FISH) to assess HER2 over­
amplification. COX-2 levels in prostate cancer were significantly higher than in BPH, 
but they were not related to Gleason score, PSA or overall survival in this cohort. But 
COX-2 levels were greater in T3 and T4 versus organ confined T1 and T2 tumours. 
There were similar COX-2 levels between T1 and T2 and BPH samples. No 
significant over-expression of HER2 was observed in either cancerous or BPH 
samples.
Uotila et al. (2001) used prostate cancer specimens from 12 patients and compared 
them to control prostates from 13 patients with bladder cancer. COX-2 staining and 
NOS-2 was stronger in cancer cells compaied to the epithelia of control prostates. No 
difference for COX-1 was detected. This suggests that inducible genes COX-2 and 
NOS-2 are stimulated in human prostate adenocarcinoma and may also be expressed 
in PIN, considered a precursor for malignant disease.
Yoshimura et al (2000) performed a study to investigate expression of COX-1 and 
COX-2 in prostate cancer, BPH, PIN and normal prostate specimens. Via 
immunohistochemistry and RT-PCR, they detected COX-1 mRNA in all samples, but 
COX-2 was highly expressed in cancer samples only. COX-2 was also detected in 
blood vessels and stromal tissue of cancer samples, but not in BPH, PIN and normal 
prostate samples. No significant difference in COX-2 staining between prostate cancer 
grading groups was found. Figure 1.7 illustrates the potential involvement of COX-2 
in the various stages of carcinogenesis.
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Figure 1.7 Possible involvement of COX-2 in multistage prostate carcinogenesis.
COX-2 has been implicated in various stages of prostate carcinogenesis (Taken from 
Kirschenbaum et al. 2001).
COX2 is also reported to be over-expressed in several other tumour tissues such as 
colon (Sheehan et al. 1999), cervical (Kulkami et al. 2001), gastiic, breast (Hwang et 
al 1998), gallbladder (Asano et al 2002), hepatocellular, lung, oesophageal and 
pancreatic carcinomas (Yoshimura et al. 2000).
Some studies do not find an elevation of COX-2 in prostate cancer compared to 
normal tissue. For example, Zha et al. (2001) showed that by immunohistochemistry 
normal prostate tissue was negative for COX-2 staining, prostate cancer and HGPIN
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Stained only weakly but there was strong COX-2 staining in PIA, particularly in 
mononuclear macrophages. There was no conelation between COX-2 staining and 
Gleason score, which opposes the findings of Lee et al. (2001). Even aggressive 
tumours which metastasised to lymph nodes were COX-2 negative. RT-PCR analysis 
suggested COX-2 mRNA was down-regulated in prostate cancer compared to normal 
tissue. Thus, they hypothesised that PIA may be a precursor for prostate cancer and is 
associated with acute and sometimes chronic inflammation.
Tanji et al. (2000) investigated the localization of COXs and Bcl-2 expression in 
prostatic adenocarcinoma after androgen blockade, using 12 samples from patients 
with cancer and 3 from prostatic hyperplasia by immunohistochemistry. They showed 
that COX-1 expression occuiTed mainly in the stromal cells of all samples. Many 
infiltrating cells in prostate cancer also expressed COX-1, suggesting it may also play 
a role in tumour development. The study did not find significant conelation between 
COX-2 and Bcl-2 expression. However, there was no COX-2 protein detected in 
noimal human prostate and prostate adenocarcinoma, in contradiction to the findings 
of many publications reviewed here.
We have seen in this section that COX-2 mRNA and protein is reported to be elevated 
in prostate cancer, although some studies do not show elevation over non-cancerous 
tissue. In Chapter 1.2.5 the carcinogenic effects of COX-2 were presented. Because of 
this, COX-2 inhibitors are thought to be potentially useful agents in the management 
of prostate cancer. This is briefly discussed below.
54
Chapter 1 Introduction
1.2.7 COX inhibition
NSAIDs are among the most widely used therapeutic agents, taken for a range of 
pathophysiological conditions, including cardiovascular prophylaxis, analgesia for 
headaches and minor injuries and severe pain alleviation caused by inflammatory 
diseases such as rheumatoid arthritis. However, NSAID use can lead to ischemia, 
mucosal damage and ulceration as prostaglandins alter blood flow in the gastric 
mucosal microcirculation (reviewed by DuBois et al. 1998). Due to the discovery of 
the second COX isoform, COX-2, and the belief that it was responsible for 
exacerbation of inflammatory disease symptoms but not responsible for gastric 
protection, COX-2 inhibitors were developed to be as clinically useful as non-COX 
specific NSAIDs but to spare the gastric toxicity. Focus was put on COX-2 inhibitors, 
as COX-2 was observed to be present in increased amounts in tumour tissue compared 
to normal tissue, whereas COX-1 expression is low in both normal and cancer 
specimens (Chapter 1.2.6).
As will be discussed elsewhere in this thesis in greater detail, some COX-2 inhibitors 
at concentrations greater than those needed to inhibit prostaglandin production have 
anti-cancer activity in cell lines, in animal models of cancer and in human disease. 
Some studies suggest that COX-2 inhibition is an important factor in the ability of 
COX-2 inhibitors to induce growth atxest and apoptosis. Evidence given for this is the 
inability of COX-2 inhibitors to affect the viability of COX-2 non-expressing cells 
and the ability of prostaglandins to modulate the effect of the COX-2 inhibitor (Hsu et 
al. 2000, Kamijo et al. 2001).
The evidence that COX-2 inhibitors affect cell viability independent of COX-2 levels 
or expression is more convincing. The concentration of COX-2 inhibitor needed to 
induce growth aiTest or apoptosis is typically 1000 times higher than that needed to
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inhibit the enzyme (Liu et al. 1998, Johnson et al. 2001, Arico et al. 2002). Also, 
COX-2 inhibitors with similar IC50 values in COX-2 inhibition have varying 
efficacies in apoptosis induction (Zhu et al. 2002), implying involvement of different 
molecules. Further, these agents can affect cell viability in cells which do not express 
COX-2. This observation does not necessaiily minimise the potential role of COX-2 
in promoting carcinogenesis. Firstly, non-catalytic effects i.e. protein binding, of 
COX-2 may be partly responsible for mediating apoptotic resistance. Furthermore, 
COX-2 can cause numerous other carcinogenic effects (Chapter 1.2.5) in addition to 
its effects on apoptosis, so although concentrations of COX-2 inhibitors in excess of 
those needed for enzyme inhibition, these agents may have anti-angiogenic or anti- 
invasive effects at enzyme inhibitory levels.
This complicates the question as to whether COX-2 expression is useful as a 
predictive factor for either therapeutic or chemopreventive measures. With regaids to 
apoptosis, COX-2 mediates a RESISTANCE, not complete INHIBITION. If COX-2 
is over-expressed in a pai'ticulai* malignancy, inhibiting COX-2 therefore may not 
necessarily cause apoptosis of COX-2 expressing cancer cells. As the relative 
importance of prostaglandin-dependent and -independent effects of COX-2 in 
carcinogenesis is fully understood, the potential usefulness of assessing COX-2 
expression as an indicator for response prediction is still not confirmed.
Non-COX-2 tai'gets of COX-2 inhibitors have been recently identified (Figure 1.8). 
These include proteins involved in PI3K and ERK signalling and the NF-kB pathway. 
The result of COX-2 inhibitor mediated anti-proliferative activity is the up-regulation 
or activation of growth aixest or pro-apoptotic proteins or the down-regulation or 
inactivation of anti-apoptotic proteins, or a combination of both. These mechanisms 
will be discussed in greater detail in Chapters 5 and 6.
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Figure 1.8 The vast array of identified cellular targets for NSAlDs and COX-2 
inhibitors. The diagram summarises some of the known targets of NSAIDs and 
COX-2 inhibitors, which results in growth inhibition or apoptosis. Signalling 
pathways which are implicated include PI3K/ Akt, MAPK, NF-kB and cyclin/ CDK 
complexes (Taken from Tegeder et a i 2001).
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There have been several attempts to classify COX inhibitors, using different criteria.
These include kinetic behaviour, such as competitive or covalent binding (reviewed I
I
by Fosslien 2000), selectivity of the COX isoforms (reviewed by Flower 2003), or '
chemically, referring to the individual groups as belonging to the salicylates, 
pyrazolones, fenamates, proprionates, oxicams and indomethacin.
Below, we briefly describe some characteristics of NSAIDs and then COX-2 
inhibitors that possess anti-proliferative or apoptotic potential and, therefore, anti­
cancer activity.
1.2.7.1 Non-selective COX inhibitors
Before the introduction of COX-2 inhibitors in 1999, all NSAIDs inhibited both 
COX-1 and COX-2. Aspirin was the first member of the NSAID family. Whereas 
aspirin inactivates COX activity of COX-1 by covalent binding, it modifies COX 
activity of COX-2 without covalent inhibition. Aspirin has non-COX inhibition 
related activities, which could be useful in anti-tumourigenesis; it can inhibit the NF- 
kB transcription factor (reviewed by Taketo 1998a).
Sulindac is an analogue of indomethacin and is a pro-drug that needs to be 
metabolised into sulindac sulphide to become biologically active (reviewed by Chau 
& Cunningham 2002). This can occur either hepatically or by colonic bacteria. 
Sulindac can also be converted to the sulphone metabolite, but this does not exhibit 
COX inhibitory activity. Sulindac compounds inhibit growth and Idll prostate cells in 
vitro, even in cells which over-express Bcl-2, a known mediator of cellular resistance 
to chemotherapy and radiotherapy (Lim et al. 1999)
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1.2.7.2 COX-2 selective inhibitors
DuP-697 was the first COX-2 inhibitor described in the literature (reviewed by 
Flower 2003). DuP-697 iiTeversibly and competitively inactivates COX-2 (Copeland 
et ah 1994). In a study in rats, Gans et al (1990) showed that DuP-697 had 
compai’able anti-inflammatory, anti-pyretic and analgesic activity in inflammation 
induced pain to piroxicam, indomethacin and sulindac, but did not produce 
gastrointestinal toxicity or altered renal blood flow.
Celecoxib (Celebrex®, Seaiie-Monsanto and Pfizer) was the first COX-2 inhibitor to 
be approved by the FDA for the treatment and management of inflammation in 
rheumatoid arthritis and osteoarthritis in 1998. A year later, its use was expanded as 
an adjunct to usual care in familial adenomatous polyposis (FAF). Celecoxib is a 
benzene sulphonamide. Reported IC50 values for the COX isoforms are: COX-1 15 pg 
/mL, COX-2 0.04 pg/ mL (Kulp et al. 2004). In cells expressing either COX-1 or 
COX-2 I C 5 0  values aie: 13-15 and 0.05 pg/mL respectively i.e. celecoxib has 
approximately 375 selectively for COX-2 over COX-1 (reviewed by Davies et al. 
2000). Commercially, oral doses of 100 mg and 200 mg aie available. Celecoxib has 
known in vitro and in vivo anti-tumour activity. This will be explored further in 
Chapters 4, 5 and 6 .
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Figure 1.9 The celecoxib molecule. The chemical structure of the COX-2 inhibitor 
celecoxib.
NS398 was the second COX-2 inhibitor described in the literature. NS398 was 
reported as a compound that had similar anti-inflammatory and analgesic properties as 
indomethacin but minimal stomach lesions (Reviewed by Taketo 1998a). Copeland et 
al. (1994) provided evidence that NS398 iiTeversibly and competitively inactivates 
COX-2, in a manner similar to Du-P697. This agent has been shown to cause 
apoptosis in a vaiiety of cancer cell lines and to decrease in vivo xenograft tumour 
growth (Liu et al. 1998, 2000).
Rofecoxib, like celecoxib has pro-apoptotic activity, but it less potent and is slower 
acting. Whereas celecoxib can induce cell kill within a few hours in prostate cancer 
and colon cancer cells, higher doses of rofecoxib take days to cause the same effect 
(Johnson et al. 2001, Yamazald et al. 2002). Rofecoxib has 10 times more selectivity 
for COX-2 than celecoxib (reviewed by Gasparini et al. 2003).
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1.3 Aims of the Project
We have seen that COX-2 protein is reported to be elevated in several cancers, 
although not unequivocally so in the literature for prostate cancer (Chapter 1.2.6). 
However, COX-2 has tumoungenic properties (Chapter 1.2.5). One of these 
properties is to attenuate the apoptotic response to a variety of cytotoxic stimuli 
(Chapter 1.2.5.2).
We, therefore, wished to assess the effect, if any, of COX-2 on the apoptotic or 
growth inhibitory response of prostate cancer cells following cytotoxic insult. In order 
to answer this question we used two approaches to elevate COX-2 protein in our cells, 
both stable and tiansient transfection of human COX-2 cDNA and pharmacological 
induction of COX-2. If COX-2 expressing cells were found to be resistant to 
apoptosis or growth inhibition then the nature of the resistance would be investigated. 
Further, we performed gene microaixay experiments in LNCaP COX-2 null and over­
expressing cells to identify genes which were differentially expressed due to COX-2.
It should also be noted that COX-2 is not always reported to be expressed in prostate 
cancer cells (discussed in Chapter 3) and it could be argued that the rationale for this 
study is weakened. We have used primarily late-stage disease, metastatic cell lines 
and (as discussed in Chapter 3) COX-2 expression may be temporal during the 
inflammatory phase of the carcinogenic process and reduced in end-stage disease.
61
CHAPTER 2
MATERIALS AND METHODS
62
Chapter 2 Materials and Methods
Chapter 2 Materials and Methods
2.1 Reagents
Agilent Technologies, West Lothian, UK 
RNA NanoLabchip®
Alexis Biochemicals, Notts, UK 
SuperKilleH^ human recombinant TRAIL
Ambion (Europe Ltd.), The RNA Company 
RNase-free microfuge tubes, RNase Zap
Amersham Biosciences
Cy®3 and Cy®5 dCTP fluorescent cDNA labels
Bio-Rad Laboratories Ltd, Herts, UK 
Bio-Rad DC protein assay kit
BioSource International Inc., Nivelles, Belgium 
Polyclonal antibodies to total Akt and phosphor-Akt ser'^ ^^
CalbioChem (Merck Biosciences), Beeston, Nottingham, UK 
Wortmannin, goat anti-mouse IgM-HRP conjugate
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Cayman Chemical, (IDS Ltd), obtained from Alexis Corp.
16,16-dimethyl Prostaglandin E2 ; LY294002, antibody to COX-2, COX-2 protein 
standard
Corning Incorporated, Schiphol, Netherlands 
UltraGAPS'^^ slides for gene microanay
DakoCytomation, Glostrup, Denmark
Anti-mouse and anti-rabbit HRP-conjugated immunoglobulins
Eastman Kodak Company, (distributed by Sigma Aldrich, Poole, UK)
Kodak BioMax Light Film
PC-3 and DU145 cell lines 
Genosys Inc., Haverhill, UK
Sense and anti-sense primers for COX-2 and P2-niicroglobulin
Immunotech Coulter, Bucks, UK 
CD95 Fas IgM (CH-11 clone)
Invitrogen-Gibco Life Technologies, Paisley, UK
NuPAGE® Novex Bis-Tris gels, MOPS electrophoresis running buffer, Western 
blotting transfer buffer, foetal bovine serum (FBS), neomycin antibiotic
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Oncogene Research Products, (distributed by CN Biosciences, Beeston, UK)
Antibody to p-actin, Annexin V-FITC (Fluorescein isothiocyanate) apoptosis 
detection kit
Pharmacia, NY, USA 
Celecoxib
Fierce, Æ, U&4
SuperSignal® West Pico Chemiluminescent Substrate 
Promega Corporation, Southampton, UK
ImProm-n™ Reverse Transcriptase, Recombinant RNasin® Ribonuclease Inhibitor 
oligo(dT)i5 primer, dNTPs, reverse transcription buffer, Taq DNA Polymerase, Mg^ '*'- 
PCR buffer, diethylpyrocarbonate (DEPC) H2O
Qiageninc, West Sussex, UK
HiSpeed Plasmid Midi Kit, Cancer Oligos for gene microarray
Roche Diagnostics Corporation, East Sussex, UK 
FuGene 6  Transfection reagent
Santa Cruz Biotechnology Inc (Autogen Bioclear), Wiltshire, UK 
Antibodies to Bcl-2, B c1-x l , cyclin B l, p27^'^\ p53, survivin
65
Chapter 2 Materials and Methods
Schleider and Schuell BioScience, (distributed by VWR International, Lutterworth, 
HybriSlip™ plastic cover slips 
Sigma, Poole, Dorset, UK
Tri reagent™, 0.4% Trypan blue, L-glutamine, Porcine Trypsin-EDTA, RPMI-1640 
and DMEM cell culture media, Ribonuclease A, propidium iodide (PI), Etoposide 
(VP-16), Sulindac, Carboplatin, Tween®20 detergent (polyoxyethylene sorbitan 
monolaureate), Nonidet® P-40 detergent, sodium dodecyl sulphate (SDS), 
phenylmethyl sulphonyl fluoride (PMSF), aprotinin, leupeptin, sodium orthovanadate 
(NaV0 4 ), 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 
ethidium bromide, Lipopolysaccharide (LPS) from Salmonella abortus equi
Stratagene, Cedar Creek, Tx, USA 
Universal human reference for gene microaiTay
2.2 Solutions and buffers
Phosphate buffered saline (PBS)
For x l strength: 80.0g NaCl, 11.5g Na2HP0 4 , 2.0g KCl, 2.0g KH2PO4 in lOL de­
ionised water.
Tris buffered saline -  tween (TBS-T)
For x5 strength: 12. Ig Tris base (C4H11NO3), 40.0g NaCl, in IL de-ionised water, 
adjusted to pH7.6 with concentrated HCl, 0.05% Tween®20 detergent.
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Cell lysis buffer
50mM Tris-HCl (C4H11NO3 HCI), 150mM NaCl, adjusted to pH7.0 with concentrated 
HCl, in de-ionised water. This was supplemented with 1% Nonidet® P-40 detergent, 
0.2% SDS, 1 mM phenylmethyl sulphonyl fluoride (PMSF), 10 pg/mL aprotinin, 10 
pg/mL leupeptin and 1 mM sodium ortho vanadate (NaV0 4 ), made fresh on ice, prior 
to cell lysis.
Electrophoresis running buffer
Purchased as x20 strength solution (Invitrogen Corp), diluted with de-ionised water: 
0.05M 3-(N-morpholino) propane sulphonic acid (MOPS), 0.05M Tris base 
(C4H 11NO3), 3.45mM SDS, l.OmMEDTA, pH7.7.
Western blotting transfer buffer
Purchased as x20 strength solution (Invitrogen Coip), diluted with de-ionised water: 
pH 8.3, supplemented with 10% methanol for 1 gel transfer or 20% methanol for 2 
gels.
Nitrocellulose membrane stripping buffer
2% w/v SDS, 62.5mM Tris HCl adjusted to pH6 . 8  with NaOH, lOOmM P- 
mercaptoethanol in 200 mL de-ionised water.
2.3 Cell culture
Prostate cancer cell lines PC-3 and DU145 were obtained from the European 
Collection of Cell Cultures (ECACC). LNCaP stable transfectants (Neo and COX-2)
67
Chapter 2 Materials and Methods
were a kind gift from Dr Atsushi Mizokami (Kanazawa University, Japan). Stock 
cells of LNCaP transfectants were treated every third passage with 0.35 mg/mL 
neomycin to select for cells which maintained the plasmid containing either the Neo 
or COX-2 cDNA. All prostate cancer cells were grown in RPMI-1640 medium, 
supplemented with 10% FBS and 2 mM L-glutamine. HeLa cells, a kind gift from Dr 
George Kass, University of Surrey, were grown in DMEM medium, also 
supplemented with 10% FBS and 2 mM L-glutamine. FBS was heat inactivated at 
55°C for 2 hours prior to use.
Cells which were not used for experiment were treated at each passage with 20 pg/mL 
ciprofloxacin for prophylaxis against mycoplasma infection.
Cells were grown in a humidified incubator with 5% CO2 at 37°C. At each passage, 
cells were detached from the culture flask with porcine trypsin-EDTA solution. Cells 
were counted using a haemocytometer prior to plating for experiments.
2.4 Cell cytotoxicity assays
Cell cytotoxicity assays were perfoimed via MTT assay, using the method described 
by Mosmann (1983). Drugs were all dissolved in dimethyl sulphoxide (DMSO) as 
stock solutions and stored at -20°C. All cells were plated at 3xlO" /^mL in 96 well 
plates in a volume of 200 pL. Cells were allowed to grow and attach in the humidified 
incubator for 24 hours at 37°C and 5% CO2 , unless stated otherwise. Typically, eight 
different concentrations of drugs were used, with a 2-3 log fold range (0.5-100 pM for 
celecoxib, 0.2-50 pM for etoposide, 5-1000 pM for sulindac). Drug sensitivity data 
was obtained in both 10% FBS and serum-free conditions. For assessment of drug 
sensitivity in 10% serum, 50 pL of drug was added to 200 pL of medium already 
present in the wells. For drug sensitivity in serum-free conditions, drugs were
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dissolved in serum-free RPMI medium and 250 pL of it replaced the 10% medium. 
Cells were incubated with drug for 48-72 hours (equivalent to 3 or 4 cell doublings). 
The assay was terminated when the cells were incubated with 0.05 mg/mL MTT for 
approximately 4 hours at 37°C. The medium was removed and the formazan crystal 
products were dissolved in 200 pL DMSO. The absorbance of each well was read at 
540 nm using an automated plate reader (Labsystems Multiskan RC plate reader) with 
Genesis 3.05 software. A graph of cell viability against drug concentration was 
produced from the mean absorbance values, by calculating the percentage growth of 
drug treated cells against control cells. For each drug concentration treatment was set 
up in triplicate or quadruplicate, which were averaged and the percentage of control 
growth calculated. The I C 5 0  for each experiment was inteipolated from this dose- 
response curve. The I C 5 0  values from a minimum of three independent experiments 
were averaged and reported here, along with the standard deviation.
For experiments requiring Trypan blue exclusion cell counts, cell pellets were re­
suspended in serum free RPMI-1640 medium and equal volumes of cell suspension 
and Trypan blue solution were mixed and applied to the haemocytometer and counted. 
This was repeated in triplicate for control and all drug tieated cells. Percentage of 
viable cells at each drug concentration was calculated by dividing the percentage of 
viable cells at a particular drug concentration by the percentage of viable control cells.
2.5 Western blot analysis
Cells were giown in either T25 or T75 flasks, washed in PBS, trypsinised as per 
noimal, centrifuged at 1200 ipm for 5 minutes, resuspended in ice cold PBS and 
centrifuged again. The supernatant was removed and the cell pellet was incubated for
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10 minutes on ice with freshly prepared cell lysis buffer. Cells were lysed using ultra- 
sonication with a MSE Soniprep 150 sonicator, on ice for 20 seconds.
Cell protein content was estimated using a modified Lowry method, the Bio-Rad DC 
protein assay, according to manufacturer’s instructions. SDS was added to 1-5% 
NaOH solution in ratio 1:50 and 25 pL was added to cell lysate samples or BSA 
protein standard in the range 0.2-1.5 mg/mL in a 96-well plate. 200 pL Folin reagent 
was added, mixed, allowed to stand at room temperature for 15 minutes. The 
absorbance was taken at 690 nm in a Labsystems Multiskan RC plate reader. Protein 
concentration of cell lysates was estimated by inteipolation of the BSA protein 
standai'd curve.
Cell lysates were prepared in 0.5 M dithiothreitol (DTT) reducing buffer (protein load 
ranged from 25 to 100 pg), heated for 5 minutes at 85°C then subject to 
electrophoresis. The protein content was separated on an SDS-PAGE NuPAGE® 
Novex Bis-Tris gels (either 10%, 12% or 4-12% gradient gel and transfened to a 
nitrocellulose membrane in an assembly provided by the manufacturer. Non-specific 
binding sites on the membrane were blocked with a protein solution ranging from 2  -  
5 % BSA or milk in TBS-Tween®20.
Primary antibodies (either mono- or polyclonal), dissolved in a protein solution at the 
concentration recommended by the manufacturer, were used to probe the 
nitrocellulose membrane for 1 hour at room temperature or at 4°C overnight by gently 
shaking. Non-specific Ig antibodies in place of primary antibodies were not used as 
negative controls. Appropriate secondary horse radish peroxidase (HRP) conjugated 
IgG or IgM antibodies (anti-mouse, goat or rabbit) were used against the primaiy 
antibody, in a protein solution recommended by the manufacturer for 1 hour at room 
temperature. The membrane was washed after exposure to both the primary and
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secondary antibody with TBS-T 3 times for 5 minutes. The signal was detected using 
X-ray film via enhanced chemiluminescence (ECL) reagents. To demonstrate 
equivalent protein loading, the same membrane was stripped by incubating the 
membrane at 60°C for 30 minutes in 2% w/v SDS, 62.5 mM Tris-HCl pH 6 .8 , 100 
mM (3-mercaptoethanol, and gentle shaking. Then the membrane was exposed to a 
murine anti-P-actin IgM antibody at a 1:10000 dilution. A goat anti-mouse IgM 
conjugated to HRP was used at a 1:2000 dilution.
2.6 RT-PCR mRNA analysis
Total RNA was extracted using a guanidine thiocyanate/ phenol method. TRI 
reagent™ was added to adherent cells to dissociate nucleoprotein complexes. 
Chlorofoim was added to separate RNA, DNA and protein phases. After 15 minutes 
centrifugation at 13000 ipm and 4°C, RNA was decanted with isopropanol addition. 
After a brief ambient temperature incubation, samples were centrifuged at 13000 ipm 
and 4°C, the RNA pellet washed with 75% ethanol and dissolved in RNase free water. 
The PCR machine used for both reverse transcription (RT) and polymerase chain 
reaction (PCR) was the Techne Touchgene (supplied by Jencons-PLS). Total RNA 
was converted to cDNA using ImProm-n^^ reverse transcriptase kit from Promega 
Corp (250 mM Tris-HCl pH 8.3, 375 mM KCl, 50 mM DTT, dNTPs, 5 mM MgClg 
and a ribonuclease inhibitor RNasin. Priming for the RT reaction was done with 
oligo(dT)i5 primers. As a negative control no RNA was added to the oligo(dT) for 
priming. RNA was primed with 50 ng/mL random hexamers, 10 mM dNTPs and 
DEPC water for 5 minutes at 65°C, followed by at least one minute on ice. RT buffer, 
0.1 M DTT and RNase inhibitor were then added and incubated at 25°C for 2 
minutes. 200 units of Superscript II reverse transcriptase was added, incubated at
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25°C for 10 minutes, then 42°C for 50 minutes and the reaction teiminated at 70°C 
for 15 minutes. RNaseH was added and the reaction mix incubated at 37°C for 20 
minutes. Samples were then subject to the PCR reaction.
cDNA was amplified using Taq Polymerase (5 units/ pL), buffer containing 500 mM 
KCl, 100 mM Tris-HCl (pH 9.0), 1% Triton® X-100 and 15 mM MgCh 10 mM 
dNTPs. 10 pM sense and anti-sense primers were obtained from Genosys Inc.
To ensure equivalent loading of cDNA for PCR, total RNA was approximated by 
peiforming RT-PCR of the p2-microglobulin housekeeping gene. The sense strand 
was 5 ’ - ACCCC ACTG AAA AAGATGA-3 ’ ; anti-sense sense strand was 5’- 
ATCTTCAAACCTCCATGATG-3’. After an initial dénaturation step of 94.0°C for 3 
minutes, 35 cycles of PCR were performed: denature at 94.0°C for 45 seconds, anneal 
at 54.0°C for 45 seconds and chain extension at 72.0°C for 90 seconds. This gave rise 
to a 1 2 0  bp product which was separated on a 1 .2 % agarose gel and visualised with 
ethidium bromide. The strength of the bands were used to approximate levels of total 
RNA and cDNA loading for COX-2 PCR was adjusted accordingly.
2-7 Plasmid amplification and purification
Before PC-3 cells could be transfected with either pBOSNeo (mock transfectant) or 
pBOSNeoCOX-2 (COX-2 transfectant), the plasmids had to be amplified. The 
construct of the plasmid is shown in Figure 2.1. These plasmids were a kind gift from 
Dr Atsushi Mizokami (Kanazawa University, Japan).
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Figure 2.1 pBOSNeo Plasmid Gene Construct. Map of the plasmid constructs used 
for both transient (PC-3) and stable (LNCaP) transfection. For our studies either no 
cDNA or COX-2 cDNA had been inserted in the Xbal restriction sites. Taken from 
Fujita et al. (2002).
Amplification was performed in the competent E. CoU strain DH5a. 0.5 pg pBOSNeo 
and pBOSNeoCOX-2 plasmid were added to 50 pL E. Coli and kept on ice for 30 
minutes. The cells were heat shocked at 42°C for 45 seconds then left on ice for 5 
minutes. 200 pL Luria broth was added and cells were incubated at 37°C for 60
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minutes. A further 50 mL Luria broth was added which contained 0.125 pg/mL 
ampicillin, and left to agitate overnight at 37°C. The cells were then centrifuged at 
3000 ref for 12 minutes at room temperature. The supernatant was removed and the 
cells frozen at -20°C prior to plasmid purification.
Plasmid was isolated using a plasmid DNA isolation kit from Qiagen Ltd, a modified 
alkaline lysis procedure, according to the manufacturer’s instructions. Briefly, 
transfected cells were reconstituted in 50 mL Luria broth and harvested by 
centrifugation at 6000g for 15 minutes at 4°C. After removing the supernatant, cell 
lysis was achieved using 6  mL of a resuspension buffer containing RNase A. 
Precipitation of genomic and plasmid DNA was achieved with 6  mL of lysis buffer. 
The precipitate was filtered through the manufacturer’s cartridge. After neutralisation 
and wash, DNA was precipitated with isopropanol. This eluate was forced through the 
manufacturer’s precipitator and washed with 70% ethanol. The membrane was dried, 
and DNA eluted with 1 mL DEPC water.
Plasmid yields were quantified by agarose gel analysis. 1 pL of the purified plasmids 
were subject to electrophoresis in a 1.2% agarose gel (0.2 pg/mL ethidium bromide) 
at 90V. Lambda (!) standards in the range 200 -  1000 ng were used along with a 10 -  
0.25 kbp DNA ladder.
2.8 Transient transfection
PC-3 cells were plated at IxloVmL in 96 well plates in 200 pL of 10% serum 
supplemented RPMI-1640 medium. The cells were allowed to attach and grow 
overnight. After 24 hours the medium was replaced with serum-free medium. 
Concentrations of plasmid DNA and transfection medium and duration of transfection 
were determined by optimisation studies to determine the conditions which produced
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the greatest level of COX-2 transfection. FuGene 6  transfection reagent was mixed 
with serum-free media and either Neo or COX-2 plasmid in sterile eppendorf tubes 
and allowed to mix at room temperature for 15 minutes. The DNA/ transfection media
I
complex was added drop wise to the cells whilst shaking gently. The cells were I
incubated with plasmid DNA and transfection medium for 4 hours at 37°C. This
created either PC-3-Neo or PC-3-COX-2 transient transfectants. The medium was
then changed back to 1 0 % serum containing cytotoxic drugs at the specified
concentrations. To ensure transfection was successful, the procedure was scaled up in
6  well plates. Cells were recovered by trypsinisation, and COX-2 protein levels
assessed by Western blot (see Chapter 2.4 for Western blot protocol).
2.9 Flow cytometric ceii cycle analysis
LNCaP-Neo and LNCaP-COX-2 cells were plated at 3xlO" /^mL in T25 flasks and 
allowed to adhere for 24 hours. The cells were treated for either 24 or 48 hours with 
either 50 pM or 100 pM carboplatin. Both floating and attached cells were harvested, 
centrifuged at 1300rpm for 3 minutes and then washed in ice cold PBS. The samples 
were vortexed and ice cold 75% ethanol in PBS was added drop-wise. The samples 
were then stored at 4°C for a minimum of 24 hours. The cells were centrifuged at 
1300rpm for 3 minutes and washed in ice cold PBS and centrifuged again. The cells 
were resuspended in 500 pL PBS which contained 0.8mg/mL ribonuclease A and 
lOpg/mL PI. The samples were incubated at 37°C for 30 minutes in the dark, and 
analysed using a Beckman Coulter Epics XL flow cytometer (argon laser, excitation 
wavelength 488 nm). A minimum of 20000 events were acquired and analysed in FL- 
3 (PI detector, 620 nm).
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2.10 Annexin V/ PI apoptosis assay
Apoptosis was detected by flow cytometric analysis of AVI PI binding using a kit 
from Oncogene, following the manufacturer’s instructions. Briefly, LNCaP-Neo and 
LNCaP-COX-2 cells were plated at SxlO'^/mL in T25 flasks and allowed to adhere for 
24 hours. The cells were treated for either 24 or 48 hours with either 50 pM or 100 
pM carboplatin. Both floating and attached cells were harvested and resuspended in a 
media binding reagent, which enhanced AV binding to PS in tissue culture media. 
A V-FITC was added to a concentration of 0.002% and incubated at room temperature 
for 15 minutes in the dark then centrifuged for 5 minutes at 1000 ipm. The media was 
removed and the cells resuspended in ice cold binding buffer (10 mM HEPES, pH 7.4, 
150 mM NaCl, 2.5 mM CaCL, 1 mM MgCl2 , 4% BSA). PI was added to a 
concentration of 0.02%, on ice and away from light and analysed using a Beckman 
Coulter Epics XL flow cytometer (ai'gon laser, excitation wavelength 488 nm). A 
minimum of 20000 events were acquired analysed in FL-3 (PI detector, 620 nm).
2.11 Gene Microarray Analysis
RNA was extracted from LNCaP-Neo and LNCaP-COX-2 cells as described in 
section 2.6. The quality of the RNA was checked with an Agilent 2100 Bioanalyser 
using an RNA NanoLabchip® according to the manufacturer’s instructions. The RNA 
was also diluted 1 in 10 with RNase free water and quantified using a nanodrop 
spectrophotometer (Agilent).
5 pg total RNA, 3 pg/pL random primers, 2 pg/pL oligo(dT) primers, 2 pL spike mix 
(universal ScoreCard, as analytical control) were prepared to a final volume of 20 pL
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with nuclease free water, then incubated at 70°C for 10 minutes and placed on ice. 
The reaction was also prepared with 5 pg total RNA from a universal human 
reference (Stratagene), and used as an internal control for the normalization of the 
microaiTay data.
Cy®3 (for the test sample) and Cy®5 (for the universal human reference) labelling 
mixes were prepared, protected from light, both at 0.02 mM, using ChipShot™ RT 
buffer and RT, 5 mM MgCL, dNTP mix and nuclease free water to a final volume of 
20 pL. This labelling mix was added to each primed RNA solution respectively, spun 
briefly, incubated at 25°C for 10 minutes, then at 42°C for 2 hours. RNase treatment 
was performed after labelling total RNA, by adding 1 pL RNase H (1.5 U/pL) and 
0.35 pL RNase solution and incubating at 37°C for 15 minutes, away from light. 
cDNA was purified using a Spin-X® column following the manufacturer’s 
instructions. Briefly, binding paiticles, 3 M sodium acetate and binding solution were 
added to 40 pL of labelled cDNA, vortexed gently for 10 seconds and incubated at 
22-25°C for 1 minute. The entire contents were applied to the column and centrifuged 
at lOOOOg for 1 minute. The flow through was discarded and the column washed with 
500 pL of 80% ethanol and centrifuged at lOOOOg for 1 minute. This wash step was 
repeated 3 times, with the flow through being discarded. cDNA was eluted with 60 pL 
of elution buffer and stored away from light at -20°C. The amount of Cy®3 and 
Cy®5 incorporation (FOI) in the cDNA was quantified using the nanodrop.
Printing of 3000 cancer oligos (from Qiagen Inc.) onto microarxay slides was 
performed by the microanay group facility, led by Professor Colin Smith.
Prior to hybridization, the arrays were prepared according to manufacturer’s 
instructions. They were immersed in sodium borohydride solution at 42°C for 20 
minutes and then transferred to a wash solution at ambient temperature for 30
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seconds. This last step was repeated. The arrays were then incubated in a pre­
hybridization solution at 42°C for 15 minutes and washed at ambient temperature 
twice, then transferred to nuclease free water and incubated at ambient temperature 
for 30 seconds and dried by centrifugation at 2500 rpm for 2 minutes.
30 pmoles of sample cDNA and human reference were mixed in a sterile 1.5 mL 
Eppendorf and samples were dried using a speed-vacuum centrifuge (UniScience) at 
1200 rpm for 45 minutes. Then the cDNA was dissolved in 32 pL of the 
manufacturer’s hybridization solution and incubated at 95°C for 5 minutes. The array 
was placed in a hybridisation chamber and the 32 pL labelled cDNA was pipetted 
onto the array and a plastic cover slip (HybriSlip™, Schleider and Schuell 
BioScience) was carefully placed onto the array. The chamber was sealed and 
incubated at 42°C for 16 hours overnight.
Following hybridization, the arrays were washed in manufacturer’s solutions at 42^C 
to remove the plastic cover slip from the array, followed by several washes at ambient 
temperature, according to the manufacturer’s instructions. The arrays were dried by 
centrifugation at 2500 rpm for 2 minutes and stored away from light in preparation for 
scanning. The arrays were scanned on an Affymetrix 428 array scanner and the data 
were then imported into analysis software : BlueFuse (BlueNome, Oxford, UK). The 
16bit TIFF images were processed with normalisation per cDNA spot relative to the 
internal reference control (Cy5 labelled). This was earned out by dividing control 
channel per chip and data were normalised to the 50^  ^percentile. Data were omitted 
with p values >0.05. BlueFuse data were then imported into GeneSpring (version 4.2, 
Silicon Genetics Inc/Agilent Technologies UK Ltd, Stockport, UK) for hierarchical 
clustering to produce a ‘gene tree’ using Spearman’s correlation (unsupervised). The 
arrays were analysed using Blue Fuse software and the data was exported into
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GeneSpring for the statistical analysis. GeneSpring uses the ‘centroid’ clustering 
method. This is based on the distance between 2 clusters being regarded as the 
distance between the averages of the data points under one branch and the averages of 
the data points under another.
2.12 COX-2 Induction with PM A
PC-3 cells were plated at 3xlO'^/mL in 10% serum in 96 well plates and allowed to 
grow/ attach for 24 hours. The media was then changed to serum free and drug was 
added at the indicated concentration either alone (this constituted the control) or 
concomitantly with 100 nM PMA. Cells and drugs with or without PMA were 
incubated for 72 hours at 37°C in a humidified incubator. Cell viability was 
deteraiined with the MTT assay, as described in section 2.4.
2.13 Statistical analysis
Data was expressed as mean ± standard deviation. Significance was determined by the
2-tailed, paired, Student’s t-Test using Microsoft Excel. P-value < 0.05 indicated a 
significant difference.
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Chapter 3 Development of Cell Line Models Over- 
expressing COX-2
3.1 Aims
To address the main hypothesis of this study, that COX-2 expression effects apoptotic 
sensitivity to cytotoxic agents and to other apoptotic inducing agents, the levels of 
COX-2 enzyme in the cell lines had to be determined. We assessed both the 
constitutive (basal) protein and mRNA levels of COX-2 using Western blotting and 
RT-PCR respectively in LNCaP, PC-3 and DU 145 cells. As COX-2 protein could not 
be detected in any of our prostate cancer cell lines, mechanisms to elevate cellulai* 
COX-2 levels were sought. These included both stable and transient transfection and 
pharmacological induction. This chapter describes the rationale and development of 
these cell line models over-expressing COX-2.
3.2 Introduction
Cancer cell lines can either be derived from primary cancer or metastatic sites. Cell 
selection problems are minimised if tissue from metastatic sites selected for in vitro 
study. Therefore, metastatic lines have proved to be more reliable models for study. In 
our studies the three most commonly used prostate cancer lines (PC-3, DU 145 and 
LNCaP, which are all metastatic) were used.
The PC-3 cell line was established by Kaighn et al. (1979) from tumour tissue 
obtained from lumbar vertebra removed from a 62 year old Caucasian who presented 
with urinary retention, weight loss and anaemia. The PDT was reported to be
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approximately 33 hours. A biopsy revealed poorly differentiated prostatic 
adenocarcinoma. Hence, PC-3 is a prostate cancer cell line derived from bone 
métastasés of human prostatic cancer.
Stone et al. (1978) established the DU145 cell line from a 69 year old Caucasian who 
presented with lymphocytic leukaemia and had been given diethylstilbestrol hormone 
treatment. An autopsy revealed metastasis to the femoral neck, vertebral column, 
liver, lungs and brain. The histological appearance of the prostate and brain tumours 
was similar, both poorly differentiated. Tissue was taken from a metastatic CNS 
lesion and taken for in vitro culture. PDT is reported to be 34 hours. Hence, DU145 is 
a metastatic human prostate cancer line, as for PC-3, but it is derived from a CNS 
lesion.
The LNCaP cell line was obtained from a 50 yeai* old Caucasian with moderately 
differentiated adenocaicinoma by Horoszewicz et a l (1980). The patient had rapidly 
advancing disease which was resistant to hoimonal therapy and subsequently to 
chemotherapy. Cell culture was started from a lymph node needle aspiration. The 
cells were initially reported to have a PDT of approximately 72 hours. Thus, LNCaP 
is cell line also of human origin from lymph node métastasés of prostatic 
adenocarcinoma.
The levels of COX-2 in human prostatic cancer samples was discussed in Chapter 
1 .2 .6 , where it was concluded that a consensus on the levels, temporal nature and 
mechanisms of COX-2 elevation in prostate carcinogenesis has not been reached. We 
assessed the levels of COX-2 mRNA and protein in our cells. The results aie reported 
in this chapter.
Transfection of the COX-2 gene into cell lines is the prefened method to elevate 
COX-2 protein above basal levels in order to assess the biological effects of this
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protein. Although transfection is a ‘clean’ method for elevating a cellular protein, it 
has the disadvantage that the expression of the transfected protein is not under control 
of normal cellular control mechanisms, as it is constitutively expressed via a viral 
promoter. We used LNCaP cells stably transfected with a plasmid mammalian 
expression vector called pBOS containing human COX-2 cDNA (pBOS-Neo-COX-2) 
or empty plasmid (pBOS-Neo). The resultant cell lines were designated LNCaP- 
COX-2 and LNCaP-Neo respectively. The plasmid contains a gene which confers 
resistance to neomycin, thus allowing transfected cells to be selected. A genetic map 
of the plasmid construct is shown in Chapter 2.7. These LNCaP cells and the plasmids 
alone were a kind gift from Dr Atsushi Mizokami (Kanazawa University, Japan).
We also performed a transient transfection of PC-3 using these plasmids, to provide 
us with an additional cell line over-expressing COX-2 via transfection. It should be 
noted that this method (i.e. without long teim selection of transfected cells with 
neomycin, as performed when establishing a stably transfected line) produces an 
increase in transfected gene product over a short period of time and often the increase 
in protein elevation is not as great as that observed following stable transfection. 
Conversely, another cellular approach to elucidate COX-2 function is to deplete 
cellular COX-2 levels in a controlled fashion. Song et al. (2002) cloned COX-2 anti­
sense cDNA into a tetracycline response element and perfoimed a stable transfection 
in PC-3, DU145 and LNCaP. In this model, the addition of tetracycline mediates 
expression of anti-sense COX-2 mRNA which interferes with and reduces the levels 
of endogenous mRNA. Thus, cellular COX-2 protein levels can be effectively 
switched on or off in the presence or absence of tetracycline, the agent which controls 
the expression of the gene cloned to the promoter.
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In addition to transfection, COX-2 can be induced pharmacologically i.e. use of 
endogenous or chemical agents to induce COX-2 gene expression. This method is 
considered less precise than transfection because in addition to COX-2 induction, a 
variety of other genes may also be expressed concomitantly, making the true 
biological response of COX-2 more difficult to interpret. A number of endogenous 
and pharmacological inducers of the COX-2 gene are known (Chapter 1.2.4). We 
attempted to induce COX-2 in PC-3, LNCaP and DU145 using phorbol 12-myristate 
13-acetate (PMA) and LPS.
PMA is a diacylglycerol analogue and therefore an activator of PKC and it is a known 
tumour promoter. PMA has been used to induce COX-2 in a variety of different cell 
types, for example, prostate cancer cells (Zha et al. 2001), oesophageal cancer cells 
(Souza et al. 2000), human umbilical cells (Ristimaki et al. 1994) and human foresldn 
fibroblasts (Gilroy et al. 2001).
LPS is a component of gram negative bacteria cell walls and a known pyrogen (Inoue 
et al. 1995). It perfoims a protective function for bacteria such as Salmonella abortus 
equi but it also stimulates human mononuclear cells to produce TNF and activates 
macrophages. As described in Chapter 1.2.4, TNF can induce COX-2, and in this 
context it is part of the host inflammatory response against the bacteria in 
immunological cells. Inoue et al. (1995) in vascular endothelial cells and Monick et 
al. (2002) in human alveolar macrophages have used LPS to induce COX-2 protein. 
Thus, we have attempted to establish a minimum of two models of COX-2 over­
expression using widely used prostate cancer cell lines and the techniques of 
transfection and gene induction, with the understanding that each technique has 
limitations and disadvantages not only when compared with each other but also with 
normal physiological induction and regulation of COX-2.
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3.3 Results -  Cellular COX-2 mRNA and protein levels
3.3.1 LNCaP stable transfectant
In order to assess the effect COX-2 may have on the cellular response to cytotoxic 
treatment, the amount of COX-2 mRNA and protein expressed by three prostate 
cancer cells PC-3, DU145 and LNCaP had to be assessed. RT-PCR was used to detect 
cellular COX-2 mRNA levels and Western blotting was used to detect cellular COX-2 
protein levels. Materials and Methods are described in Chapter 2. DU145 and parental 
LNCaP (LNCaP-Neo) do not express COX-2 mRNA, whereas a little was detected in 
PC-3 (Figure 3.1). There was strong COX-2 mRNA expression in LNCaP-COX-2.
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Figure 3.1 COX-2 mRNA levels in prostate cancer cells. Levels of COX-2 mRNA 
in prostate cancer cells PC-3, DU 145 and stable LNCaP transfectants -Neo and - 
COX-2. Bands show 300 base pair COX-2 PCR and 120 base pair Pi-microglobulin 
products. Isolated RNA was reverse transcribed, amplified by PCR using specific 
primers as described in Materials and Methods, run on 1.2% agarose gel and 
visualised with ethidium bromide.
As can be seen in Figure 3.2 COX-2 protein could not be detected in any parental 
prostate cancer cell line, even when 1 0 0  pg of protein was used (data not shown). 
Thus, these cell lines in their parental forms do not express COX-2 protein. However, 
stable transfection of LNCaP with COX-2 plasmid produces a cell line with a 
significant increase in COX-2 protein compared to LNCaP-Neo (Figure 3.2).
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Figure 3.2 COX-2 protein levels in prostate cancer cells. Near confluent PC-3, 
DU 145 and LNCaP eells were lysed as described in Materials and Methods. 50 pg 
protein was electrophoresed on a 1 0 % polyacrylamide gel, transferred to 
nitrocellulose membranes and exposed to murine IgG monoclonal COX-2 antibody 
(Cayman Chemical) at a 1:1000 dilution and a murine IgM p-aetin antibody 
(Oneogene) at a 1:10000 dilution. HRP conjugated antibodies to detect murine IgG 
(Sigma) and IgM (Calbiochem) were used at a 1:2000 dilution. Bands were detected 
using ECL (Pieree). 50 ng of purified COX-2 (Cayman Chemical) served as a positive 
control.
3.3.2 PC-3 transient transfectant
Having established that PC-3, LNCaP or DU 145 do not express COX-2 protein in 
their basal states, but stable transfection of LNCaP can produce a cell line which 
expresses high levels of COX-2 mRNA and protein, we transiently transfected the 
PC-3 line with either the empty plasmid or COX-2 plasmid to ereate PC-3-Neo or PC-
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3-COX-2 transient transfectants. LNCaP and PC-3 are cell lines with different 
characteristics. They differ in their dependence of androgen; PC-3 is androgen 
independent whilst LNCaP is androgen dependent. Another important difference is 
their p53 status; PC-3 does not express p53 whilst LNCaP has wild type p53.
Figure 3.3 shows the increase in COX-2 protein after transfection with the COX-2 
plasmid. Optimisation experiments showed that maximal induction occuiTed between 
36 and 48 hours post transfection and by 72 hours COX-2 protein could not be 
detected. In contrast, transfection with the empty Neo plasmid did not result in an 
increase in COX-2 protein over the same time period (data not shown). It should be 
stressed that immunoblots with 100 fig of protein had to be run to detect COX-2 
protein in this PC-3 model, whereas protein loads of 50 fig and less, and up to 15 
passages, consistently demonstrated strong COX-2 expression in LNCaP-COX-2 
(Figure 3.2).
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Figure 3.3 Levels of COX-2 protein in PC-3 cells following transient transfection.
PC-3 cells were lysed following transient transfection as described in Materials and 
Methods. 100 pg protein was electrophoresed on a 10% polyacrylamide gel, 
transferred to nitrocellulose membranes and exposed to murine IgG monoclonal 
COX-2 antibody (Cayman Chemical) at a 1:1000 dilution and a murine IgM p-actin 
antibody (Oncogene) at a 1:10000 dilution. HRP conjugated antibodies to detect 
murine IgG (Sigma) and IgM (Calbiochem) were used at a 1:2000 dilution. Bands 
were detected using ECL (Pierce). 50 ng of purified COX-2 (Cayman Chemical) 
served as a positive control.
3.3.3 COX-2 induction in PC-3
As well as elevating cellular COX-2 levels by both transient (PC-3) and stable 
(LNCaP) transfection, we attempted to induce COX-2 protein by inducing the gene 
pharmacologically or by using agents which stabilise COX-2 mRNA or protein. LPS 
has been shown to induce COX-2 in a variety of cell types (see section 3.2), but we 
were unable to demonstrate COX-2 induction in any of the prostate cancer cell lines 
with this agent. PMA is also a well-documented inducer of COX-2 via its ability to
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activate PKC. Figure 3.4 shows the effect of 100 nM PMA (a dose determined by 
optimisation experiments) on the PC-3 line. PMA produced an increase in COX-2 
with maximal induction observed at 72 hours. Thus, there was a narrow time window 
in which COX-2 was over-expressed using this method. This was a similar time 
window as that observed for transient transfection. It should be noted that 100 pg was 
needed for COX-2 detection. This effect was observed in serum free media only and 
not if cells were treated in serum supplemented media. The mechanisms as to why 
serum should influence the COX-2 gene induction process were not investigated. We 
were unable to induce COX-2 with PMA in DU 145 and LNCaP (data not shown).
COX-2 
P-actin
control 4 24 72
PMA treatment (hours)
Figure 3.4 COX-2 protein levels in PMA treated PC-3 cells. Cells were lysed as 
described in Materials and Methods, at 4, 24 and 72 hours after 100 nM PMA 
treatment in serum free medium. 100 pg protein was electrophoresed on a 10% 
polyacrylamide gel, transferred to nitrocellulose membranes and exposed to murine 
IgG monoclonal COX-2 antibody (Cayman Chemical) at a 1:1000 dilution and a 
murine IgM p-actin antibody (Oncogene) at a 1:10000 dilution. HRP conjugated 
antibodies to detect murine IgG (Sigma) and IgM (Calbiochem) were used at a 1:2000 
dilution. Bands were detected using ECL (Pierce).
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The results of transfected COX-2 both stably and transiently and gene induction aie 
summarised in Table 3.1.
Cell line model mRNA Protein
DU145 - -
LNCaP-Neo - -
LNCaP-COX-2 +++ +++
PC-3 + -
PC-3-Neo N.D. -
PC-3-COX-2 N.D. +
PC-3 plus PMA N.D. +
Table 3.1 Summary of COX-2 mRNA and protein levels. The levels of COX-2 
detected in our DU145, LNCaP and PC-3 cells. -  indicates none detected, + and +++ 
indicate weak and strong expression respectively, N.D. is not done.
3.4 Discussion
The data presented in this Chapter shows that our prostate cancer lines have low 
levels of COX-2 mRNA and protein. We were unable to detect COX-2 protein in PC- 
3, DU145 and LNCaP prostate cancer cells. Small amounts of COX-2 mRNA were 
present in PC-3 but not in DU145 or LNCaP. We did not investigate why COX-2 
mRNA in PC-3 did not translate into protein. Possible explanations include an mRNA
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transcript with reduced stability or rapid degradation of COX-2 protein in PC-3. This 
may also be the case for LNCaP-Neo and DU145.
Different research groups report a variation in the amounts of COX-2 mRNA and 
protein that these prostate cancer cells express. Zha et al. (2001) showed that both 
COX-2 mRNA and protein could not be detected at all in PC-3, LNCaP and DU145. 
Patel et al. (2005) and Lim et al. (1999) also report undetectable levels of COX-2 
protein in PC-3 and LNCaP. Subbaiayan et al. (2001) report all three lines to be 
negative for both COX-2 mRNA (measured by both Northern blotting and RT-PCR) 
and protein. However, Nithipatikom et al. (2002) found moderate levels of COX-2 
protein in PC-3 and Fujita et al. (2002) demonstrated some COX-2 protein and 
mRNA in LNCaP.
In contrast to our findings, Tjandrinawata et al. (1997) showed that PC-3 cells were 
negative for COX-2 mRNA but mRNA was detected in LNCaP. Hsu et al. (2000) 
found strong COX-2 protein in LNCaP and PC-3 and Song et al. (2002) also detected 
COX-2 protein in PC-3. The findings in the cuiTent study, namely that COX-2 protein 
could not be detected in any of our three parental cell lines, agree with some but not 
all the published research.
There are several possible reasons for these differences. The actual reported cell lines 
themselves may not be the same. Slight differences in cell culture conditions, such as 
the type of serum, antibiotic or culture media used may effect the expression of COX- 
2 or the stability of the mRNA or protein. Also, there are differences in detection 
methods used in these published studies, for example, immunoblotting,
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immunohistochemistry or mRNA analysis. Even if the same method is employed, use 
of different antibodies with varying performance could also be a factor.
Because COX-2 protein could not be detected in any of these three cell lines, methods 
were needed to elevate COX-2 protein in one or more of these cells. Transfection is a 
method of introducing sustained increases in cellular levels of a protein of choice. The 
gene of the desired protein is inserted into a suitable vector and the synthesis of 
protein (COX-2 in this instance) is under the control of a viral promoter.
Another method to elevate protein levels is to induce protein expression 
pharmacologically, using agents which are known to either enhance transcription of 
the gene or to stabilise the mRNA transcript or protein. We attempted to induce COX- 
2 in these cells using PMA and LPS. We achieved weak COX-2 induction with PMA 
but were unable to demonstrate any induction with LPS.
Zha et al (2001) showed that 0-80 nM PMA for 6 hours induced COX-2 protein and 
mRNA in a dose-dependent manner in PC-3 and TSU cells, but not in DU 145 or 
LNCaP. These findings are similar to our own in that PMA could induce COX-2 in 
PC-3 cells but not LNCaP. However, the authors did not give data for a time 
dependent PMA response. Souza et al. (2000) used 50 ng/mL PMA (equivalent to 
approximately 80 nM) for 4.5 hours on oesophageal carcinoma lines to induce COX- 
2. However, increased COX-2 expression was only possible in cell lines which had 
basal COX-2 protein expression. Ristimaki et al (1994) showed that 10 ng/mL PMA 
(equivalent to 16 nM) at 4 and 24 hours elevated COX-2 mRNA levels human 
umbilical cells. Also, PMA had a growth inhibitory effect in these cells. Gilroy et al 
(2001) used 100 nM PMA over 1-24 hours in serum free conditions and found a peak 
COX-2 mRNA induction at 7 hours in human foreskin fibroblasts. De Ledinghen et 
al (2002) used 50 ng/mL (80 nM) PMA for 6 hours to induce COX-2 protein and
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mRNA in transformed rat hepatocytes. Adderley et al. (1999) demonstrated a rise in 
PGE2 levels following PMA treatment of rat cardiac myocytes, an effect which was 
abolished by the COX-2 inhibitor NS398. Thus, PMA can induce COX-2 in a variety 
of cell types, including cancer cells.
An indirect method of assessing COX-2 mediated changes in cell phenotype is to 
introduce the major COX-2 catalytic product into the cell. In the case of cancerous 
epithelial cells, this is the prostaglandin PGE2 . This approach has been used by Chen 
& Hughes-Fulford (2000) and Nithipatikom et al. (2002) in prostate cancer lines, 
Jabbour et al. (2002) in bladder epithelial cells and Munkaiah et al. (2002) in ovarian 
epithelial cancer cells. However, this technique would not take into account the 
effects that the presence of the enzyme would have, for example by binding to other 
proteins and modulating their activity.
In summaiy, this chapter described the development of a cell line models with 
elevated cellulai’ COX-2 protein levels. Elevation was required because COX-2 
protein could not be detected in either PC-3, LNCaP or DU145 cells. The methods 
employed to elevate cellular COX-2 were transfection and phamiacological induction. 
Having established these models, the next chapter is concerned with what effect this 
elevated COX-2 has on the response of these cells to cytotoxic agents.
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Chapter 4 Effects of COX-2 Over-expression on 
Sensitivity To Cytotoxic Agents
4.1 Aims
Having elevated COX-2 levels via either transfection or chemical induction in LNCaP 
and PC-3 cells, we wished to assess the sensitivity of these transfected prostate cancer 
cell lines to COX-2 non specific and specific inhibitors in addition to 
chemotherapeutic agents. The aim of this approach was to assess if cell viability 
correlated with cellular COX-2 expression levels. Cytotoxic agents can affect cell 
viability by mechanisms such as growth inhibition, apoptosis or a combination of 
both. Therefore, we have tried to use more than one technique in order to assess 
processes relating to growth inhibition or cell death.
4.2 Introduction
In Chapter 3 the development of suitable models of prostate cancer cell lines over­
expressing COX-2 were described. Following on from this, we wished to assess the 
effect that COX-2 over-expression had on the sensitivity of those prostate cancer cells 
to cytotoxic agents. In this Chapter the effect of COX-2 on cellular response to two 
disparate groups of cytotoxic agents, chemotherapeutic drugs and COX inhibitors, is 
described.
The evidence that COX-2 mediates a pro-survival, anti-apoptotic phenotype was 
reviewed in Chapter 1.2.5.2. This effect has been reported in a variety of cell lines, 
both cancerous and non-cancerous and with a diverse group of cytotoxic agents. 
These include cell lines for prostate cancer (Subbaiayan et al 2001), lung cancer (Lin
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et al. 2001 and Krysan et al. 2004), colon cancer (Sun et al. 2002 and Tang et al. 
2002), cholangiocarcinoma (Nzeako et al. 2002), bladder cancer (Jabbour et al. 2002) 
and rat intestinal (Tsuji & DuBois 1995) and gastric epithelial cells (Shimada et al. 
2000). Transfection was not the sole method used to elevate COX-2 levels in these 
studies. Some studies used an approach of enzyme induction via inflammatory 
cytokines and growth factors.
The fact that clinically advanced prostate cancers frequently develop resistance to 
conventional chemotherapy was discussed in Chapter 1.1.5. Etoposide and carboplatin 
are two chemotherapeutic agents, which have been used to effectively treat several 
different cancers, but have little efficacy in the treatment of prostate cancer. As will 
be discussed in Chapter 5, prostate cancer cell lines may also exhibit a drug resistant 
phenotype. Possible mechanisms for this resistance will be discussed in the Chapters 
following, but it can be hypothesised that COX-2 may exacerbate this inherent 
resistance further.
Etoposide (VP-16) is a topoisomerase II inhibitor, and an established anti-cancer 
agent. Topoisomerase II is an enzyme which plays an important role in the unwinding 
and integrity of DNA, by making transient breaks in double stranded DNA. These 
enzymes are essential for replication, transcription and recombination of DNA 
(reviewed by Hande 1998). It has been combined clinically with hormonal 
manipulations in the treatment of prostate cancer (Berchem et al. 1995). Interestingly, 
etoposide induced cell death may be proliferation independent (Salido et al. 1999). 
Carboplatin is a second generation analogue of cisplatin. Both are platinum containing 
DNA interactive agents. Cisplatin forms DNA adducts which contain DNA-protein or 
DNA intrastrand and DNA-interstrand cross links. This leads to a distortion in the 
DNA helix, causing a cell cycle aiTest in S phase, and this may manifest in a G2M
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blockade and apoptosis (Di Felice et al. 1998). Repair of this damaged DNA can 
occur by nucleotide excision repair, which is p53 regulated. Cisplatin has been shown 
to induce apoptosis via caspase-3 activation (Nakamura et al. 2004). Carboplatin is 
better tolerated than cisplatin, with reduced nausea, vomiting and neuro- and 
nephrotoxicity side effects but resistance is frequently observed to this agent (Siemer 
et al. 1999). Thus, both etoposide and caiboplatin are classical anti-cancer agents in 
the sense that they mediate their toxicity by targeting DNA and its replication.
Various studies have reported the sensitivity of prostate cancer cell lines to many anti­
cancer agents. Throughout the literature the data sometimes appear contradictory. For 
example, McEleny et al. (2002) showed that PC-3, LNCaP and DU145 were all 
resistant to etoposide but previously Salido et al. (1999) reported that etoposide 
caused cell cycle block and apoptosis in these three prostate cancer cell lines. 
Lebedeva et al (2000) showed that B cI-x l  down-regulation, an anti-apoptotic protein, 
sensitised LNCaP and PC-3 to etoposide, mitoxantrone and carboplatin, but Vilenchik 
et al. (2002) showed the exact opposite, namely B c1-x l  down-regulation mediated a 
resistance to similar cytotoxic agents.
Yee et al. (1998) showed that caiboplatin did not cause apoptosis in LNCaP and PC-3 
although DNA fragmentation was detected. In the same study these cells were shown 
to be relatively resistant to paclitaxel also, in comparison to HeLa cells, which were 
sensitive to the effects of both carboplatin and paclitaxel. Gibbons et al. (2000) 
demonstrated resistance to etoposide in LNCaP and PC-3 after brief temperature 
elevation and heat shock protein induction. Haidar et al. (1996) showed that DU145 
were sensitive to paclitaxel, but PC-3 and LNCaP were resistant. Wang et al. (1999) 
reported that LNCaP were sensitive to camptothecin whilst PC-3 were resistant. The
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role of PTEN and PI3K signalling will be explored further in Chapter 6, but we can 
mention here that Yuan & Whang (2002) showed that f  TEW transfection into LNCaP 
gave rise to sensitisation to mitoxantrone, amongst other apoptotic stimuli. Grunwald 
et al. (2002) used the same principle to sensitise PC-3 to doxorubicin, whilst DU145 
did not require this sensitisation as they were inherently sensitive.
This brief review above highlights the difficulty in determining an accurate 
assessment of the sensitivity of LNCaP, PC-3 or DU145 to chemotherapeutic agents. 
The reasons for these differences are likely to be similar to those given in Chapter 3, 
for differences in COX-2 levels in the same cell lines, namely variations in cell line 
strains, cell culture conditions, the use of different techniques and large differences in 
passage number, or indeed different clones of the same cell line used.
Sulindac is a non selective COX inhibitor, an analogue of indomethacin which has 
been shown to cause apoptosis in prostate cancer cells (Lim et al. 1999). The most 
commonly used non-specific COX inhibitor, or NSAID is aspirin. As well as 
inhibiting both COX isoforms, other cellular targets for sulindac and aspirin have 
been reported. With regards to anti-cancer activity, these include inhibition of IKB 
kinase (IKK), the inhibitory protein of NE-kB, a transcription factor which can act to 
attenuate apoptosis (reviewed by Karin et al. 2002). Sulindac is a pro-drug and is 
metabolised hepatically in vivo to sulphide and sulphone derivatives, but interestingly, 
sulindac sulphone is devoid of either COX-1 or COX-2 inhibitory activity (Goluboff 
etal. 1999).
Epidemiological evidence has suggested long term aspirin and other NSAID use 
provides a protective effect against the development of colorectal cancer e.g. in those 
individuals with rheumatoid and osteoarthritis who take NSAIDs to relieve the pain
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and inflammation associated with these conditions (reviewed by Fosslien 2000). This 
effect appears to be dose and duration dependent. These anti-cancer properties of 
aspirin in colon cancer are also partly a result of suppression of COX-2 gene 
expression and not just inhibition of COX-2 activity (Xu et a l  1999).
The adenomatous polyposis coli (APC) gene is located on human chromosome 5q21 
and was discovered in FAP patients. Mutations in this gene are responsible not only 
for FAP, but also other colorectal cancers, and in stomach and oesophagus. An 
inherited gei*m line mutation results in the formation of hundreds of polyps. The gene 
encodes a laige protein of 2840 amino acids located on the plasma membrane and is 
involved in cell migiation. Almost all patients with FAP develop colorectal cancer 
(Steinbach et al. 2000). Early studies demonstrated disappearance of polyps in FAP 
patients given sulindac resulted in their disappearance and drug discontinuation 
caused return of the polyps. Subsequently, randomised, placebo controlled studies 
have been conducted with similai' results, however side effects common to other 
NSAIDs are observed, such as ulceration and bleeding (reviewed by Taketo 1998b). 
COX-2 over-expression in prostate and other cancers was reviewed in Chapter 1.2.6. 
Celecoxib is a COX-2 selective inhibitor and was the first COX-2 inhibitor to be 
approved by Food and Drug Administration (FDA), in the USA, for the treatment of 
pain management of rheumatoid aithritis and osteoarthritis in 1998. It has not been 
licensed yet for analgesia (Davies et al. 2000). However, there are concerns over 
cardiovascular safety with COX-2 inhibitors as a whole (reviewed by Warner & 
Mitchell 2004).
As COX-2 is over-expressed in cancer and the enzyme has pro-carcinogenic 
properties (Chapter 1.2.5), it appears to be a valid target for therapy. The utility of 
COX-2 inhibitors in cancer therapy is currently being assessed, even though celecoxib
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has been licensed for use as an adjunct to standard treatment and surgery in patients 
with FAP (reviewed by Chau & Cunningham 2002).
Because of the reported resistance observed in both clinical tumours and prostate 
cancer cell lines to chemotherapeutic agents and the fact that COX-2 is reported to be 
over-expressed in prostate cancer, the data in this Chapter describe the rationale for 
assessing the effect of COX-2 over-expression on prostate cancer cell viability. As 
COX inhibitors also have growth inhibitory and pro-apoptotic activity, and they 
inhibit the COX isoforms with differing specificities, we have assessed if COX-2 
over-expression mediates a differential response to these agents.
4.3 Results
4.3.1 Effect of COX-2 on chemotherapeutic drugs
We assessed the effect that COX-2 over-expression had on the response of DU145, 
LNCaP and PC-3 lines to chemotherapeutic drugs. These included a number of drugs 
which have been tested as potential agents in the treatment of prostate cancer, 
although their clinical benefit in the treatment of this disease remains uncleai*. 
Although PC-3 expresses some COX-2 mRNA whereas DU145 and LNCaP-Neo do 
not (Figure 3.1) we have not attempted to correlate the sensitivity of these three lines 
to their COX-2 mRNA levels. This is because they are genetically different and, 
therefore, their differential sensitivities to cytotoxic agents are likely to be mediated 
by a diverse range of other proteins and genes and not by COX-2 specifically. 
Therefore, we only attempted to coiTelate the effect of COX-2 on the stable LNCaP 
and transient PC-3 transfectants and COX-2 induction models. The initial screen for 
resistance was performed using the MTT cell viability assay.
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[Etoposide] (jiM)
(gM) 0.25 0.5 1 2 5 10 20 50
Reading 1 1.627 1.459 1.021 0.681 0.437 0.359 0.268 0.284
Reading 2 1.66 1.456 0.948 0.715 0.412 0.301 0.27 0.321 1.797
Reading 3 1.693 1.451 1.006 0.766 0.482 0.351 0.275 0.296 1.722
Reading 4 1.714 1.512 1.121 0.795 0.458 0.307 0.359 0.309 1.838
Average 1.6735 1.4695 1.024 0.7393 0.4473 0.3295 0.293 0.3025 1.911
% of control 90.182 79.189 55.182 39.837 24.102 17.756 15.789 16.301
1.8557 Average Control
Figure 4.1 An example of a dose-response curve plotted from a single cell 
cytotoxicity experiment. The table shows the absorbance values from an MTT assay 
of DU 145 cells treated with VP-16, over the range 0.25-50 pM. The line drawn 
vertically down represents the IC50 for this particular experiment.
Figure 4.1 shows an example of a cell cytoxicity MTT assay. The tabulated data 
shows the individual absorbance values (in quadruplicate) over 0.25-50 pM VP-16 
concentration range. This data was used to plot the graph depicted in Figure 4.1. from 
this graph, the I C 5 0  value is interpolated. As described in Chapter 2 Materials and 
Methods, I C 5 0  values obtained from a minimum of three experiments were averaged 
and reported here, along with the SD, This method was used to obtain all I C 5 0  data 
presented in this thesis.
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Cell line Etoposide Caiboplatin
PC-3 18.9±6.7 -
DU145 1.8±0.2 -
LNCaP-Neo 2.7±1.4 39.0±10.r*
LNCaP-COX-2 3.2±L8 123.0±28.4"
**p=0.006 Student’s t-Test, 2-sided, paired
Table 4.1 Sensitivity of prostate cancer cell lines to chemotherapeutic drugs.
Figures show IC50 values (pM) ± S.D. for etoposide and carboplatin as determined by 
MTT assay. Cells incubated with drug for 72 hours in presence of 10% serum. All 
experiments were repeated a minimum of 4 times.
Table 4.1 shows the IC50 values of parental PC-3 and DU145 cells and the stable 
LNCaP transfectants to etoposide and carboplatin. In LNCaP, COX-2 over-expression 
caused a slight but insignificant resistance to etoposide in the presence of 10% serum. 
However, COX-2 mediated a much larger and significant (p=0.006) resistance to 
caiboplatin. LNCaP-COX-2 is found to be three fold resistant to carboplatin than 
LNCaP-Neo, with IC50 values of 123.0 pM ± 28.4 and 39.0 (xM ± 10.1 respectively, 
as determined by the MTT assay.
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Cell line Etoposide Carboplatin
PC-3 parental 18.9+6.7 —
PC-3-Neo 22.3±5.9 85.3+18.1
PC-3-COX-2 24.6+6.2 84.0±6.0
Table 4.2 Sensitivity of transiently transfected PC-3 cells to chemotherapeutic 
drugs. Figures show IC50 values (juM) ± S.D. for etoposide and carboplatin as 
determined by MTT assay. Parental cells indicate untransfected cells. Cells incubated 
with drug for 72 hours in presence of 10% serum. All experiments were repeated a 
minimum of 3 times.
Table 4.2 shows the IC50 values of transiently transfected PC-3 cells to etoposide and 
carboplatin. No resistance was observed in PC-3-COX-2 in comparison to either PC- 
3-Neo or parental PC-3 cells. Thus, although resistance to 72 hour carboplatin 
treatment is observed in COX-2 over-expressing LNCaP cells, it is not evident in 
COX-2 over-expressing PC-3 cells. Therefore, sensitivity to carboplatin does not 
always conelate to levels of COX-2 expression.
Although resistance to etoposide was not observed in LNCaP-COX-2 compared to 
LNCaP-Neo with 72 hour exposure and in 10% serum, significant resistance to 
etoposide was observed under some (Figure 4.3) but not other conditions (Figure 4.2).
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Figure 4.2 LNCaP-COX-2 cells are not resistant to etoposide over 3 days.
Sensitivity of LNCaP-Neo and LNCaP-COX-2 to etoposide for 72 hours in serum free 
medium. Figures show IC50 values (pM) ± S.D. determined by MTT assay. Cells were 
plated in 96 well plates at 3x10"^ / mL, allowed to grow for 48 hours then incubated 
with etoposide for 72 hours in serum free medium. All experiments repeated a 
minimum of 4 times. p=0.1, 2-sided, paired Student’s t-Test.
Figure 4.2 shows the difference in I C 5 0  values for LNCaP-Neo and LNCaP-COX-2 
cells when treated with etoposide in serum free medium for 72 hours. No difference in 
sensitivity to etoposide is detected under these conditions (p=0 .1 ), a situation similar 
to that observed when cells are grown in 10% serum (Table 4.1). The I C 5 0  value for 
etoposide in LNCaP-COX-2 (50.0 pM ± 12.5) is significantly higher than that for 
LNCaP-Neo (26.0 pM ± 12.2) when cells are incubated in the absence of serum.
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Figure 4.3 LNCaP-COX-2 cells are resistant to etoposide over 6 days. Sensitivity 
of LNCaP-Neo and LNCaP-COX-2 to etoposide for 6 days in serum free medium. 
Figures show lC$o values (pM) ± S.D. determined by MTT assay. Cells were plated in 
96 well plates at BxlO' /^mL, allowed to grow for 48 hours then incubated with 
etoposide for 6 days in serum free medium. All experiments repeated a minimum of 4 
times. **p=0.01 2-sided, paired. Student’s t-Test.
Figure 4.3 shows the difference in I C 5 0  values for LNCaP-Neo and LNCaP-COX-2 
cells when treated with etoposide in serum free medium for an extended period of 
time, 6 days. 6 day drug exposure results in a much greater difference in sensitivity to 
etoposide (p=0.01), with I C 5 0  values of 2.8 pM ± 0.7 and 13.0 pM ± 4.2 for LNCaP- 
Neo and LNCaP-COX-2 respectively.
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4.3.2 Effect of COX-2 on response to COX inhibitors
The third type of pharmacological agent we exposed prostate cancer cells to were the 
COX inhibitors. Both celecoxib and sulindac have growth anest and apoptotic 
inducing abilities (Zweifel et al. 2002, Wu et al. 2003, Lim et al. 1999, Goluboff et al. 
1999). We wished to assess if celecoxib, a COX-2 inhibitor in particular, had a 
differential effect in COX-2 expressing or non-expressing cells.
The sensitivity of all prostate cancer cell lines to COX inhibitors is shown in Table 
4.3.
Cell line Celecoxib Sulindac
PC-3 75.1±7.9 232.2+48.0
PC-3-Neo 72.6±9.9 -
PC-3-COX-2 67.2+9.1
DU145 74.9+7.7 410.0+81.9
LNCaP-Neo 58.3±16.1 235.0+76.0
LNCaP-COX-2 63.6±12.6 233.8+75.7
Table 4.3 Sensitivity of prostate cancer cells to COX inhibitors. Figures show I C 5 0  
values (jttM) ± S.D. for celecoxib and sulindac as determined by MTT assay. Parental 
cells indicate untransfected cells. Cells incubated with drug for 72 hours in presence 
of 10% serum. All experiments were repeated a minimum of 3 times.
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PC-3 expresses some COX-2 mRNA, whereas none is detected in DU145 or LNCaP- 
Neo (Figure 3.1). Thus, no correlation exists between the levels of COX-2 mRNA or 
protein and sensitivity to the COX-2 inhibitor celecoxib. It can also be seen from 
Table 4.3 that COX-2 transfection of LNCaP (which produces elevated COX-2 
protein -  Figure 3.2) does not mediate a difference in sensitivity to either the COX-2 
inhibitor celecoxib or the non-selective COX inhibitor sulindac, as measured by the 
MTT assay.
As demonstrated in Table 4.3 transient transfection of COX-2 in PC-3 does not 
mediate a resistance to the effects of celecoxib, despite the fact that COX-2 protein is 
expressed up to 48 hours post transfection (Figure 3.3). It should be noted again that 
levels of COX-2 protein in this transient method of transfection in PC-3 cells were 
appreciably lower than the levels consistently measured in LNCaP. Unlike LNCaP- 
COX-2, where COX-2 mediates a marked resistance to the growth inhibitory effects 
of carboplatin (Table 4.1), COX-2 does not have the same effect in PC-3. A possible 
explanation for this is the much lower levels of COX-2 in the PC-3 model. We did not 
test if COX-2 expression gave rise to a change in celecoxib sensitivity in PC-3 as 
observed in LNCaP. However, we hypothesised that it would not for two reasons: 
COX-2 expression is not as strong and is transient and PC-3 is does not express p53. 
Possible involvement of p53 in COX-2 mediated apoptotic resistance is discussed 
further in Chapter 5.
As we had assessed the potential effect of COX-2 on sensitivity to COX inhibitors 
using only a single assay (MTT) and this assay failed to detect a difference in 
sensitivity to celecoxib in LNCaP- or PC-3 Neo or COX-2 cells, we performed 
another assay. Trypan blue exclusion cell counts, to confiim this. The results of these 
in the LNCaP stable transfectant are shown in Figure 4.4.
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control
□ LNCaP-NEO □ LNCaP-COX-2 Celecoxib concentration (uM )
Figure 4.4 LNCaP-COX-2 cells are resistant to celecoxib -  Trypan blue assay.
Percentage of viable cells as determined by Trypan blue counts after 72 hours 
celecoxib treatment of LNCaP-Neo and LNCaP-COX-2. There are significantly more 
non-viable LNCaP-Neo cells than LNCaP-COX-2 cells after 100 pM celecoxib 
(**p=0.004) 2-sided, paired. Student’s t-Test.
This graph shows that at higher celecoxib concentrations (100 pM) a significantly 
higher percentage of viable cells existed after 72 hour celecoxib treatment in LNCaP- 
COX-2. With 80 pM celecoxib the viability of LNCaP-Neo and LNCaP-COX-2 are 
66% and 93% respectively (p=0.06) and with 100 pM celecoxib the difference in cell 
viability increases with values of 18% and 40% (p=0.004). These results appear to 
contradict data from Table 4.3 which show little difference in I C 5 0  between LNCaP- 
Neo and LNCaP-COX-2 following 72 hour celecoxib treatment. Thus, COX-2 over­
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expression causes a resistance to the growth inhibitory effects of celecoxib in LNCaP 
in a Trypan blue cell viability assay but not the MTT cell viability assay.
4.3.3 COX-2 induction in PC-3
It was established that PMA produced a time dependent increase in COX-2 protein in 
PC-3 cells (Figure 3.4) under serum free conditions. To test if this induction had an 
effect on the apoptotic sensitivity of PC-3 cells, we treated these cells with celecoxib, 
sulindac and etoposide, agents which had previously shown to have a growth 
inhibitory effect in those cells as measured by the MTT assay (Table 4.1 and Table
4.2).
Control 100 nM PMA
Celecoxib 31.8±3.9 34.5±1.3
Sulindac 128.6±62.6 129.0±57.7
Etoposide 44.9±14.9** 76.8+19.0"'
*^p=0.02 Student’s t-Test, 2-sided, paired
Table 4.4 PMA treatment of PC-3 cells mediates resistance to etoposide.
Sensitivity of PC-3 cells to COX non-specific and COX-2 specific inhibitors and 
etoposide after induction of COX-2 with 100 nM PMA. Figures show I C 5 0  values 
(/xM) ± S.D. as deteimined by MTT assay. Cells incubated with drug for 72 hours in 
serum free medium. All experiments were repeated a minimum of 3 times.
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Following PMA induction of COX-2 in PC-3 cells in serum free media, no significant 
differences in IC50 for celecoxib or sulindac (Table 4.5) were observed. However, PC- 
3 demonstrated a significant resistance to etoposide (p=0.02) after 100 nM PMA 
treatment, as the IC50 increased from 44.9 jiM in control cells to 76.8 /xM in PMA 
treated cells.
4.3.4 Inability of COX-2 enzymatic activity to modulate carboplatin 
resistance
To investigate the modulation of the sensitivity to carboplatin we see in LNCaP- 
COX-2, the enzymatic activity of COX-2 was probed. We assessed if PGE2, the major 
prostaglandin metabolite in these epithelial cells, could cause a resistance in LNCaP- 
Neo to the effects of carboplatin, in the same way that COX-2 transfection did.
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Figure 4.5 PGE2 does not increase sensitivity of LNCaP-Neo to carboplatin.
Modulation of LNCaP-Neo sensitivity to 10 pM carboplatin by PGE2 for 72 hours. 
Figure shows the effect on cell viability of 0.1-20 pg/mL PGE2 ± S.D. when 
administered concomitantly with 10 pM carboplatin, as determined by MTT assay. 
Cells were plated in 96 well plates at 3x10"^ / mL, allowed to grow for 24 hours then 
incubated with PGE2 and carboplatin for 72 hours. All experiments were repeated a 
minimum of 3 times.
Figure 4.5 shows the effect of PGE2 over a wide, biologically relevant concentration 
range, on the cell viability of LNCaP-Neo following 72 hour treatment with 10 pM 
carboplatin treatment. This dose of carboplatin has been previously shown to be 
cytotoxic to these cells (Table 4.1). However, PGE2 was not able to significantly 
modulate the effects of carboplatin in LNCaP-Neo (Figure 4.5). These results shed 
doubt on the importance of COX-2 enzymatic activity in mediating the observed 
resistance to carboplatin.
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Figure 4,6 Celecoxib does not sensitise LNCaP-COX-2 to carboplatin. Modulation 
of LNCaP-COX-2 sensitivity to 100 pM cai'boplatin by celecoxib for 72 hours. Figure 
shows the effect on cell viability of 1-20 pM celecoxib ± S.D. when administered 
concomitantly with 100 pM carboplatin, as determined by MTT assay. Cells were 
plated in 96 well plates at 3x10"^ / mL, allowed to grow for 24 hours then incubated 
with carboplatin and celecoxib for 72 hours. All experiments were repeated a 
minimum of 3 times.
To confirm if COX-2 catalytic activity played an insignificant role in mediating 
resistance to carboplatin in LNCaP, the reverse experiment was also performed, 
namely concomitant COX-2 inhibition with 100 pM carboplatin treatment in LNCaP- 
COX-2. The results are summarised in Figure 4.6. Celecoxib, at doses at which it is 
COX-2 inhibitory, rather than cytotoxic, cannot significantly sensitise LNCaP-COX-2 
to 72 hours exposure of 100 pM carboplatin treatment Similar experiments with 24 
hour pre-treatment of celecoxib yielded the same result (data not shown).
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4.4 Discussion
In this Chapter we have shown that COX-2 mediates a selective resistance to the 
growth inhibitory or cytotoxic effects of some but not all chemotherapeutic agents and 
COX inhibitors. Changes in experimental conditions have indicated that loss of drug 
sensitivity is sometimes dependent on cell culture conditions. COX-2 over-expression 
in LNCaP, but not PC-3, caused resistance to the effects of carboplatin, etoposide and 
celecoxib. There may be three possible explanations for this. Firstly, COX-2 levels are 
lower and are transient only in the PC-3 transfectant in comparison to the stable 
LNCaP transfectant. Thus, if COX-2 levels in PC-3 could be elevated to the same 
extent as in LNCaP then it would be interesting to see if the same resistance to 
carboplatin occurs. Secondly, LNCaP is wild-type for p53, whereas PC-3 is mutant 
for p53. The role of p53 will be explored in Chapter 5, but it can be hypothesised that 
any effects COX-2 may have had on growth inhibition or apoptosis in PC-3 may not 
occur as p53 is not functional in PC-3. Thirdly, as COX-2 (via PGE2) activates 
aromatase activity (reviewed by Bundred & Barnes 2005), and that estrogens in turn 
induce COX-2, this positive feedback may occur in LNCaP, but is unlikely to occur in 
PC-3 (as we did not get strong COX-2 expression and aromatase has not been 
reported to be detected in PC-3 cells). A review of other cell types in which COX-2 
has mediated resistance to specific apoptotic stimuli was reviewed in Chapter 1.2.5.2. 
In a standard 72 hour MTT assay where control and drug treated cells are allowed to 
grow under normal growth conditions, i.e. in the presence of serum, resistance to 
etoposide in both COX-2 over-expressing LNCaP (Table 4.1) and PC-3 cells (Table
4,2), and also in the absence of serum (Figure 4.2) for LNCaP, is not observed. 
However, in the absence of serum, conditions in which cell proliferation is reduced in 
LNCaP, the effects of COX-2 on 6 day (Figure 4.3) etoposide treatment becomes
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significant i.e. COX-2 mediates a resistance. A possible explanation for these findings 
will be elaborated further in Chapter 6, when the role of PI3K/ Akt signalling will be 
considered.
It is known that a paiticular cytotoxic drug may require specific culture conditions for 
cytotoxic effects to be manifest. For example, Chang & Weng (2001) showed that the 
COX-2 inhibitor NS398 induced apoptosis in a lung adenocarcinoma cell line in 
serum free conditions. However, in the presence of 10% serum NS398 caused growth 
aiTest rather than apoptosis. It should be noted that NS398 and etoposide aie two very 
different cytotoxic agents and serum may affect their activity in different ways. We 
do, however, know that agents such as etoposide and celecoxib are extensively protein 
bound (>90%) based on widely reported in vivo studies. We have not assessed if the 
effects of switching from 10% serum to a serum free environment causes a change in 
the mechanism of cell viability reduction in LNCaP cells, but COX-2 appears to 
change the sensitivity of the cells only in the absence of serum in our cells.
Resistance to the effects of carboplatin were seen in the LNCaP-COX-2 stable 
transfectant, but not the PC-3 transient transfectant. The MTT assay demonstrated a 
significant difference in IC50 values between COX-2 non- and over-expressing 
LNCaP cells, with values of 39.0 [xM and 123.0 jxM respectively (Table 4.1). The 
mechanisms which may be responsible for the difference in sensitivity between these 
two transfectant lines will be elaborated in Chapters 5 and 6.
Yee et al. (1998) showed that 10 fiM carboplatin, an ICso dose for both LNCaP and 
PC-3 cells, caused DNA fragmentation but not apoptosis. However, in the same 
experiments, HeLa cells readily apopotosed. HeLa cells were also considerably more 
sensitive to paclitaxel than the two prostate cancer cell lines, suggestive of an inherent
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resistance mechanism. This dose of carboplatin was lower than the doses we needed 
to reduce cell viability by 50%.
Siemer et al. (1999) demonstrated apoptosis in testicular carcinoma cells with 800 /xM 
carboplatin but as little as 33 /xM cisplatin had the same effect. Itoh et al. (2000) 
demonstrated apoptosis with as little as 8  /xM carboplatin in squamous cell carcinoma 
lines over 48 hours. Di Felice et al. (1998) also confirmed enhanced potency of 
cisplatin versus carboplatin, with IC50 values of 30 and 200 /xM over 4 days, in 
retinoblastoma cells. Thus, in vitro cell culture experiments show that carboplatin has 
varying efficacy in different cancer cell lines. In Chapters 5 and 6 , the mechanisms of 
cai'boplatin induced toxicity in LNCaP COX-2 non- and over-expressing cells will be 
investigated further.
Surprisingly, inhibition of COX-2 in LNCaP-COX-2 cells, with sub-cytotoxic doses 
of celecoxib, using drug combination studies with MTT assays and isobologram 
analysis, did not sensitise this cell line to the effects of carboplatin (Coley HM, 
personal communication). Similarly, addition of PGE2 did not cause a carboplatin 
resistance in LNCaP-Neo cells. These data strongly support the notion that COX-2 is 
responsible for mediating a prostaglandin independent mechanism that gives rise to 
resistance to carboplatin. We can postulate that this effect is due to COX-2 binding to 
other proteins to either enhance or attenuate their activities. Candidate molecules for 
activation could be any of a number of pro-oncogenic, anti-apoptotic or anti-growth 
arrest proteins, or COX-2 may bind to and inactivate tumour suppressor gene 
products, for example p53. We will continue to develop this theme in Chapter 5. Both 
Trifan et al. (1999) and Zahner et al. (2002) also report COX-2 dependent, but 
prostaglandin independent effects of the COX-2 enzyme.
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Other groups have demonstrated that NSAEDs and COX-2 inhibitors are able to 
sensitise cancer cells to chemotherapeutic agents. For example, Ricchi et al. (2002) 
showed that 24 hours pre-administration of NS398 enhanced apoptotic effects of 
irinotecan and etoposide in COX-2 expressing Caco-2 cells. 10 and 50 pM NS398 
treatment was associated with lower Bcl-2 levels. Hida et al. (2000) used the COX-2 
inhibitor nimuselide at sub IC50 doses to enhance the sensitivity of various cytotoxic 
drugs, including etoposide, in lung cancer lines. They also demonstrated that cells 
expressing COX-2 were more sensitive to nimuselide.
However, the effect of COX-2 over-expression on sensitivity to celecoxib yielded 
different findings when the Trypan blue exclusion assay was utilised (Figure 4.4). The 
MTT assay is a colorimetric, absorbance based measure of cell viability and is 
dependent on mitochondiial metabolism of a tétrazolium salt via dehydrogenase 
enzymes to generate a signal, i.e. the absorbance measured at 540 nm (Mosmann 
1983). Actively proliferating cells with a higher energy requirement will have greater 
mitochondrial activity than quiescent, growth anested cells, and will generate a larger 
signal too, although this assay cannot distinguish between these two processes. In 
addition, if cells are swollen due to drug treatment this can sometimes give an 
increased foimazan signal. The Trypan blue assay is conceptually very different from 
the MTT assay. The dye is taken up by non-viable cells only, viable cells exclude the 
dye, and thus it is an indicator of membrane integrity. Viable and non-viable cells can 
be visualised under a hematocytometer and counted. However, unlike in the MTT 
assay in which quiescent and proliferating cells provide a differential signal, the 
Trypan blue assay discriminates only between viable and non-viable cells. A 
diagrammatic representation which offers a possible explanation for the different
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celecoxib sensitivity data that the MTT and Trypan blue exclusion assays provides is 
shown in Figure 4.7.
LNCaP-Neo LNCaP-COX-23
1 ■  proliferating ■  quiescent □  non-viable | !■  proliferating ■quiescent □  non-viable |
Figure 4.7 The MTT assay versus Trypan blue exclusion. Celecoxib induces a 
different effect on COX-2 non- or over-expressing LNCaP cells. The pie charts show 
how the proportion of cells which are proliferating, quiescent or non-viable may be 
apportioned after 72 hour celecoxib treatment in 10% serum. The actual percentages 
have not been measured.
The signal generated by the MTT assay for any particular celecoxib concentration, is 
the same for LNCaP-Neo and -COX-2, and this is indicated by similar I C 5 0  values of 
around 60 pM. The total contribution of the two cells in various stages of growth 
arrest and/or cell death must, in theory, be identical. At 80 and 100 pM celecoxib in 
LNCaP-Neo there are populations of proliferating and non-viable cells, but for 
LNCaP-COX-2 there are likely to be fewer proliferating and non-viable cells. We can
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postulate the presence of a third population comprising quiescent cells, in LNCaP- 
COX-2 which provides a smaller signal to compensate for the fewer proliferating 
cells. However, the Trypan blue assay suggests that there are differences in the cell 
populations between LNCaP-Neo and LNCaP-COX-2 but these give rise to an 
identical MTT signal. As summarised in Figure 4.7, celecoxib treatment results in a 
larger percentage of cell kill in LNCaP-Neo. There are fewer non-viable cells amongst 
LNCaP-COX-2 as some undergo growth anest. It should be noted that the proportion 
of cells shown in Figure 4.7 have not actually been accurately measured, it serves 
only to illustrate the point that the data from the two assays combined indicates the 
existence of three cell populations following celecoxib treatment.
PMA was shown previously to induce COX-2 in PC-3 (Chapter 3.3.3). Concomitant 
treatment of PMA and cytotoxic agents in serum free media in PC-3 cells caused 
significant resistance to the effects of etoposide, but not celecoxib or sulindac (Table 
4.4). This scenario is similar to that observed when using serum free media with the 
transfected LNCaP lines, as the COX-2 over-expressing cells appeared resistant to 
etoposide in the absence of serum. As mentioned in Chapter 3.2, PMA mimics the 
actions of DAG in vitro and therefore is a PKC activator. PMA is also a recognised, 
established tumour promoter. The significance and specificity of PC-3 resistance to 
etoposide after PMA induced COX-2 induction is not clear. PMA treatment in these 
cells may induce many other proteins in addition to COX-2, and these may play a 
more significant role in resistance to etoposide than COX-2 itself. Furthermore, COX- 
2 inhibitory doses of celecoxib were not able to reverse the resistance to etoposide 
caused by PMA induction of COX-2 (data not shown).
Our experiments showed that sulindac was the least potent cytotoxic agent in reducing 
the viability of prostate cancer cells. COX-2 over-expression in LNCaP cells did not
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significantly change the sensitivity to sulindac (Table 4.3). Both PC-3 and LNCaP 
cells were more sensitive to this NSAID than DU145 cells which had an IC50 of 410 
/xM. Sulindac was typically 4-5 times less potent than celecoxib in reducing the 
viability of the prostate cancer cells used in this study (Table 4.3).
Sulindac compounds have previously been shown to induce apoptosis in human colon 
cancer and prostate cancer cell lines. For example, Lim et ah (1999) demonstrated an 
apoptotic effect of sulindac metabolites in LNCaP and PC-3 cells and these effects 
were independent of Bcl-2, B c1-x l  and COX-2 as two metabolites aie devoid of COX- 
2 inhibitory activity, suggesting that these compounds affect targets other than COX- 
2. It should be stressed that blood serum levels of 0.5 mM for the sulindac compounds 
represents values that are ten times higher than those obtained after administration of 
maximum recommended doses (Andrews et ah 2002). Hanif et al. (1996) used 
colorectal cell lines which were either COX negative or positive and found that 200 
pM sulindac sulphide or 900 pM piroxicam for 72 hours induced apoptosis in both. 
Further, PGE2 did not rescue the cells from apoptosis, but did increase the 
proliferation rate. Huang et ah (2001) demonstrated apoptosis in DUI45 cells with 
200 pM sulindac sulphide and sulphone. Yamamoto et ah (1999) showed a growth 
inhibitory effect of 1000 pM sulindac and sulindac sulphone and 200 pM sulindac 
sulphide in COX deficient colorectal cells. It should be noted that they do not report 
an apoptotic effect of these compounds, even at these doses.
Other potential NSAIDs which have demonstrable apoptotic activity in cancer cells 
are ibuprofen and naproxen. Andrews et ah (2002) showed that these two agents 
induced apoptosis in LNCaP and DU145 cells at clinically achievable doses; 1 mM 
ibuprofen in vitro equates to 3200 mg/ day, the maximum clinically acceptable dose.
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Goluboff et al. (1999) inoculated LNCaP into athymic nude mice to assess the effects 
of exisulind, sulindac sulphone, the non-COX inhibitory metabolite of sulindac, on 
tumour volume and markers for apoptosis and proliferation. Exisulind-fed mice 
showed significantly smaller tumours with higher apoptotic bodies and lower 
proliferation.
We have not measured the conversion of sulindac to its biologically active 
metabolites in this study. Indeed, it is not certain if this occurs at all in our in vitro 
experiments and this may be an explanation for its lack of potency. Although we have 
found that sulindac is less potent in mediating a reduction in prostate cancer cell 
viability and the effects of this NSAID are independent of COX-2 levels, other in 
vitro cell culture, in vivo animal experiments and clinical data from FAP patients 
suggest a role for sulindac and its metabolites in the management of prostatic 
neoplasias.
Celecoxib was virtually equipotent in reducing cell viability of all parental and COX- 
2 or mock transfected cell lines, with an IC50 ranging from 60-75 pM. These MTT 
data suggest that the cytotoxic mechanism of celecoxib is independent of cellular 
COX-2 expression, p53 status or androgen sensitivity. However, as discussed below. 
Trypan blue experiments suggested celecoxib may mediate a different effect in COX- 
2 non- and over-expressing LNCaP cells.
Various in vitro cell culture studies have also demonstrated a beneficial anti-cancer 
effect of COX-2 inhibitors and a diverse set of moleculai' mechanisms have been 
reported. Because COX-2 inhibitors can induce apoptosis in both androgen-dependent 
(LNCaP) and -independent (PC-3 and DU145) prostate cancer cell lines, the 
possibility exists that these agents could be efficacious in biologically diverse prostate
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cancers. Celecoxib is not the only agent with these properties: NS398 and SC58125 
are also two widely used experimental COX-2 inhibitors.
Several studies suggest that COX-2 is a key target for COX-2 inhibitor induced cell 
kill in prostate cancer cells. Liu et al. (1998) showed that NS398 caused apoptosis in 
LNCaP cells which expressed COX-2 mRNA, but not in human foetal prostate 
fibroblasts, which were COX-2 negative. Hsu et al, (2000) demonstrated that 50 pM 
celecoxib caused apoptosis in COX-2 expressing PC-3 and LNCaP within 3-4 hours, 
but the COX-1 selective inhibitor piroxicam had no effect. Furthermore, noimal 
prostate cancer cells which did not express COX-2 were insensitive to celecoxib. 
Although 10 pM celecoxib in this Hsu study reduced the viability of both PC-3 and 
LNCaP cells, 800 mg/ day celecoxib (levels greater than therapeutic levels) equates to 
less than 10 pM in the blood (Andrews et al. 2002). Kamijo et al. (2001) also 
demonstrated apoptosis in PC-3 and LNCaP cells with the COX-2 inhibitors etodolac 
and NS398 and non-COX-2 expressing noimal prostate cells were insensitive to these 
agents. Minter et al. (2003) showed that 75 pM NS398 over 3 days was needed for 
consistent growth inhibition of oral carcinoma cells, whereas 20 pM only was needed 
for PGE2 production inhibition. However, in a 6-12 day assay 5 pM NS398 exhibited 
growth inhibition, which could be modulated by PGE2, suggesting COX-2 dependent 
effects of NS398. Sumitani et al. (2001) showed that 25 pg/mL NS398 over 4 days 
inhibited the viability of oral cancer cell lines which expressed COX-2 only. 100 
pg/mL PGE2 suppressed the anti-proliferation effect of NS398. COX-2 anti-sense 
oligonucleotides also inhibited cell proliferation. Hashitani et al (2003) showed that 
10 pM celecoxib caused growth inhibition only in COX-2 expressing head and neck 
carcinoma cells and not in COX-2 negative cells. 100 pg/mL PGE2 pre-treatment 
prevented celecoxib mediated reduction in cell proliferation. Sulindac was
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significantly less potent. Souza et al. (2000) showed that 0.1-10 pM NS398, a dose 
range which was selective for COX-2 inhibition, induced apoptosis in oesophageal 
adenocarcinoma cells which expressed COX-2 but not in a cell line which did not, 
whereas a COX-1 inhibitor, flurbiprofen, had no effect in either line. Wu et al. (2003) 
used both COX-2 expressing and negative cholangiocarcinoma cell lines to assess the 
apoptotic properties of 40 pM celecoxib. It caused apoptosis only in COX-2 
expressing cells and 200 pg/mL PGE2 rescued these cells only from the effects of 
celecoxib.
It is also accepted that COX-2 inhibitors cause apoptosis in cells in which COX-2 
protein or mRNA cannot be detected. Williams et al (2000) showed that 40 pM 
celecoxib reduced cell viability of various colorectal cancer lines over 1 2  hours and 
induced apoptosis. These effects were COX-2 independent as similar effects observed 
in COX-2 positive or negative fibroblasts. Grosch et al. (2001) used colon cancer cells 
which were either COX-2 negative or positive but celecoxib induced apoptosis in 
both. They also showed that a COX-1 selective inhibitor, SC-560 was less potent than 
celecoxib. Arico et al. (2002) demonstrated time and dose dependent celecoxib 
mediated apoptosis in a COX-2 negative colorectal cell line. Yamazaki et al (2002) 
assessed the effect of six different COX-2 inhibitors on COX-2 positive and negative 
colon adenocarcinoma lines. Only celecoxib induced apoptosis, within 6  hours, 
although all six agents inhibited PGE2 production.
Zhu et al. (2002) provided evidence for COX-2 inhibitory independent apoptotic 
activity of celecoxib, by synthesising alternative forms of celecoxib and rofecoxib 
with modified chemical structures. By creating a library of related compounds, they 
were able to identify chemical groups within the molecules which were responsible 
for COX-2 inhibition and those that induced apoptosis in PC-3 and LNCaP cells.
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There was no coiTelation between a compound’s ability to inhibit COX-2 or induce 
apoptosis. Song et al. (2002) also found no correlation between the COX-2 inhibitory 
and apoptotic activity of celecoxib derivatives in PC-3, LNCaP and DLF145 cells. 
Furthermore, COX-2 ablation did not cause apoptosis, whereas 50 jxM celecoxib did. 
Johnson et al. (2001) showed that 100 jtiM celecoxib caused rapid apoptosis in PC-3 
cells within 2 hours, whereas other COX-2 inhibitors rofecoxib, NS398 and DuP697 
were less potent, taking 48 hours. Non selective and COX-1 specific inhibitors did not 
have this effect. Although COX-2 levels were not assessed, non-COX-2 targets of 
celecoxib were identified. These targets will be explored further in Chapters 5 and 6 . 
Data from animal model also provides evidence for an anti-tumour effect of COX-2 
inhibitors and implicates COX-2 in the carcinogenic process. For example, NS398 in 
PC-3 xenografts in nude mice reduced tumour growth by inducing apoptosis and 
decreasing VEGF and angiogenesis (Liu et al. 2000). Williams et a l (2000) showed 
that in athymic mice, 1250 mg/kg celecoxib, which equated to 2.3 jiM in plasma, a 
dose which was not toxic in vitro, resulted in reduced tumour volumes. Zweifel et al. 
(2 0 0 2 ) showed that 160 ppm celecoxib and a PGE2 neutialising antibody reduced 
tumour volume in a head and neck cancer cell xenograft in nude mice, but the COX-1 
inhibitor SC-560 did not. Sheng et al. (1997) injected both COX-2 positive and 
negative COX-2 expressing colorectal cells into athymic nude mice. The COX-2 
inhibitor SC-58125, at 5 mg/kg, reduced tumour growth in the COX-2 expressing 
xenografts only. Gupta et al (2004) showed that 1500 ppm celecoxib given to 
TRAMP mice (transgenic adenocarcinoma of the mouse prostate model) over 8-32 
weeks reduced tumour incidence and metastasis, reduced COX-2 levels and activity, 
increased apoptosis {in vivo AV assay), decreased differentiation status of tumours, 
reduced proliferating cell nuclear antigen (PCNA) and VEGF, caused retention of E-
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cadherin and catenins and increased survival. Also, COX-2 protein and activity was 
higher in TRAMP mice prostates compared to non-transgenic littermates. In support 
of these findings COX-2 knock out mice have been shown to exhibit reduced 
tumourigenesis (reviewed by DuBois et al. 1998).
What contribution does COX-2 inhibition have in modulating cell viability due to 
treatment with COX-2 inhibitors? The review of the above studies suggests that this is 
a cell line specific effect. It is likely that the answer to this question is dependent on 
cell type and the particular COX-2 inhibitor used. By inference, how important is 
COX-2 inhibition in mediating anti-tumour activity? The two questions aie subtly, but 
crucially different. Because COX-2 inhibitors may be mediating an apoptotic or 
growth inhibitory effect independently of COX-2 in vitro, COX-2 is also expressed in 
other cell types associated with tumour growth (Chapter 1.2.6) and when administered 
in vivo, COX-2 inhibitor anti-tumour activity may well be COX-2 dependent. Even 
though agents such as celecoxib kill cells which do not express COX-2, expression 
levels of the enzyme itself can mediate a resistant phenotype.
Data from clinical trials also provides evidence for an anti-cancer effect of celecoxib 
in human malignancy and pre-malignant conditions. In a placebo controlled study to 
assess the effects of celecoxib, 100 mg or 400 mg twice daily, on colorectal polyps in 
FAP patients, Steinbach et al. (2000) report a dose dependent reduction in the number 
of polyps after 6  months with celecoxib.
In summary, this Chapter showed that both transfection and induction of COX-2 into 
prostate cancer cells mediated a resistance to the cytotoxic effects of etoposide and 
carboplatin under different conditions and COX-2 over-expression also had the same 
effect on the activity of celecoxib. We have also reviewed the evidence in the
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literature which suggests that COX-2 inhibitors reduce the viability of cancer cells 
independently of COX-2. Having established an effect of COX-2 on cell viability, in 
the next Chapter we try to determine the exact growth inhibitory and cell cycle arrest 
mechanisms underlying this resistance.
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Chapter 5 Effects of COX-2 on the Cell Cycle and 
Apoptosis
5.1 Aims
As COX-2 was shown to mediate an attenuation of the effects of carboplatin, 
etoposide and celecoxib under various conditions in stably transfected LNCaP-COX-2 
cells, we wished to assess the mechanisms which may be responsible for this. 
Consequently, we measured changes in cell cycle events and apoptotic markers 
caused by elevation of COX-2 in LNCaP cells. We concentrated on the resistance 
observed with carboplatin because it was achieved when cells grew normally in serum 
(which was not the case for etoposide) and was confirmed by the MTT cell viability 
assay (which was not the case for celecoxib).
5.2 introduction
5.2.1 The Cell Cycle and its Regulation
In the context of the cell cycle, the cell has three options (i) remain metabolically 
active but not undergoing either proliferation or death, i.e. be quiescent or in Go; (ii) 
undergo DNA synthesis (S), mitosis (M) and divide i.e. proliferate; (iii) undergo 
apoptosis (reviewed by Denmeade et al. 1996). Cell cycle progression has two main 
checkpoints; GiS prior to DNA replication and G2M prior to mitosis. In cancer 
development, the disruption of the cell cycle can be an important event.
Gi is the phase at which the main regulatory events for cell proliferation occur. 
Possible events in tumourigenesis include changes in cyclins and cyclin dependent
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Idnases (CDKs) during Gi (reviewed by Kyprianou et aL 2000). Cyclin D l and its 
catalytic subunits CDK4 and 6  are activated in mid-Gi. Cyclin E i s a  late Gi cyclin, 
which combined with its catalytic subunit CDK2, phosphorylates the retinoblastoma 
(Rb) protein. Cyclin E/ CDK2 is needed for Gi to S phase transition, whereas Rb 
regulates or inhibits Gi to S phase transition. Growth anest conelates with 
dephosphorylation and activation of Rb, whilst the reverse occurs for progression 
from Gi to S phase. Rb associates with the E2F family of transcription factors, 
preventing them from promoting cell proliferation. Over-expression of cyclin E 
accelerates Gi to S phase progression. Activity of the cyclin E/ CDK2 complex is also 
regulated by Cip/ Kip family of CDK inhibitors. CDK inhibitors bind to the CDK/ 
cyclin complex and inhibit their activity. Two classes of inhibitor exist; the p21 
family p5V“ '’^ ) and the INK4 family (pl6 , pl5, p l 8 , pl9) (Cheng
et al. 2004).
Loss or decreased expression of p27 '^^^ can be a prognostic marker for a number of 
malignancies (reviewed by Kyprianou et al. 2000). p27^ ^^  ^ regulates the GiS 
checkpoint, as does p21^"^^\ Cyclin A/ CDK2 is needed for entry into S phase, i.e. 
for DNA synthesis to begin. Cyclins A and B and cdc2 (also refened as CDKl) are 
needed for G2M transition. p21^^^^ regulates both GiS and G2M checkpoints (Cheng 
era/. 2004).
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Figure 5.1 The Cell Cycle and its Regulation. The phases of the cell cycle, the 
various cyclins and CDKs which drive it, and some regulatory aspects. See text for 
details.
p53 is a transcription factor which regulates cell cycle progression and is considered 
very important in cancer because of its large number of downstream targets. p53 can 
either instigate DNA repair in response to damage, inhibiting cell cycle entry or 
induce apoptosis. Thus, it is a multi-faceted tumour suppressor and plays a key role in 
the defence against cancer. p53 is also plays a key role in stress induced apoptosis and 
can induce the expression of genes involved in the mitochondrial pathway of
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apoptosis (e.g. Bax, apoptotic protease activating factor-1 [Apaf-1]) or the death 
receptor pathway (e.g. CD95/ Fas, F ADD, DR4, DR5) (see section below) (reviewed 
by Igney & Ki'ammer 2002). Other p53 responsive genes include p21^"^^\ which 
mediates a Gi anest as described above, and it down-regulates Bcl-2, an anti- 
apoptotic protein (reviewed by Kyprianou et al. 2000), PTEN, WIPl and IGF-BP3 
(reviewed by Vousden & Lu 2002).
Most cells are programmed to stop proliferating or to kill themselves, by apoptosing, 
if survival signals aie not regularly received from their environment. Also, if there is 
DNA damage, molecules such as the tumour suppressor p53 are activated by 
phosphorylation, which regulates its DNA binding ability and therefore transcriptional 
activity, leading to cell cycle anest or apoptosis. Thus, in response to DNA damage, a 
cell can initiate repair processes, anest growth or undergo apoptosis and p53 is central 
to this (reviewed by Tapia-Vieyra & Mas-Olivia 2001). Various stress signals (loss of 
survival signalling, DNA damage, hypoxia or microtubule inhibitors) induce p53 by 
stabilising the protein, increasing its levels.
We have discussed previously (Chapter 1.2.4) that COX-2 transcription is negatively 
regulated by p53 in some cell types. Cells negative for or expressing mutant p53 could 
allow increased COX-2 induction by oncogenes, growth factors or cytokines. Also, 
p53 decreases synthesis of VEGF and inhibits tumour cell induced angiogenesis. 
Repression of COX-2 transcription could be important for p53 mediated apoptosis, as 
over-expression of COX-2 results in resistance to apoptosis following diverse 
cytotoxic insults (Subbai'amaiah et al. 1999 and Chapter 1.2.5.2).
Because COX-2 has been reported to enhance cellular proliferation (Chapter 1.2.5.1), 
and to modulate cell cycle parameters (Chapter 1.2.5.6), and our data showed that
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over-expression of the enzyme was concomitant with resistance to carboplatin, 
celecoxib and etoposide (Chapter 4), we wished to explore further the mechanisms 
which may be responsible for this resistance in COX-2 over-expressing LNCaP cells.
5.2.2 Apoptosis
Apoptosis is a form of programmed cell death, distinct from necrosis. In apoptosis the 
cell plays an active part in its own demise, whereas it is passive in necrosis. In 
necrosis, pathological changes result in increased plasma membrane pemieability, 
cellular oedema, whereas in apoptosis the cell death is orderly, energy dependent and 
signal specific (Chan et al, 1998).
Apoptosis is a widespread phenomenon, occumng in processes such as 
morphogenesis, growth and development and normal turnover in adult tissue. It can 
be initiated by endogenous tissue specific agents such as hormones or cytokines or 
exogenous cell damaging agents such as radiation, virus, toxins or chemicals 
(reviewed by Eamshaw et al. 1999).
It is a complex process involving many molecules which may act in distinct ways 
depending upon the cell type. Most cells aie programmed to die if survival signals are 
not received regularly from their environment. Apoptosis occurs frequently when 
cytokines or growth factors aie removed in several cell types. As inappropriate 
apoptosis may be involved in a number of diseases, apoptosis is an important potential 
tai’get for therapeutic intervention (reviewed by Riss 2001).
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5.2.2.1 Characteristics of Apoptosis
The process of apoptosis has distinct moiphological and biochemical characteristics 
and can be divided into 4 stages: (i) reception of either external or internal stimuli (ii) 
transduction of these stimuli (iii) an effector phase where nuclear, biochemical and 
cytoskeletal changes occur (iv) a post-mortem phase which involves phagocytosis of 
the apoptosed cell. Characteristics of apoptosis include DNA fragmentation and loss 
of mitochondrial function which has three apoptotic effects: an alteration of electron 
transport and ATP production and general disruption of cellular redox potential, 
release of apoptotic molecules, and activation of caspases, the protease effectors of 
this phenomenon (reviewed by Tapia-Vieyra & Mas-Oliva 2001). Moiphological 
chai'acteristics of apoptosis include chromatin aggregation, nuclear and cytoplasmic 
condensation and fragmentation of cells into apoptotic bodies, which are membrane 
bound segments containing cellular organelles. These bodies are readily 
phagocytosed. The fragmentation of genomic DNA commits the cell to die and occurs 
before changes in membrane penneability (reviewed by Denmeade et al. 1996). The 
biocheimcal characteristics of apoptosis include phosphatidylserine (PS) 
externalisation, translocation of molecules between cellular locations and cleavage of 
specific cellular polypeptides, mainly by the caspases (reviewed by Eamshaw et al.
1999).
5.2.2.2 Apoptotic Pathways
It is accepted that at least two apoptotic pathways exist, the receptor or extrinsic 
pathway and the intrinsic or mitochondrial pathway. The two pathways can function 
separately or interact together to execute the apoptotic program.
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Death Receptor Pathway
The receptor pathway can be activated by one of three endogenous ligands upon 
binding of their receptors; Fas or CD95, Tumour necrosis factor related apoptosis 
inducing ligand (TRAIL) and TNF-a.
Fas or CD95 is a glycosylated cell surface molecule which can be up-regulated by 
cytokines such as interferon-y and TNF-a. Fas belongs to the TNFR family of 
receptors. Fas mediated apoptosis is triggered by Fas ligand (FasL or CD95L) which 
can exist as a transmembrane molecule as well as a cytosolic form. There are two 
different pathways downstream of Fas: either caspase- 8  is activated at the receptor- 
ligand complex or the mitochondria amplifies the cascade signal if the complex of 
proteins do not form with Fas (reviewed by Igney & Kiammer 2002).
The DISC (death inducing signalling complex) is an assembly of adapter molecules 
which form at the ligated receptor as pait of the signalling process. The DISC 
comprises activated Fas, the Fas associated death domain (FADD or MORTl) and the 
initiator caspases- 8  and -10. These adaptor molecules allow higher oligomerisation of 
receptor molecules and better recruitment of zymogens to the complex (reviewed by 
Eamshaw et al. 1999). Then activated caspase- 8  leaves the DISC and activates 
effector caspases. Caspase- 8  also cleaves pro-apoptotic Bid, which induces 
Cytochrome c (cyt c) release; thus Bid provides a link between the receptor and 
mitochondrial pathways. However, in some cell types Fas mediated apoptosis is 
mitochondrial independent as Bcl-2 does not protect against Fas killing i.e. the DISC 
is sufficient to activate downstream caspases to cause apoptosis (Gewies et al. 2000b). 
c-FLIP (FLICE inhibitory protein) is a caspase- 8  homologue which lacks the catalytic 
site and inhibits apoptosis at the DISC by preventing caspase- 8  activation. It has two
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fonns: c-FLIPl and c-FLIPs (55 and 26 kDa respectively). This is another mechanism 
to regulate caspase activity. In some cells high c-FLIP expression con elates with a 
TRAIL resistant phenotype in cancer cells (Kelly et al. 2002).
Some studies report that PC-3, LNCaP and DU145 all express the Fas receptor 
(Rokhlin et al 1997). However, Takeuchi et al. (1996) did not detect Fas in both PC-3 
and LNCaP. As will be discussed later, these reported differences in expression of 
apoptosis inducing agents or their receptors in prostate cancer cells does not always 
account for the reported resistance or sensitivity of these cells to either Fas, TRAIL or 
TNF-a.
TRAIL (or Apo-2 ligand) is a member of the TNF super family of cytokines. TRAIL 
has homology with FasL and TNF-a (Roldilin et al. 2002). Four receptors for TRAIL 
have been identified; TRl or DR4 and TR2 or DR5 which induce apoptosis as they 
contain cytoplasmic death domains, whereas TR3 and TR4 do not. These ‘decoy’ 
receptors also bind TRAIL but have truncated death domains which cannot transduce 
the death signal (Kelly et al. 2002).
TRAIL appears to be far less toxic than Fas. Fas has been shown to cause hepatocyte 
degeneration, necrosis, haemontage and death (Griffith et al. 2000). Moreover, 
TRAIL mRNA is constitutively expressed in a number of cells but FasL is more 
tightly regulated, due to its toxicity (Griffith et al. 2000). TRAIL appears to 
differentiate between tumour and normal cells, unlike Fas and TNF-a. But a large 
number of tumour cells are still resistant to TRAIL (Sah et al. 2003). TRAIT, and its 
receptors aie ubiquitously expressed in tissues, suggesting that mechanisms exist 
which protect normal tissues from TRAIL induced apoptosis (Nesterov et al. 2001).
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The TRAIL DISC involves recruitment of FADD and caspase- 8  also and thus is 
similar to Fas signalling in this respect (Roldilin et al. 2001).
TNF-a mediated apoptosis occurs via binding to its receptor, TNFRl. TNF-a 
apoptotic signalling is similar to Fas mediated apoptosis as both involve intracellular 
domains which contain death domains; FADD/MORTl for Fas, TRADD for TNFRL
One pathway activated after chemotherapy is the SAPK or INK stress activated 
pathway (see Chapter 1.2.4). SAPK regulates the activity of the AP-1 transcription 
factors, whose targets include FasL and TNFa (reviewed by Igney & Krammer 2002).
Mitochondrial Pathway
The role of Bid as the link between death receptor activation and the mitochondrial 
pathway was briefly described above. Bid causes mitochondrial membrane 
depolarisation to release apoptotic factors such as cyt c and SMAC. This leads to 
formation of the apoptosome, a teim for the second initiator complex. This consists of 
mitochondrial factors (cyt c, second mitochondria derived activator of caspase 
(SMAC) and direct lAP binding protein with low pi (DIABLO)) and cytoplasmic 
factors Apaf-1 and pro-caspase-9). lAPs are inhibited by SMAC/ DIABLO (reviewed 
by Igney & Kiammer 2002). Apaf-1 binds cyt c, and then binds procaspase-9, 
activating it, although mechanism of cyt c mitochondrial release is unknown 
(Eamshaw et al. 1999). Once caspase-9 is activated it is able to activate downstream 
effector caspases.
In non-apoptotic cells SMAC/ DIABLO is located on the inner mitochondrial 
membrane space and is released along with cyt c during apoptosis, where it binds
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XIAP and other lAPs, preventing their action (reviewed by Salvesen & Duckett 
2002).
5.2,2.3 Pro- and Anti-apoptotic factors 
Pro-apoptotic Factors
Proteases play a crucial role in apoptosis, particularly the caspases (the cysteine 
dependent aspartate directed proteases). Proteins cleaved during apoptosis include (i) 
cytoplasmic and cytoskeletal (ii) nucleai' (iii) DNA repair, metabolism and structure 
e.g. PARP (iv) protein kinases e.g. PKC, ERK, Akt (v) signal transduction e.g. 
interleukins and PLC (vi) cell cycle and proliferation regulation (vii) apoptotic 
regulators, both survival and pro-apoptotic. Some substrates are cleaved later and less 
completely, some are cleaved in some cells but not others and some are cleaved in 
different locations depending upon cell type (reviewed by Eamshaw et aL 1999). 
Three levels of caspase regulation exist; (i) gene transcription (ii) anti-apoptotic 
members of Bcl-2 family that inhibit proximity induced activation of some pro- 
caspases and (iii) cellular inhibitors which bind to caspases, the lAPs. Caspases can 
efficiently activate other caspases, for example caspase- 8  cleaves pro-caspases-3, -4, - 
7 and -9 in vitro and caspase-10 cleaves pro-caspases-3, -7 and - 8  in vitro. Caspase-9 
also activates caspase-3 (reviewed by Eamshaw et al. 1999). Because all caspases 
have similai* cleavage specificities, an activated caspase can activate a number of pro- 
caspases (reviewed by Tapia-Vieyra & Mas-Oliva 2001).
Effector caspases include -3, -6 , -7 and -9 (reviewed by Kyprianou et al. 2000). 
Caspase-3 exists as a 32 kDa inactive precursor and is activated by cleavage during 
apoptosis into 20 and 10 kDa active products (Yang et al. 1997). Nicholson et al.
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(1995) showed that caspase-3 cleaves poly[adenosine diphosphate-ribosejpolymerase 
(PARP), a DNA repair enzyme, cleavage of which commits cells to apoptose 
(reviewed by Kyipianou et al. 2000). Cardone et al. (1998) showed that pro-caspase-9 
was inactivated by phosphorylation via Akt. Initiator caspases include -1,-2, - 8  and - 
10 .
Pro-apoptotic factors promote cell death. When Bcl-2 associated x-protein (Bax) 
homodimerizes it enhances apoptosis. The anti-apoptotic effect of Bcl-2 may be due 
to its ability to inhibit Bax homodimerization (Denmeade et al. 1996). Bax inserts into 
mitochondrial membrane, induces hypeipolaiisation of the proton gradient, triggers 
cyt c release and generates reactive oxygen species. But Bax can Idll independent of 
Apaf-1 and cyt c by generating reactive oxygen species which damage molecules and 
membranes (reviewed by Jin & Reed 2002).
Bad is a member of the Bcl-2 family that promotes cell death and is resident in the 
cytosol. BAD exerts its apoptotic effects by combining with the anti-apoptotic B c1-x l . 
Del Peso et al. (1997) demonstrated that Bad can be phosphorylated and inactivated 
by Akt. Bad phosphorylation by P13K was confiimed by Datta et al (1997). 
Treatment of cells with an inhibitor of MEK did not significantly block BAD 
phosphorylation, whereas inhibition of PI3K did. BAD phosphorylation at one or both 
of its sites (ser-112 or ser-136) prevents its interaction with Bcl-2 or B c1-Xl .
Cyt c is located in the mitochondrial inter-membrane space and its release into the 
cytosol is necessai'y for the mitochondrial pathway of apoptosis. Cyt c is released into 
the cytosol is required for caspase-3 activation. It is synthesised by cytosolic 
ribosomes as apocytochrome c and then translocated to the mitochondria where 
covalent attachment of haem group occurs (Yang et al. 1997). Caspase-9 is activated
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by cyt c combining with Apaf-1 (apoptotic protease activating factor) -  this is the 
apoptosome (reviewed by Igney & Krammer 2002).
Ceramide is one example of lipid second messengers involved in signal transduction. 
Actions of ceramide include apoptosis, cell proliferation, differentiation and 
inflammation and modulating immune system. Apoptotic or mitogenic effects of 
ceramide appear to be cell type specific (reviewed by Ballou et al. 1996).
Activating sphingomyelinase leading to ceramide production could play an important 
part in apoptosis. Zhou et al. (1998) demonstrated that ceramide inhibited Akt and 
therefore decreased activity of a survival pathway. Targets for ceramide include 
ceramide activated protein kinase and ceramide activated protein phosphatase, but it is 
not known how ceramide decreases Akt activity.
Anti-apoptotic Factors
Anti-apoptotic factors include Bcl-2, Bcl-xl, Mcl-l and the lAPs. They mediate cell 
survival. Bcl-2 family members regulate apoptosis at the mitochondrial level. Some 
are pro-apoptotic (described above); here some of the anti-apoptotic, oncogenic 
members are briefly described.
Bcl-2 is a 26 kDa protein located mainly on the outer mitochondrial membrane. Its 
over-expression prevents cells from undergoing apoptosis in response to a variety of 
stimuli (reviewed in the Discussion). Many homologues of Bcl-2 have been described. 
They include Bcl-2 itself, B c1-Xl and Bax. They form homo- or heterodimers with 
each other or with pro-apoptotic Bcl-2 family members (reviewed by Denmeade et al. 
1996). Purified recombinant Bcl-2 exhibits pore forming activity. Its induced over­
expression can lead to malignant transformation, but it is unique among the oncogenes 
because it decreases apoptosis, rather than increasing proliferation rate. Haidar et al.
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(1995) showed that Bcl-2 serine phosphorylation resulted in its inactivation. Mcl-l is 
a cell survival factor, induced by a number of growth factors and cytokines. For 
example, Lin et al. (2001) demonstrated the importance of Mcl-l in mediating a 
resistant phenotype in lung adenocarcinoma cells.
Seven members of the lAPs have been identified in human cells: NIAP, cIAPl, 
cIAP2, XIAP, survivin, apollon and livin. All except NIAP inhibit caspases-3 and -7, 
cIAPl, cIAP2 and XIAP also inhibit caspase-9 (Mceleny et al. 2001). Caspase 
inhibition is not the only function of lAPs . They are also involved in cell cycle 
regulation, protein degradation and caspase independent signal transduction pathways. 
Whilst the first level of caspase regulation is by controlling zymogen activation, the 
second level involves lAPs, which inhibit activated caspases. Survivin transcription is 
controlled in a cell cycle dependent manner and is induced at the G2M boundary. 
XIAP, cIAP2 and Bcl-2 are regulated by NFKB (reviewed by Salvesen & Duckett 
2002).
Elevated survivin has been reported in many cancers, including prostate (Ki'ajewska et 
al. 2003). As survivin is associated with poor survival and more aggressive cancers it 
has been postulated as a potential prognostic marker. For example, in gastric cancer 
patients who received cisplatin, survival was longer for patients with low survivin (38 
months) in comparison to patients with raised survivin (24 months) (Nakamura et al. 
2004).
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Figure 5.2 The Two Major Apoptotic Pathways. An overview of the interaction 
between the death receptor and mitochondrial pathways in effecting the apoptotic 
response (Taken from Igney & Krammer 2002).
The apoptotic response and some key factors involved in this process is summarised 
in Figure 5.2. It shows how the death receptor and mitochondrial pathways can 
operate independently or in concert to effectuate apoptosis.
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S.2.2.4 Apoptotic Defects in Cancer
The biochemistry of apoptosis has been briefly outlined above. When cells no longer 
receive a growth stimulus (androgen ablation for prostate cancer for example) or their 
DNA is damaged (treatment with carboplatin for example) it is intended that they 
commit to the apoptotic program. Cancer cells frequently acquire genetic changes 
which allow them to survive signals which would noimally kill them. This can occur 
either by inactivation of apoptotic factors or over-expression/ activity of anti- 
apoptotic factors. COX-2 involvement in mediating a resistance to apoptosis was 
reviewed in Chapter 1.2.5.2. Prostate cancer cells aie resistant to apoptosis inducing 
agents (Chapter 4 and this Chapter), and this could be achieved by redundancy in the 
systems involved in preventing, repairing or tolerating DNA damage. This means that 
a cell may have several anti-apoptotic mechanisms and to enhance therapy, targeting 
of more than one pathway may be required. Here we discuss other reported changes in 
cancer cells which can mediate an oncogenic, anti-apoptotic phenotype.
Changes implicated in modulating the apoptotic threshold in advanced prostate cancer 
include p53 mutation, Bcl-2 over-expression and androgen receptor constitutive 
activity or amplification. Other genes that might influence the apoptotic threshold are 
retinoblastoma, c-myc, p21^^^\ p l 6 , PTEN and ras (reviewed by Howell et al.
2000). Reported inactivation/ down-regulation of pro-apoptotic factors implicated in 
carcinogenesis include Bax (which is induced by p53), Apaf-1, caspase-8 . Fas and 
DR4 and DR5 (reviewed by Igney & Kiammer 2002). FLIP has been shown to be up- 
regulated in some tumours as have death receptor decoys. Survivin, the lAP is found 
in most tumours but not normal tissues (reviewed by Igney & Kiammer 2002).
It is thought that androgen ablation in androgen independent cells does not result in 
sustained increase in intracellulai* calcium. Experiments show that androgen
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independent prostate cancer cells can be induced to apoptose at any stage of the cell 
cycle i.e. is proliferation independent, by increasing intracellular' calcium for a 
sufficient time (reviewed by Denmeade et al. 1996). Thus, calcium could be a target 
for therapy for androgen independent cells, in particular the endoplasmic/ 
sarcoplasmic reticulum Ca^^-ATPase. Treatment of androgen independent prostate 
cancer cell line with thaspigargin, an inhibitor of ER/SR Ca^^-ATPase, results in 
increase in intracellular calcium and eventually apoptosis after characteristic 
biochemical and morphological changes (reviewed by Tapia-Vieyra & Mas-Oliva 
2001).
In cancer, alterations in either the DNA damage sensing machinery or the mechanisms 
that implement the response become important. One role of p53 is to transduce DNA 
injury stimuli into the apoptotic or cell cycle anest programme. p53 is mutated in half 
of all cancers. The majority of these are point mutations, resulting in amino acid 
substitutions (reviewed by Vousden & Lu 2002).
CDKN2A is the gene which encodes for ARE, which binds to and inactivates MDM2, 
which targets p53 for degradation). This mutation is common in many tumours. 
Sometimes wild type p53 is expressed but it fails to suppress tumour growth and this 
may be due to lack of ASPP (apoptosis stimulating protein of p53), which enhances 
the transcriptional activity of p53 (reviewed by Igney & Krammer 2002).
Various studies show Bcl-2 over-expression in cancer cells and tumour samples in 
comparison to normal, non-cancerous samples. These will be reviewed in greater 
detail in the discussion. Alterations in the PTEN and PI3K pathways is frequently 
cited in the literature as causative factors in carcinogenesis. This will be discussed 
further in Chapter 6 . Indeed, PTEN is one of the most frequently mutated genes in 
human cancer (Yuan & Whang 2002).
143
Chapter 5 Effects o f COX-2 on the Cell Cycle and Apoptosis
The experimental evidence for the involvement of COX-2 in attenuating apoptosis 
was presented in Chapter 1.2.5.2. In this Chapter we have briefly described events in 
cell cycle control and apoptosis. We now present our data which demonstrates the role 
of COX-2 in modulating the cell cycle and apoptosis.
5,3 Results
5.3.1 Effects of COX-2 on the cell cycle
We hypothesised that the resistance mediated by COX-2 in LNCaP cells to 
carboplatin could be caused by modulation of the cell cycle, apoptosis or both. We 
assessed the effect of COX-2 on cell cycle events by a variety of mechanisms. These 
included PI staining by flow cytometry and measuring changes in proteins levels of 
p53, p27^ ^^  ^ and cyclin Bl, key molecules involved in the control of the cell cycle. 
Activation of cyclin Bl has been shown to facilitate the transition from S phase to the 
G2M phase. These phases of the cell cycle are important when considering the effects 
of agents like carboplatin on cell cycle blockade.
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Figure 5.3 Changes in the cell cycle caused by carboplatin in LNCaP-Neo and 
LNCaP-COX-2. DNA histograms measured by flow cytometric analysis of PI 
binding after 24 and 48 hours treatment with 70 pM earboplatin. Cells were 
harvested, fixed at 4°C for 24 hours, incubated with 0.8 mg/ mL ribonuelease A and 
10 pg/ mL PI and analysed using a Beekman Coulter Epies XL flow cytometer, as 
described in Chapter 2.9. 48 hour data from a further three experiments is tabulated in 
the appendix.
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Figure 5.3 shows examples of typical data obtained from PI analysis of DNA content. 
The percentages in each histogram is an arbitrary assignment of the cell cycle phases, 
Gi, S and G2M, respectively, based on DNA content, following 24 or 48 hours 
carboplatin treatment. These data show that there is a slight differential cell cycle 
response between LNCaP-Neo and LNCaP-COX-2 following 70 pM carboplatin 
treatment, in paiticular an S phase block, which is evident at 24 hours, but becomes 
more prominent at 48 hours. At 24 hours the increases in the S phase cell population 
from contiol is 11% and 5% for LNCaP-Neo and LNCaP-COX-2 respectively and 
34% and 26% at 48 hours. The cell cycle data from a further three experiments is 
tabulated in the appendix.
Carboplatin is more commonly associated with causing a G2M block (Dhanalakshmi 
et aL 2003) in DU145 cells. It is also reported to not cause apoptosis in LNCaP and 
PC-3 cells (Yee et al. 1998). In our LNCaP transfected cells the effect of carboplatin 
is more growth inhibitory and results in the non-classical S phase we observe. 
Because sufficient statistical analysis of the cell cycle effects of carboplatin was not 
performed, cell cycle effects have been assessed by other methods also for 
confirmation of these effects. However, these experiments demonstrated that the 
resistance of LNCaP-COX-2 to carboplatin, as measured by the MTT cell viability 
assay (Chapter 4) relates to cell cycle involvement.
Because there is a differential effect of COX-2 in LNCaP on the cell cycle, as 
assessed by PI binding, we next probed the molecular nature of these events, by 
looking at basal levels and changes in levels of proteins which have cell cycle 
regulatory activity, following carboplatin treatment. These included p53, p27 '^^  ^ and 
cyclin BL
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Figure 5.4 p53 induction following carboplatin treatment is attenuated due to 
COX-2. Levels of p53 protein in control or carboplatin treated LNCaP-Neo and 
LNCaP-COX-2 cells. Both attached and floating cells were harvested following 72 
hour treatment with 100 pM carboplatin, as described in Materials and Methods. 50 
pg protein was electrophoresed on a 1 0 % polyacrylamide gel, transferred to 
nitrocellulose membranes and exposed to murine IgG monoclonal p53 antibody 
(Santa Cruz Biotechnology) at a 1:1000 dilution and a murine IgM p-actin antibody 
(Oncogene) at a 1:10000 dilution. HRP conjugated antibodies to detect murine IgG 
(Sigma) and IgM (Calbiochem) were used at a 1:2000 dilution. Bands were detected 
using ECL (Pierce).
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It can be seen from Figure 5.4 that p53 protein is virtually undetected in control 
LNCaP-Neo and LNCaP-COX-2 cells, but after 100 pM carboplatin treatment for 72 
hours, there is greater p53 induction in Neo versus COX-2 cells. These data are in 
agreement with the IC50 values obtained using carboplatin (Table 4.1). The induction 
of p53 due to DNA damage recognition seen in Neo cells is greater than in COX-2 
cells where presumably less damage is recognised as these cells are more tolerant to 
the effects of carboplatin. These finding suggest that COX-2 mediated attenuation of 
p53 induction is in part responsible for the carboplatin resistance seen in LNCaP- 
COX-2.
The CDK inhibitor p27^ ^^ * is a downstream effector of p53. Because COX-2 
mediated a reduced p53 response after carboplatin treatment, we next assessed if the 
enzyme had the same effect on p27^^^  ^ transactivation.
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Figure 5.5 Transactivation of following carboplatin treatment is
attenuated due to COX-2. Levels of p27^^^ protein in control or carboplatin treated 
LNCaP-Neo and LNCaP-COX-2 cells. Both attached and floating cells were 
harvested following 48 hour treatment with carboplatin, as described in Materials and 
Methods, (a) control cells (b) 10 pM (c) 20 pM (d) 50 pM (e) 100 pM treated cells. 
50 pg protein was electrophoresed on a 10% polyacrylamide gel, transferred to 
nitrocellulose membranes and exposed to rabbit IgG polyclonal p27^ '^^  ^ antibody 
(Santa Cruz Biotechnology) at a 1:1000 dilution and a murine IgM p-actin antibody 
(Oncogene) at a 1:10000 dilution. HRP conjugated antibodies to detect rabbit IgG 
(Dako) and murine IgM (Calbiochem) were used at a 1:2000 dilution. Bands were 
detected using ECL (Pierce).
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It can be seen from Figure 5.5 that both LNCaP-Neo and LNCaP-COX-2 do not 
express p27^ ""^ ^^  basally. Following 48 hour carboplatin treatment, p27^ ^^ ^^  
transactivation occurs for both cell lines, but there is reduced induction in LNCaP- 
COX-2. This is consistent with the data presented in Figure 5.4, which show a 
reduced p53 response in COX-2 over-expressing LNCaP cells. This may not be 
surprising as p27^^^  ^ is a down-stream transcriptional target of p53. Furthermore, as 
P2 7 KIP1 s  phase kinases and we demonstrated a greater S phase block in
LNCaP-Neo (Figure 5.3), it is possible that this is due to greater transactivation of 
p27^ ^^  ^ in LNCaP-Neo.
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Figure 5.6 Changes in the cell cycle caused by celecoxib in LNCaP-Neo and 
LNCaP-COX-2. DNA histograms measured by flow cytometric analysis of PI 
binding after 24 hours treatment with 20 pM celecoxib. Cells were harvested, fixed at 
4°C for 24 hours, incubated with 0.8 mg/ mL ribonuelease A and 10 pg/ mL PI and 
analysed using a Beckman Coulter Epics XL flow cytometer, as described in Chapter 
2.9. Data shown are representative of repeat experiments (n=3).
It can be seen from Figure 5.6 that celecoxib causes a Gi arrest in both cell lines but 
the effect is larger in LNCaP-Neo. Compared to control cells, there are increases of 
16% and 9% in the Gi population for LNCaP-Neo and LNCaP-COX-2, respectively.
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Figure 5.7 p27*^ **** induction following celecoxib treatment is attenuated due to 
COX-2. Levels of protein in control or celecoxib treated LNCaP-Neo and
LNCaP-COX-2 cells. Both attached and floating cells were harvested following 24 
hour treatment with celecoxib, as described in Materials and Methods, (a) control 
cells (b) 5 pM (c) 10 pM (d) 20 pM (e) 50 pM treated cells. 50 pg protein was 
electrophoresed on a 1 0 % polyacrylamide gel, transferred to nitrocellulose 
membranes and exposed to rabbit IgG polyclonal p27*^ ’^ * antibody (Santa Cruz 
Biotechnology) at a 1:1000 dilution and a murine IgM p-actin antibody (Oncogene) at 
a 1:10000 dilution. HRP conjugated antibodies to detect rabbit IgG (Dako) and 
murine IgM (Calbiochem) were used at a 1:2000 dilution. Bands were detected using 
ECL (Pierce).
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Figure 5.7 confirms that constitutively, p27^^^‘ expression in LNCaP-Neo and 
LNCaP-COX-2 could not be detected. After celecoxib treatment, however, there is a 
dose dependent accumulation of p27^^^  ^ in LNCaP-Neo but very little induction in 
LNCaP-COX-2. This finding, in addition to the Trypan blue data (Chapter 4) provides 
accumulating evidence of a resistance to celecoxib in LNCaP-COX-2.
Cyclin Bl expression is necessary for cell cycle progression from the S phase to the 
G2M phase. Alterations in its levels may affect the ability of a cell to proceed past this 
cell cycle check point. We wished to investigate further the nature of the resistance to 
carboplatin in COX-2 over-expressing LNCaP cells, by also assessing the levels of 
this cell cycle progression protein.
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LNCaP-Neo
LNCaP-COX-2
control 10 20 50 100
pM carboplatin, 48 hours
Densitometric scans of Western blot data:
Control 10 pM 20 pM 50 pM 100 pM
LNCaP-Neo 1 . 0 0 1.57 1 . 2 2 0.81 0.99
LNCaP-COX-2 1 . 0 0 1.13 1.04 0.69 0.35
Figure 5.8 Cyclin Bl levels are attenuated in LNCaP cell lines following 
carboplatin treatment. Both attached and floating cells were harvested following 48 
hour treatment with 10-100 pM carboplatin, as described in Materials and Methods. 
50 pg protein was electrophoresed on a 10% polyacrylamide gel, transferred to 
nitrocellulose membranes and exposed to rabbit IgG polyclonal cyclin Bl antibody 
(Santa Cruz) at a 1:200 dilution. HRP conjugated antibodies to detect rabbit IgG 
(Dako) was used at a 1:2000 dilution. Bands were detected using ECL (Pierce). 
Figures in table are from densitometric analysis performed with Quantiscan 
(Biosoftware, Cambridge, UK).
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It can be seen from Figure 5.8 that LNCaP-COX-2 has higher basal levels of cyclin 
Bl than LNCaP-Neo. Following 48 hour carboplatin treatment, there is dose- 
dependent decrease in cyclin Bl levels in both cells. These levels decrease in LNCaP- 
COX-2 to a greater extent than in LNCaP-Neo, but the levels are still more elevated 
than LNCaP-Neo. This suggests that the elevated basal cyclin Bl levels could 
contribute to maintaining LNCaP-COX-2 in cell cycle progression following 
carboplatin treatment. The lower levels observed in LNCaP-Neo may render these 
cells to leave the cell cycle, either by becoming quiescent or aiTesting, by undergoing 
apoptosis, or a combination of these effects. Furthermore, as a greater S phase block is 
in LNCaP-Neo (Figure 5.3), this could be due to the decreased cyclin Bl levels seen 
in these cells.
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LNCaP-Neo 
LNCaP-COX-2
control 10 20 50
pM celecoxib, 24 hours
Densitometric scans of Western blot data:
Control 5 pM 10 pM 20 pM 50 pM
LNCaP-Neo 1 . 0 0 1.32 0.76 0.56 0.25
LNCaP-COX-2 1 . 0 0 1.51 1.64 1.34 0.82
Figure 5.9 Levels of cyclin Bl protein in control or celecoxib treated LNCaP-Neo 
and LNCaP-COX-2 cells. Both attached and floating cells were harvested following 
24 hour treatment with 5-50 pM celecoxib, as described in Materials and Methods. 50 
pg protein was electrophoresed on a 1 0 % polyacrylamide gel, transferred to 
nitrocellulose membranes and exposed to rabbit IgG polyclonal cyclin Bl antibody 
(Santa Cruz) at a 1:200 dilution. HRP conjugated antibodies to detect rabbit IgG 
(Dako) was used at a 1:2000 dilution. Bands were detected using ECL (Pierce). 
Figures in table are from densitometric analysis performed with Quantiscan 
(Biosoftware, Cambridge, UK).
156
Chapter 5 Effects o f COX-2 on the Cell Cycle and Apoptosis
We demonstrated in Chapter 4 that celecoxib had a differential effect on COX-2 non­
expressing and over-expressing LNCaP cells. We postulated that COX-2 mediated a 
different effect following celecoxib treatment and Figure 5.9 shows that the COX-2 
over-expression in LNCaP which mediates a resistance to the effects of the COX-2 
inhibitor may also be due to these changes in cyclin B1 expression. It also confirms 
elevated basal levels of cyclin B1 seen in Figure 5.8. Celecoxib treatment results in a 
dose-dependent decrease in cyclin B1 protein in both LNCaP-Neo and LNCaP-COX- 
2 cells, however, the reduction is much greater in LNCaP-Neo. The explanation 
provided for the resistance to carboplatin of LNCaP-COX-2, in terms of basal cyclin 
B1 levels, may also be partly responsible for the resistance observed to celecoxib i.e. 
COX-2 causes increased cyclin B1 levels after celecoxib treatment.
5.3.2 Effect of COX-2 on apoptosis and apoptotic markers
Having established that COX-2 mediates an inhibition of the growth inhibitory effect 
of cai'boplatin, as determined by IC50 values calculated with the MTT assay (Table 
4.1), we next assessed if over-expression of the enzyme had a similai* effect on the 
apoptotic response of LNCaP cells to carboplatin. We initially utilised the Annexin V- 
FITC apoptosis flow cytometric detection assay, following the manufacturer’s 
instructions (Oncogene Research Products). This assay uses two fluorescent probes, 
PI and AV conjugated to FITC, to distinguish between viable, early apoptotic, late 
apoptotic and necrotic cells. AV binds to a membrane phospholipid, phosphatidyl 
serine (PS), when it is externalised during the apoptotic process. In viable cells, this 
phospholipid is located on the inner surface of the cell membrane and consequently a 
low fluorescent signal is detected.
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Figure 5.10 LNCaP-COX-2 cells are resistant to carboplatin-induced apoptosis.
LNCaP-Neo and LNCaP-COX-2 cells were treated with 100 pM carboplatin for 48 
hours and both floating and attached cells were harvested and prepared for apoptotic 
AV/ PI analysis as described in section 2.10, Materials and Methods. Percentage of 
cells in late stage apoptosis are (a) LNCaP-Neo control 6.9% (b) LNCaP-COX-2 
control 6.1% (c) LNCaP-Neo carboplatin 23.3% (d) LNCaP-COX-2 carboplatin 
10.3%.
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Sample cytograms are from the AV/ PI apoptotic assay are shown in Figure 5.10 for 
control LNCaP-Neo and LNCaP-COX-2 cells (a) and (b), and cells treated with 
carboplatin for 48 hours, (c) and (d). These cytograms show the range of intensity of 
the two fluorescent probes amongst the cells, and data from the upper right quadrant, 
late stage apoptotic cells, is presented and analysed here. A low percentage of 
apoptosis is detected in both control cells, around 6.0% (Figure 5.10a and 5.10b). 
However, greater apoptosis is detected in LNCaP-Neo (23.3%) compared to LNCaP- 
COX-2 (10.3%) after carboplatin treatment. Thus, these data thus confii*m the 
carboplatin resistance of LNCaP-COX-2 that was apparent when we used these cells 
in the MTT assay (Chapter 4). As a result of demonstrating reduced apoptosis in 
COX-2 over-expressing LNCaP cells, we next attempted to claiify if this was due to 
alteration in proteins which modulate the apoptotic response. This was important 
because statistical analysis was also not peifoimed using this flow cytometric analysis 
of apoptosis.
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Figure 5.11 Anti-apoptotic proteins are elevated in LNCaP-COX-2 compared to 
LNCaP-Neo cells. Near confluent cells grown in serum were harvested as described 
in Materials and Methods. 50 pg protein was electrophoresed on a 10% 
polyacrylamide gel, transferred to nitrocellulose membranes and exposed to murine 
IgG monoclonal Bcl-2 and B c 1-xl antibodies and a rabbit IgG polyclonal rabbit 
survivin antibody (all from Santa Cruz) at 1:1000, 1:100 and 1:200 dilution, 
respectively. A murine IgM p-actin antibody (Oncogene) was used at a 1:10000 
dilution. HR? conjugated antibodies to detect murine IgG (Sigma), rabbit IgG (Dako) 
and IgM (Calbiochem) were used at a 1:2000 dilution. Bands were detected using 
ECL (Pierce).
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The Western blot analyses of basal cells in Figure 5.11 demonstrates that three anti- 
apoptotic proteins, Bcl-2 , B c1-x l  and survivin are expressed at a greater level in 
LNCaP-COX-2 in comparison to control transfected LNCaP-Neo cells. Although 
individually, the elevation of these three proteins in LNCaP-COX-2 is not massively 
increased on an individual basis when compared with LNCaP-Neo, the elevation of 
the proteins combined could be a contributing factor towards the resistance to 
carboplatin in COX-2 expressing cells. We also assessed if transient transfection of 
COX-2 into PC-3 cells had the same effect as in LNCaP. However, no significant 
elevation of anti-apoptotic proteins was obseiwed in PC-3-COX-2 transient 
transfectant cells compared to PC-3-Neo (data not shown).
5.3.3 Effect of COX-2 on TRAIL and Fas
Having established that anti-apoptotic proteins are relatively increased in LNCaP- 
COX-2 versus LNCaP-Neo and that there is reduced apoptosis in these cells, we 
wanted to assess if COX-2 could affect the sensitivity to the endogenous apoptosis 
inducing ligands Fas and TRAIL. Because the effect these agents have on these cells 
often appeal's contradictory in the literature (Chapter 5.2.2.2), we measured cell 
viability using more than one technique.
Because the transfection of PC-3 was transient only, we performed Fas and TRAIL 
experiments in LNCaP only. We used the HeLa cell line as a positive control, which 
is known to be sensitive to both Fas and TRAIL.
161
Chapter 5 Effects o f  COX-2 on the Cell Cycle and Apoptosis
120
1 0 0 -
80 -
5oO)
40 -
2 0 -
10 100 1000
TRAIL concentration (ng/ ml)
LNCaP-Neo LNCaP-COX-2 HeLa
Figure 5.12 COX-2 over-expression in LNCaP cells does not confer resistance to
TRAIL. LNCaP-Neo and LNCaP-COX-2 are resistant to 5-200 ng/mL TRAIL, whilst 
HeLa are sensitive to TRAIL, in the absence of any sensitising agent. HeLa and 
LNCaP transfectants were plated at 3x10'^ / mL in 96 well plates and grown for 24 
hours, followed by 24 hour TRAIL exposure. No difference in sensitivity to TRAIL 
between LNCaP-Neo and LNCaP-COX-2 is observed. Percentage growth determined 
by the MTT assay. Each data point represents the average of 3 independent 
experiments ± S.D.
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Figure 5.12 shows that up to 200 ng/mL human recombinant TRAIL did not cause 
any significant reduction in cell viability of either LNCaP-Neo or LNCaP-COX-2 for 
48 hours, whereas HeLa were sensitive to TRAIL in a dose-dependent manner, as 
assessed by the MTT assay. There was no significant difference in sensitivity to 
TRAIL between the LNCaP COX-2 negative and positive cells. When resistance to 
Fas or TRAIL is observed, some cells can be sensitised to these agents with the use of 
cycloheximide (CHX), or PI3K or MAPK inhibitors. Sah et al. (2003) showed that 
CHX activates the stress activated protein kinase (SAPK or INK) and p38 MAPK 
pathways. CHX inhibits protein synthesis and could prevent the synthesis of proteins 
which mediate TRAIL or Fas resistance. However, we did not observe significant 
sensitisation to TRAIL in either LNCaP-Neo or LNCaP-COX-2 when the cells were 
concomitantly treated with either CHX or the PI3K inhibitor wortmannin (data not 
shown). Thus, in LNCaP cells, COX-2 over-expression does not cause any further 
resistance to the effects of TRAIL, and this may be because mock transfected, empty 
vector cells are inherently resistant to TRAIL.
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Figure 5.13 COX-2 over-expression in LNCaP cells does not confer resistance to 
Fas. LNCaP-Neo and LNCa7P-COX-2 are resistant to Fas, whilst HeLa. HeLa and 
LNCaP transfectants were plated at BxlO' /^mL in 6  well plates and grown for 24 hours. 
Then 200 ng/mL Fas or 1 pg/mL CHX, alone or combined, or medium alone was 
added and the cells monitored visually under the microscope for evidence of cell 
death, (a) HeLa control; (b) HeLa+ CHX+ Fas; (c) LNCaP-Neo control; (d) LNCaP- 
Neo+ CHX+ Fas; (e) LNCaP-COX-2 control; (f) LNCaP-COX-2+ CHX +Fas. 
Photomicrographs magnification x200.
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We next performed a non-quantitative test to assess the effects of COX-2 over­
expression on CD95 Fas IgM (CH-11 clone) mediated cell death. Again, HeLa cells 
were used as a positive control. Because both LNCaP mock and COX-2 transfectants 
were resistant to 0.5pg/mL Fas alone (data not shown), CHX was added at the time of 
treatment. Many cell types are reported to become sensitive to Fas in the presence of 
CHX. Although this protein synthesis inhibitor had the ability to hasten the onset of 
moiphological cell death in HeLa it did not significantly sensitise either LNCaP-Neo 
or LNCaP-COX-2 to Fas (Figure 5.13). Thus, in LNCaP, COX-2 over-expression 
does not cause resistance to the effects of Fas, as mock transfected cells are inherently 
resistant to Fas. This finding is similar to the TRAIL results, namely that the LNCaP 
cell line is largely resistant to these agents and COX-2 does not affect this resistance.
5.4 Discussion
COX-2 and the Cell Cycle
These data presented in this Chapter have shown that COX-2 over-expression in 
LNCaP cells mediated an attenuation of the cell cycle inhibitory effects of carboplatin 
and celecoxib, and that COX-2 attenuated apoptotic processes underlie cai'boplatin- 
induced cytotoxicity.
We saw subtle differences in cell cycle abrogation following carboplatin treatment 
between LNCaP-Neo and LNCaP-COX-2 cells. A noticeable difference was seen by 
the lack of p53 and p27^^^  ^ induction in carboplatin treated LNCaP-COX-2 cells.
Di Felice et al. (1998) found that in p53 wild type Y79 retinoblastoma cells, both 
cisplatin and carboplatin caused apoptosis. In cis-resistant lines they developed, they 
observed reduced p53 induction with cisplatin. These data are in line with our 
findings, in the sense that a cell line resistant to the effects of carboplatin (LNCaP-
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COX-2) also demonstrated reduced p53 induction (Figure 5.4). They assessed the 
induction of a p53 down-stream target, p21^^^\ and found that it was detected only 
in the cisplatin sensitive line after cisplatin treatment. Although we did not assess 
difference in p21^^^‘ levels between LNCaP-Neo and LNCaP-COX-2, we 
demonstrate a similar effect with the CDK inhibitor, p27^^^\ i.e. reduced induction 
after carboplatin treatment.
Dhanalakshmi et al. (2003) demonstrated an S phase aixest with 20 juM carboplatin 
and a G2M aiTest with 2 fiM. cisplatin, although AV/ PI assessment showed that 
carboplatin was more effective than cisplatin in inducing apoptosis. Consistent with 
the G2M block, cdc2 (needed for progression from G2M) and cyclin B1 (which 
activates cdc2) were decreased. Thus, carboplatin has been demonstrated to cause 
apoptosis, as well as a cell cycle aixest in a variety of cancer cell lines and our data 
shows that COX-2 mediates a resistance to these effects in the LNCaP cell line. 
Grimberg et al. (2002) showed that introduction of p53 into PC-3 caused apoptosis in 
serum free media. In p53 wild type H460 lung caicinoma cells, reducing p53 levels by 
E6  gene transfection reduced apoptosis. Tang et al. (1998) showed that growth factor 
withdrawal led to differences in survival between noixnal human prostate, BPH cells 
and the metastatic prostate cancer lines LNCaP, PC-3 and DU145. These studies 
demonstrate the importance of p53 in protecting against tumourigenesis. Although we 
did not detect a difference in survival between LNCaP-Neo and LNCaP-COX-2 
following serum withdrawal (data not shown), COX-2 does attenuate p53 induction 
following carboplatin treatment.
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In agreement with findings of others (reviewed below) we showed that celecoxib 
mediated a Gi aixest in both LNCaP cell lines, but a greater Gi aixest in LNCaP-Neo 
was detected compared to LNCaP-COX-2.
There have been several reports of the cell cycle aixest properties of celecoxib in 
various cell lines. Maier et al (2004) perfoixned COX-2 tiansfection in a colon 
cai'cinoma line and found that 2 0 - 1 0 0  pM  celecoxib had a stronger apoptotic effect in 
the COX-2 expressing clone, but there were no differences between COX-2 positive 
or negative cells for levels of cyclins A and B1 in p21^^^^ and p27^^^* protein or cell 
cycle effects. This suggests that celecoxib caused COX-2 dependent apoptosis, but 
COX-2 independent Gi cell cycle aixest and that the pro-apoptotic effects of celecoxib 
here are associated with COX-2 inhibition. They found concentration dependent 
decreases in cyclins A and B1 and increases in p21^^^^ and p27^ '^ *‘^ \ which was COX- 
2 independent. These effects were noticeable at levels lower than needed for 
apoptosis. These findings were similar to those of a Hsu et al (2000) study which also 
found that COX-2 expressing cells were more sensitive to celecoxib induced 
apoptosis. Leng et al. (2003) also suggest that celecoxib causes apoptosis by both 
COX-2 dependent and independent means.
Patel et al. (2005) showed that 5(jlM celecoxib, but not rofecoxib, caused growth 
aixest in both PC-3 and LNCaP cells, which were both COX-2 negative, over 96 hours 
and this was associated with a Go/ Gi block and cyclin D l reduction. In PC-3 mice 
xenografts, celecoxib caused dose dependent reduction in tumour volume via reduced 
Ki-67, CD34, microvessel density and cyclin D l.
Cheng et al (2004) showed that 1 mM of the COX-2 inhibitor etodolac caused growth 
inhibition in two hepatocellular carcinoma cell lines, in COX-2 positive but not COX- 
2  negative fibroblasts, although PGEg addition did not protect against this growth
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inhibition, suggesting that etodolac effects were COX-2 independent. There was 
PCNA inhibition, induction of p2l''^^^^ and p27^^^\ inhibition of CDK2 and 4, 
CDC2, cyclins A and Bl.
The review of the data above in the literature confirms that COX-2 inhibitors, and 
celecoxib in particular, have cell cycle aixest properties. As will be discussed below, 
celecoxib also causes apoptosis in cancer cell lines, although typically, higher 
concentrations are needed. Our data is in general agreement with these studies, 
because we also demonstrate a Gi aixest, reduction of cyclin Bl levels and induction 
of p27^ ^^ * following celecoxib treatment of LNCaP cells. However, the main 
hypothesis of this study was to identify mechanisms responsible for COX-2 
attenuation of cell cycle aixest and, our data shows that COX-2 has the effect of 
reducing p53 and p27^^^  ^ and also elevating cyclin Bl. However, we did not assess if 
this activity is PGE2 dependent. We know that resistance to carboplatin is PGE2 or 
enzyme activity independent, but this may not be the case for celecoxib.
COX-2 and Apoptosis
A second flow cytometric assay, the AV/ PI apoptotic assay, provided evidence that 
COX-2 reduced the levels of apoptosis following carboplatin treatment, in addition to 
modulating cell cycle parameters (Figure 5.10). It was found that Bcl-2, B c1-xl  and 
survivin were elevated in LNCaP-COX-2 compared to LNCaP-Neo (Figure 5.11). 
However, COX-2 over-expression did not modulate the response of LNCaP cells to 
TRAIL (Figure 5.12) or Fas (Figure 5.13).
Other groups have demonstrated anti-apoptotic effects of COX-2, although not in 
prostate cancer cells (Tsuji & DuBois 1995, Lin et al. 2001, Nzeako et al. 2002). 
Frequently, up-regulation of Bcl-2 or other anti-apoptotic proteins is reported when
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COX-2 is elevated, which also agiees with our findings (Figure 5.11). Lin et al.
(2001) transfected COX-2 into lung adenocarcinoma cells and showed resistance to 
vinblastine induced apoptosis via elevated Mcl-l protein. Tsuji & Dubois (1995) 
showed that in rat intestinal epithelial cells, COX-2 transfection caused altered extra­
cellular matrix adhesion and resistance to butyrate induced apoptosis, increased Bcl-2 
levels and decreased expression of E-cadherin. Sulindac sulphide was able to reverse 
the inhibition of apoptosis and the increased cellulai* adhesion. Sun et al. (2002) 
transfected colon carcinoma HCT-115 cells with COX-2 cDNA and found it reduced 
apoptosis induced by NS398, sulindac sulphide and 5-fluorouridine. Bcl-2 mRNA 
levels were increased and there was reduced caspase activation. 40 and 80 pM NS398 
reduced PGE2 levels but it did not reverse COX-2 mediated apoptotic resistance. 
Kj-ysan et al. (2004) showed that COX-2 transfection and 10 pg/mL in NSCLC cells 
enhanced survivin protein levels. Survivin levels were reduced with COX-2 depletion. 
They found that survivin ubiquitination was reduced in COX-2 cells, stabilising 
survivin levels. We too report elevated survivin in COX-2 transfected LNCaP cells, 
although we have not confirmed if this is due to survivin stabilisation or enhanced 
transcription of the survivin gene.
The importance of Bcl-2 over-expression in prostate cancer has been highlighted in 
several studies, and this over-expression has been shown to mediate a resistant 
phenotype. It is interesting to note the valuations in basal Bcl-2 levels reported in 
LNCaP in particular. We observed Bcl-2 protein expression in LNCaP, however some 
groups do not detect Bcl-2 and have to perform transfection. For example Fujita et al.
(2002) transfected COX-2 into LNCaP cells but did not detect elevation of Bcl-2 
mRNA, whereas we observed elevation of Bcl-2 protein in COX-2 expressing LNCaP 
cells (Figure 5.11). Takeuchi et al. (1996) however did not detect Bcl-2 protein in
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both parental LNCaP and PC-3 cells, which highlights again differences in 
characteristics of supposedly identical cell lines between different research 
laboratories. We consistently detected Bcl-2 via Western blotting in both LNCaP and 
PC-3 cells. Tang et aL (1998) agree with oui' findings, that PC-3, LNCaP and DU145 
all express Bcl-2 and B cI-x l-
Marcelli et al. (1999) showed that Bcl-2 transfection into LNCaP cells prevented 
breakdown of the mitochondrial membrane potential in response staurosporine and 
transfection of caspase-7 restored apoptosis even in the Bcl-2 transfectant. Rokhlin et 
al. (2001) used PC-3 cells transfected with Bcl-2 and showed that this mediated a 
resistance to TRAIL. Raffo et al. (1995) used a stable LNCaP-Bcl-2 transfectant in 
vivo to show that Bcl-2 caused a resistance to apoptosis after androgen depletion. 
Furthermore, only the Bcl-2 transfected cells foi*med tumours when injected into 
castrated, male nude mice. Kajiwara et al. (1999) showed that Bcl-2 transfection into 
LNCaP caused resistance to the growth suppressing effects of androgen and serum 
deprivation. Xenografts in nude mice showed higher tumourigenicity, faster initial 
growth rate and less tumour volume decrease following castration in the Bcl-2 
transfected cells. Berchem et al. (1995) showed that DHT induced Bcl-2 protein in 
LNCaP and this resulted in a resistance to etoposide induced apoptosis. Anti-sense 
Bcl-2 abrogated this protective effect.
In contrast, some reports also suggest that Bcl-2 and B c1-Xl do not cause a resistance 
to apoptosis. Jendrossek et al. (2003) showed that in Jurkat cells celecoxib induced 
apoptosis via mitochondria, but neither Bcl-2 or B c1-Xl could rescue the cells. Hence 
the mechanism of cell kill was cyt c dependent but Bcl-2 family independent. 
However, overall, the literature supports a role for Bcl-2 in mediating a resistance to 
apoptosis. In the majority of these experiments Bcl-2 can be identified as the major
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mediator of this resistance because this protein was specifically elevated in these 
experiments by transfection. However, we cannot be certain about how important Bcl- 
2 is in mediating resistance in LNCaP-COX-2 to carboplatin, celecoxib or etoposide. 
Bcl-2 is only one of three anti-apoptotic proteins known to be raised in this model, 
and we have not attempted to assess the relative importance of each.
Studies also highlight the impact of elevated B c1-Xl  in prostate cancer cells. In a 
manner similar to Bcl-2, elevation of B c1-Xl  produces a resistant phenotype. Yang et 
al. (2003) and Li et al. (2001) showed that elevated B c1-x l  in PC-3 cells compared to 
LNCaP prevented PC-3 from apoptosing when treated with the PI3K inhibitor 
LY294002. Transfection of B c1-x l  into LNCaP caused resistance to apoptosis, and 
down-regulation of B c1-Xl  in PC-3, made PC-3 sensitive to LY294002. Lebedeva et 
al. (2000) showed that B c1-x l  transfection into PC-3 and LNCaP desensitised these 
cells to mitoxantrone, paclitaxel, etoposide and cai'boplatin. Various strategies to 
down-regulate B c1-xl  had the opposite effect. Vilenchik et al. (2002) showed that Bcl- 
Xl down-regulation in LNCaP and DU145 reduced cellular growth, but an increase in 
other anti-apoptotic proteins, PKCa, XIAP and cIAPl was observed. B c1-x l  down- 
regulation was associated with resistance to cai'boplatin, etoposide, mitoxantrone, 
paclitaxel and vinblastine. Re-introduction of B c1-Xl restored cell sensitivity and 
growth rate. This suggests that at low concentrations, B c1-xl  affected growth rate, 
rather than being anti-apoptotic.
We also reported elevation of the lAP survivin in LNCaP-COX-2 cells. Several other 
studies demonstrate lAP elevation in cancer cells. Krajewska et al. (2003) 
demonstrated elevated levels of cAIPl, cIAP2, XIAP and survivin in BPH, localised 
prostate cancer samples and T1-T4 metastatic samples and in the TRAMP mouse. 
Mceleny et al. (2001) showed that NIAP, survivin and cIAP2 were elevated in PC-3
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and DU145 compared to LNCaP and this was associated with resistance to etoposide. 
Nakamura et ah (2004) found no relationship between survivin expression and tumour 
histology, invasion depth, or lymph node metastasis or stage. But patients with lower 
survivin had higher survival. Patients who received cisplatin, survival was longer for 
patients with low survivin (38 versus 24 months). They hypothesised that high 
survivin was mediating resistance to cisplatin therapy, shortening overall survival.
Fas and TRAIL
Even though anti-apoptotic Bcl-2, B cI-xl  and survivin were elevated in LNCaP-COX- 
2 compared to LNCaP-Neo, we were not able to demonstrate a differential sensitivity 
to either Fas or TRAIL. It should be noted that the parental LNCaP cells had an 
inherent resistant phenotype to these two agents (Figures 5.12 and 5.13). As will be 
discussed below, the literature differs in the reported sensitivities of prostate cancer 
cell lines to Fas and TRAIL. Often the same clone of antibody or recombinant protein 
is not used and different clones are likely to have different potencies. Cell viability or 
apoptosis is reported in different ways. We assessed the effects of Fas by 
photomicrography and of TRAIL by MTT assay and reported a resistance of LNCaP 
cells to these two agents. Had we performed specific apoptotic assays, such as 
measuring DNA fragmentation, caspase activation or cyt c release, could sensitivity 
have been potentially reported? Even though there was no evidence of morphological 
cell death with Fas by photomicrography or with TRAIL by the MTT assay, other 
assays may detect small amounts of cell kill or growth inhibition.
There have been no reports in the literature on the effects of COX-2 on the sensitivity 
of prostate cancer cells to agents such as Fas and TRAIL. In other cancer cells, COX-
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2 has been shown to cause resistance to Fas and TRAIL. For example, Nzeako et al.
(2002) showed that in cholangiocarcinoma cells, either transfecting or inducing COX- 
2 inhibited Fas (but not TNF-a or TRAIL) mediated apoptosis. Mcl-l was up- 
regulated. Tang et al. (2002) transfected COX-2 into colorectal cells and assessed the 
effect on TRAIL induced apoptosis. COX-2 cells had lower DR5 mRNA and elevated 
Bcl-2 mRNA with less caspase-3, - 8  and -9 activation. Sun et al. (2002) performed 
COX-2 transfection in colon cancer cells and found that it caused repression of DR5 
transcription.
Rokhlin et al. (1997) showed that PC-3 and DU-145 needed CHX to be made Fas- 
sensitive, whereas LNCaP remained resistant even with CHX co-treatment. Takeuchi 
et al. (1996) report that PC-3 and LNCaP do not express the Fas receptor and 
consequently aie resistant to Fas. Transfection of the FasR into PC-3 and LNCaP 
converted PC-3 but not LNCaP to a Fas sensitive phenotype. In nude mice xenografts, 
growth of the Fas receptor transfectants was retarded compared to control cells. 
Hedlund et al. (1998) coixelated the sensitivity of prostate cancer cells to the clinical 
stage of the parental tumours. They showed that metastatic prostate cancer lines were 
resistant to Fas, but cell lines derived from primary tumours were Fas sensitive. But 
this resistance did not conelate to pathological grade or androgen sensitivity. Jiang et 
al. (2002) showed that there was elevated levels of Fas and Fas ligand in prostate 
adenocarcinoma and PIN samples versus benign prostate tissue obtained from radical 
prostatectomy. They suggest that up-regulation of Fas signalling in malignancy may 
allow cells to escape immune surveillance by lymphocytes and natural killer cells. But 
the malignant cells themselves do not undergo apoptosis.
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Reports in the literature of prostate cancer cell lines’ sensitivity to TRAIL is quite 
variable. Our data that LNCaP cells are resistant to TRAIL is in agreement with many 
other groups (Munshi et al. 2002, Kelly et al. 2002, Bid et al. 2002). Nimmanapalli et 
al. (2001) however report that LNCaP cells are sensitive to TRAIL. In addition, PI3K 
inhibition has been shown to reverse LNCaP resistance to TRAIL (Nesterov et al. 
2001, Rokhlin et al. 2002, Chen et al. 2001). Whilst there appears to be some 
consensus that DU145 cells aie sensitive to TRAIL (Nesterov et al. 2001, Yu et al. 
2000, Chen et al. 2001, Nimmanapalli et al. 2001), PC-3 cells have been reported to 
be both sensitive (Nesterov et al. 2001, Rokhlin et al. 2002, Griffith et al. 2000, Yu ef 
al. 2000, Nimmanapalli et al. 2001) and resistant (Munshi et al. 2002, Sah et al. 2003, 
Eid et al. 2002) to TRAIL.
In this chapter we have presented data which shows that the resistance observed to 
carboplatin and celecoxib in LNCaP-COX-2 versus LNCaP-Neo is due to both a 
reduced cell cycle block and lower levels of apoptosis. p53 and p27^ ^^ * induction was 
greater in LNCaP-Neo following cytotoxic carboplatin and celecoxib treatment. Basal 
cyclin Bl was elevated in LNCaP-COX-2. Elevated anti-apoptotic markers Bcl-2, 
B c1-Xl  and survivin may be associated with this resistance to carboplatin in LNCaP- 
COX-2. However, we did not observe an effect of COX-2 on the sensitivity of LNCaP 
cells to Fas and TRAIL.
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Chapter 6 Effects of COX-2 on PI3K/ Akt Signalling
6.1 Aims
It was shown in Chapter 4 that COX-2 inhibition could not reverse the carboplatin 
resistance observed in LNCaP-COX-2. Therefore, other mechanisms were sought to 
reverse this resistance in order to clarify the mechanisms responsible. We tried to 
sensitise these LNCaP cells via PI3K/ Akt signalling inhibition because they contain a 
mutation in their PTEN gene which renders the protein dysfunctional, and this PTEN 
inactivity may mediate a resistance which could mask some effects of COX-2. We 
also wished to assess if the changes in cellular apoptotic protein levels following 
COX-2 inhibitor and PI3K inhibitor treatment to help explain the differential effects 
of celecoxib and wortmannin, respectively, on reversing the resistance in LNCaP- 
COX-2 to carboplatin.
6.2 Introduction
Survival of cells in multicellular organisms requires continuous stimulation from the 
extracellular environment, in the form of growth factors. These growth factors 
activate intracellular signalling pathways to promote survival and cell growth. PI3K/ 
Akt is a major cell survival signalling pathway.
6.2.1 PI3K/Akt signalling
PI3K is activated by a number of receptors and is involved in cell survival signalling. 
It phosphorylates inositol (PI) lipids, the phosphoinositides, that act as membrane
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restricted 2"  ^ messengers for several targets, including Akt. PI3K transfers a 
phosphate group from ATP to the 3' position of the inositol ring. Growth factors, such 
as PDGF and IGF-1, can promote cell survival by activating PI3K and its downstream 
target Akt. There are multiple mammalian forms of PI3K, and they can phosphorylate 
PIP2 to PIP3 . Indeed, the primary consequence of PI3K activity is generation of PIP3 
in the membrane (reviewed by Vivanco & Sawyers 2002).
PI3Ks are heterodimers of regulatory and catalytic units. The p85 regulatory unit is a 
phosphoprotein substrate of receptor and cytosolic tyrosine kinases via its SH domain, 
pi 10 is the catalytic unit. Activation of PI3Ks follows phosphorylation of the receptor 
tyrosine kinase tail. Ras can also bind and activate the pi 10 unit. PIP3 serves as a 
ligand for recruiting PH domain containing proteins to the cell membrane, most 
important of which is Akt.
6.2.2 Akt
Akt, also known as PKB, was originally described as an oncogene, activated by a 
number of growth factors through a PI3K dependent pathway (del Peso et a l 1997). 
Akt can be directly activated by P13K by binding of PIP2 to its PKB domain. Three 
mammalian members of the Akt family exist; Aktl, Akt2 and Akt3. It is a 57 kDa 
serine/ threonine Idnase, and is located primarily in the cytosol. Its N-terminus 
contains a pleckstrin homology (PH) domain; its C-terminus has a regulatory region 
similai' to PKA and PKC and there is a central catalytic domain.
Akt mediates growth factor induced cell survival and can suppress apoptotic effects of 
a variety of stimuli, including growth factor withdrawal, loss of cell adhesion and 
DNA damage (Datta et ah 1997). The major cancerous effects of Akt activation are 
survival, proliferation and growth.
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Akt has been shown to be activated by PDGF, EGF, bFGF and insulin and this 
activation could be paralleled by phosphorylation of the kinase itself. In vitro, 
phosphatases abolish Akt kinase ability (Burgering & Coffer 1995). Other activating 
stimuli include haemopoietic cytokines (IL-2, -3, -4, -5), heat shock, hypoxia and 
nerve growth factor.
Although PI3K always results in Akt activation, the reverse does not hold; Akt can be 
activated in a PI3K independent manner by phosphoinositide dependent kinase 1 
(PDKl) and cAMP. At the plasma membrane another serine / threonine kinase with a 
PH domain, (PDKl), phosphorylates Akt at thr308, which is sufficient for its 
activation. Akt can be further activated by PDK2 at ser473. Akt activation requires 
both translocation to the membrane and phosphorylation at these 2  residues for 
maximal activation. No specific Akt phosphatases have been identified, and therefore, 
its down-regulation is not understood.
It is known that PI3K inhibition, with agents such as wortmannin and LY294002, 
block Akt activation by growth factors and constitutively activated PI3K increases 
Akt activity independent of growth factor stimulation. The observation that P13K and 
Akt are involved in cell survival could explain why so many oncoproteins, growth 
factors and cell survival factors can activate P13K.
6.2.3 Akt Targets
Akt has a number of cellular targets. It activates some taigets and inactivates others, 
in a manner consistent with its anti-apoptotic, pro-survival function.
Akt activation can rescue cells from p53 mediated apoptosis. It phosphorylates 
MDM2, the protein which taigets p53 for degradation, enhancing its activity, and thus 
promoting p53 degradation (reviewed by Vousden & Lu 2002).
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In LNCaP cells, PI3K and androgen receptor pathways can compensate for one 
another, as androgens can rescue these cells from apoptosis as a result of PI3K 
inhibitors (Carson et aL 1999). Also, PI3K activation can rescue neuronal cells from 
serum or androgen deprivation (Franlce et al. 1997). Akt has been shown to 
phosphorylate the androgen receptor residues at ser210 and ser790. Lin et al. (2003) 
showed that IGF-1 could phosphoiylate the receptor at residue 38, and this effect was 
blocked with LY294002. However, some reports state that this does not occur in 
LNCaP cells and LY294002 treatment does not change the phosphoiylation status of 
the androgen receptor.
Other cell cycle regulatory targets of Akt include E2F (Chapter 5.2.1), a family of 
transcription factors needed for Gi to S phase progression. Akt allows cyclin D l 
levels to accumulate by preventing its degradation by phosphorylation from GSK3p. 
Akt also decreases levels of p21^^^* and p27^^^\
Apoptotic targets of Akt include caspase-9, pro-apoptotic Bad and the kinase which 
degrades the inhibitory unit of the anti-apoptotic transcription factor NF-icB, IKK. 
Bad phosphorylation at 2 serine residues is associated with cell survival, and Akt is 
thought to phosphorylate one residue -  any agents that do this could provide a 
survival signal.
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Figure 6.1 The P I3K / Akt signalling pathway. The mechanism of PI3K dependent 
activation of Akt. Upon activation by PDKl and PDK2 mediated phosphorylation, 
Akt phosphorylates numerous cellular targets, promoting a pro-survival, anti- 
apoptotic response. FKHR = Forkhead transcription factors, 1RS = insulin receptor 
substrate, RAC = Rho family member, SGK = serum glucocorticoid kinase. Other 
abbreviations are referenced elsewhere (Taken from Vivanco & Sawyers 2002).
The PI3K/ Akt signalling pathway is represented diagrammatically in Figure 6.1. 
Some key targets and functions of this pathway are shown. Because of the number of 
cellular targets Akt has, dysregulation of Akt signalling can lead a cell onto the path 
of oncogenesis. This is discussed below.
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6.2.4 PTEN and PI3K/ Akt Dysregulation in Cancer
Amplification of the PI3K/ Akt pathway is observed frequently in many cancers 
(Graff et al. 2000, Nesterov et al. 2001). This can be due to up-regulation or over­
activity of factors which contribute to signalling, or down-regulation or reduced 
activity of factors which negatively regulate the pathway.
The phosphatase and tensin homologue (PTEN) is a negative regulator of the PI3K/ 
Akt pathway (Persad et al. 2000, Davies et al. 2002). It functions as both a lipid and 
protein phosphatase, but it is its lipid phosphatase activity which is important in its 
anti-tumourigenic function (Figure 6.1). Whereas SHIPS (SH2 containing inositol 5' 
phosphatase) 1 and 2 remove the phosphates from the 5' position of the inositol ring, 
PTEN removes them from the 3' position i.e. PTEN converts P I P 3  back to PIP2* In 
unstimulated cells PIP3 is barely detected due to the regulation of PI3K activity by 
PTEN.
PTEN mutation or losses have been reported in many cancers (Carter et al, 1990, 
Trotman et al. 2003). 10q23, the chromosomal location of the gene encoding for 
PTEN, is lost in many cancers, including prostate. Absence of PTEN has been shown 
to coixelate with higher Gleason score, which raises the possibility that PTEN status 
may be useful as a prognostic marker (Malik et al. 2002).
In LNCaP cells, PTEN protein is inactivated due to a frameshift mutation in its gene; 
hence the PI3K/ Akt pathway is constitutively activated, and the cells exhibit 
resistance to apoptosis (Davies et al. 1999, Chen et al. 2001). In these cells there can 
be an escape from growth factor survival dependence. However apoptosis may be 
induced in LNCaP cells with PI3K inhibitors (Carson et al. 1999).
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In cancer, the P13K catalytic unit is sometimes over-amplified, with the mutant 
catalytic unit causing constitutive activation of P13K (reviewed by Franke et al. 
1997). Certain murine strains that have constitutive activation of PI3K/ Akt signalling 
all develop cancer (reviewed by Vivanco & Sawyers 2002).
We have described above the impact of PI3K/ Akt signalling dysregulation, and how 
this is relevant to carcinogenesis. Because of the role of PI3K/ Akt signalling in 
modulating growth and apoptotic responses, and our data which demonstrated a 
modulatory effect of COX-2 on apoptosis and the cell cycle (Chapter 5), in this 
Chapter we provide evidence that COX-2 mediates these effects via activation of the 
PI3K/ Akt pathway in LNCaP cells.
6.3 Results
6.3.1 PI3K inhibition partially sensitises LNCaP-COX-2 to 
carboplatin
Our observations indicated that COX-2 inhibition using celecoxib could not sensitise 
LNCaP-COX-2 cells to caiboplatin (Coley HM, personal communication). Therefore, 
other mechanisms were sought to reverse this resistance. We next attempted 
pharmacological inhibition of the PI3K7 Akt pathway, as COX-2 has been reported to 
activate this pathway (Leng et al. 2003). The results are shown in Figure 6.2, which 
shows that 500 nM wortmannin administered concomitantly with cytotoxic doses of 
carboplatin over a 72 hour period does not significantly alter the IC50 for LNCaP-Neo, 
but there is a significant decrease for LNCaP-COX-2 (p=0.03), although complete 
reversal with PI3K inhibition was not observed.
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Figure 6.2 PI3K inhibition with wortmannin partially reverses the resistance of 
LNCaP-COX-2 to carboplatin. Graphs show IC50 values (pM), obtained from MTT 
assays for LNCaP-Neo and LNCaP-COX-2 treated with carboplatin for 72 hours or 
co-treated with 500 nM wortmannin. LNCaP-COX-2 is resistant to carboplatin in 
comparison to LNCaP-Neo (**p=0.006). Wortmannin significantly reduces the IC50 
of LNCaP-COX-2 to carboplatin (-H-p=0.03).
The data in Figure 6.2 suggests that P13K inhibition, unlike COX-2 inhibition, can 
partially sensitise COX-2 expressing LNCaP cells to carboplatin. However, it should 
be noted that complete reversal of resistance was not achieved.
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6.3.2 is elevated in LNCaP-COX-2
The fact that PI3K inhibition partially reversed the resistance of LNCaP-COX-2 cells 
to carboplatin (Figure 6.2) suggested that the over-expression of COX-2 may be 
activating the PI3K pathway. To test this hypothesis, we assessed the constitutive 
levels of P-Akt®^ '^ '*^ '^ , the downstream effector of PI3K, in LNCaP-Neo and LNCaP- 
COX-2 cells.
m
Total Akt 
LNCaP-Neo LNCaP-COX-2
Figure 6.3 P-Aktser473 levels are higher in LNCaP-COX-2 compared to LNCaP- 
Neo. Near confluent cells were lysed as described in Materials and Methods. 50 pg 
protein was electrophoresed on a 1 0 % polyacrylamide gel, transferred to 
nitrocellulose membranes and exposed to rabbit IgG polyclonal P-Akt®^ '^ '*^  ^ antibody 
(BioSource) at a 1:1000 dilution and a total Akt antibody (BioSource) also at a 1:1000 
dilution. HRP conjugated antibodies to detect rabbit IgG (Dako) were used at a 
1:2000 dilution. Bands were detected using ECL (Pierce).
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Figure 6.3 shows that, as hypothesised, levels are higher in LNCaP-COX-2
than LNCaP-Neo cells. This suggests that COX-2 transfection in LNCaP, by an 
unconfirmed mechanism, activates above basal levels the PI3K pathway. This will be 
discussed further in the Discussion. It should be noted that parental LNCaP cells (and 
hence LNCaP-Neo cells) already express P-Akt®^ "^^ ^^  constitutively due to the PTEN 
mutation -  COX-2 transfection elevates these levels further.
6.3.3 Effect of PI3K inhibition and celecoxib on P-Akt levels
Because celecoxib has also been reported to inactivate the PI3K pathway in prostate 
cancer cells (Hsu et aL (2000), Johnson et al (2001), Zhu et al (2002), Song et a l
(2002)), we hypothesised that celecoxib did not have the ability to inactivate PI3K 
signalling in our LNCaP cells, as it was unable to reverse or partially reverse LNCaP- 
COX-2 resistance to carboplatin.
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Figure 6.4 P-Aktser473 is reduced following both PI3K and COX-2 inhibition.
Levels of P-Akt protein in LNCaP-COX-2 cells following cell growth for 24 hours, 
then treatment with 500 nM wortmannin or 20 pM celecoxib for the times indicated. 
Cells were harvested as described in Materials and Methods. 50 pg protein was 
electrophoresed on a 1 0 % polyacrylamide gel, transferred to nitrocellulose
membranes and exposed to rabbit IgG polyclonal P-Akt®^ '^ '^ ^^  antibody (BioSource) at 
a 1:1000 dilution and a total Akt antibody (BioSource) also at a 1:1000 dilution. HRP 
conjugated antibodies to detect rabbit IgG (Dako) were used at a 1:2000 dilution. 
Bands were detected using ECL (Pierce).
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However, it can be seen from Figure 6.4 that celecoxib, like wortmannin and 
LY294002 (data not shown), had the ability to inhibit PI3K signalling in LNCaP- 
COX-2, as P-Akt®^ *^ ^^  ^ levels were reduced in a time dependent fashion with 20 pM 
celecoxib up to 12 hours. Interestingly, however, by 24 hours basal levels of P-Akt 
were restored. Further, 2-50 /xM celecoxib exposure for 24 hours did not result in a 
reduction of P-Akt levels in LNCaP-COX-2 at that time point (data not shown), 
confirming that at these sub-cytotoxic doses celecoxib only inhibited PI3K in LNCaP- 
COX-2 within 24 hours. Wortmannin inhibited PI3K over a similar time window to 
celecoxib, up to 24 hours. These effects were also observed in LNCaP-Neo cells (data 
not shown). Thus, both COX-2 inhibition and PI3K inhibition can attenuate or inhibit 
PI3K signalling.
6.3.4 Effect of PI3K inhibition and celecoxib on COX-2 levels
To further examine the differences in ability of COX-2 and PI3K inhibition to 
sensitise LNCaP-COX-2 to carboplatin, we asked whether wortmannin, LY294002 
and celecoxib had differential effects on COX-2 levels. We hypothesised that PI3K 
inhibition may reduce COX-2 levels, whereas COX-2 inhibition may not.
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Figure 6.5 PI3K inhibition results in COX-2 reduction. Levels of COX-2 protein 
in LNCaP-COX-2 cells following 48 hour treatment with P13K inhibitors wortmannin 
and LY294002. Cells were harvested as described in Materials and Methods. 50 pg 
protein was electrophoresed on a 1 0 % polyacrylamide gel, transferred to 
nitrocellulose membranes and exposed to murine IgG monoclonal COX-2 antibody 
(Cayman Chemical) at a 1:1000 dilution and a murine IgM P-actin antibody 
(Oncogene) at a 1:10000 dilution. HRP conjugated antibodies to detect murine IgG 
(Sigma) and IgM (Calbiochem) were used at a 1:2000 dilution. Bands were detected 
using ECL (Pierce).
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It can be seen from Figure 6.5 that for both wortmannin and LY294002, at doses 
which inhibit P-Akt levels, but at an extended time point (48 hours) reduce COX-2 
protein levels in LNCaP-COX-2.
Control 20 40
COX-2
p-actin 
60 pM celecoxib
Figure 6.6 Celecoxib causes an increase in COX-2 protein. Levels of COX-2 
protein in LNCaP-COX-2 cells following 72 hour treatment with celecoxib at the 
doses indicated. Cells were harvested as described in Materials and Methods. 50 pg 
protein was electrophoresed on a 1 0 % polyacrylamide gel, transferred to 
nitrocellulose membranes and exposed to murine IgG monoclonal COX-2 antibody 
(Cayman Chemical) at a 1:1000 dilution and a murine IgM P-actin antibody 
(Oncogene) at a 1:10000 dilution. HRP conjugated antibodies to detect murine IgG 
(Sigma) and IgM (Calbiochem) were used at a 1:2000 dilution. Bands were detected 
using ECL (Pierce).
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In contrast to PI3K inhibition, COX-2 inhibition has the opposite effect on cellular 
COX-2 levels i.e. over 72 hours there is a dose dependent increase in COX-2 levels 
(Figure 6 .6 ).
6.3.5 Effect of PI3K inhibition and celecoxib on Bcl-2 levels
As some anti-apoptotic proteins were found to be evaluated in LNCaP-COX-2 
compared to LNCaP-Neo (Figure 5.11), we wished to assess if down-regulation of 
these proteins was involved in the partial reversal of resistance of LNCaP-COX-2 to 
carboplatin by PI3K inhibition.
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Figure 6.7 P13K inhibition results in Bcl-2 reduction. Levels of Bcl-2 protein in 
LNCaP-Neo and LNCaP-COX-2 cells following 24 hour treatment with wortmannin 
and LY294002. Cells were harvested as described in Materials and Methods. 50 pg 
protein was electrophoresed on a 1 0 % polyacrylamide gel, transferred to 
nitrocellulose membranes and exposed to murine IgG monoclonal Bcl-2 antibody 
(Santa Cruz) at a 1:100 dilution and a murine IgM P-actin antibody (Oncogene) at a 
1:10000 dilution. HRP conjugated antibodies to detect murine IgG (Dako) and IgM 
(Calbiochem) were used at a 1:2000 dilution. Bands were detected using ECL 
(Pierce).
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Figure 6.7 demonstrates that PI3K inhibition with both wortmannin and LY294002 
reduced cellular Bcl-2 levels after 24 hour treatment in LNCaP-COX-2. P13K 
inhibition also caused a reduction in Bcl-2 protein in LNCaP-Neo cells but the 
reduction occurred to a smaller extent. This may be a reflection of the lower Bcl-2 
levels in LNCaP-Neo.
Control 12
Bcl-2
p-actin
24 hours
20 pM celecoxib
Densitometric scans of Western blot data, normalised for p-actin:
Control 2 hours 12 hours 24 hours
1 . 0 0 1.40 1.80 1 . 1 0
Figure 6.8 Celecoxib does not decrease Bcl-2 levels. Levels of Bcl-2 protein in 
LNCaP-COX-2 cells following treatment with celecoxib at the times indicated. Cells 
were harvested as described in Materials and Methods. 50 pg protein was 
electrophoresed on a 1 0 % polyacrylamide gel, transferred to nitrocellulose 
membranes and exposed to murine IgG monoclonal Bcl-2 antibody (Santa Cruz) at a 
1:100 dilution and a murine IgM p-actin antibody (Oncogene) at a 1:10000 dilution. 
HRP conjugated antibodies to detect murine IgG (Dako) and IgM (Calbiochem) were 
used at a 1:2000 dilution. Bands were detected using ECL (Pierce). Figures in table 
are from densitometric analysis performed with Quantiscan (Biosoftware, Cambridge, 
UK).
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Celecoxib did not mediate a reduction in Bcl-2 protein in both LNCaP-COX-2 (Figure 
6 .8 ) and LNCaP-Neo (data not shown), when normalised to p-actin, unlike the 
reduction that was observed for PI3K inhibition (Figure 6.7). There was an initial rise 
before Bcl-2 levels declined effectively to control levels. Thus, this could be an 
additional explanation for the inability of celecoxib to sensitise LNCaP-COX-2 to 
carboplatin -  it does not down-regulate anti-apoptotic Bcl-2 to the same extent as 
PI3K inhibition.
6.4 Discussion
We have demonstrated in this Chapter that PI3K inhibitors partially, but not 
completely, sensitise LNCaP-COX-2 cells to carboplatin (Figure 6.2). This 
sensitisation can be partly explained by the elevated P-Akt®®*^ ^^  ^ levels observed in 
LNCaP-COX-2, in compaiison to LNCaP-Neo (Figure 6.3). Because both PI3K 
inhibitors and celecoxib can inhibit PI3K, as evidenced by decreases in P-Akt (Figure 
6.4), but only PI3K inhibitors can sensitise LNCaP-COX-2 cells, this suggests that the 
two types of agents modulate different signalling pathways. Whereas PI3K inhibition 
reduces both cellular COX-2 (Figure 6.5) and Bcl-2 levels (Figure 6 .6 ) in LNCaP- 
COX-2, celecoxib does not modulate Bcl-2 levels and it results in an increase in 
COX-2 protein.
Partial sensitisation of LNCaP-COX-2 to carboplatin bv PI3K inhibition 
The fact that the PI3K inhibitor wortmannin does not completely sensitise LNCaP- 
COX-2 cells to caiboplatin suggests that COX-2 transfection may be impacting other 
signalling pathways in addition to PI3K/ Akt. If PI3K/ Akt was the sole pathway that 
COX-2 modulated, then pharmacological inhibition should have sensitised LNCaP-
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COX-2 cells completely. We did not investigate further which factors COX-2 may be 
modulating in addition. We have reviewed in Chapter 1.2.5 some of the oncogenic 
properties and functions of COX-2. Other potential mechanisms that COX-2 could be 
involved in these LNCaP cells include inducing c-fos and c-jun transcription factors 
which promote cell proliferation (Chen & Hughes-Fulford 2000), elevating the EGFR 
(Kinoshita et aL 1999) and activation of the MAPK ERK pathway.
We have shown here that COX-2 activates PI3K/ Akt signalling even more in LNCaP 
cells. We found that PI3K inhibition could paitially reverse this resistance. Many 
studies highlight the importance of the PI3K/ Akt pathway in LNCaP prostate cancer 
cells in mediating a resistant phenotype.
Beresford et al. (2001) showed that PI3K inhibition with wortmannin, LY294002 or 
PTEN transfection sensitised LNCaP but not PC-3 cells to TRAIL and TNF-a. Yuan 
& Whang (2002) showed that PTEN transfection sensitised LNCaP cells to Fas, 
TRAIL and TNF, staurosporine and mitoxantrone. Pfeil et al. (2004) showed that 
basally P-Akt could only be detected in PC-3 and LNCaP but not DU145. DU145 P- 
Akt phosphorylation status could be modulated by EGF and IGF-1 but not PC-3 and 
LNCaP. Furtheimore, two LNCaP androgen independent sublines were resistant to 
LY294002 induced apoptosis, unlike parental LNCaP cells. Etoposide produced 
greater apoptosis in parental LNCaP cells compared to the sublines, but LY294002 
abolished this resistance. Chen et al. (2001) showed that LNCaP had higher 
constitutive Akt activity than PC-3 and this was associated with resistance to TRAIL, 
which could be overcome with either wortmannin, LY294002 or CHX, via reduced P- 
Akt levels. Transfection with PTEN and DN-Akt also had the same effect.
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is elevated in LNCaP-COX-2 
We demonstrated that COX-2 transfection caused an elevation in P-Akt*”"*’  ^ levels in 
LNCaP cells. Other studies report a similar effect, that is enhanced PI3K signalling, in 
non-prostate cancer cell lines. For example, Leng et al. (2003) showed that either 
COX-2 transfection or PGE2 treatment caused elevation in levels in
hepatocellular carcinoma cell lines resulting in increased cell growth. LY294002 
partially reversed these effects. Lin et al. (2001) transfected COX-2 into lung 
adenocai'cinoma cells and detected increased P-Akt®®'^ ^^  ^ and increases in the anti- 
apoptotic factor Mcl-l in COX-2 expressing cells. This resulted in resistance to 
apoptosis following treatment with chemotherapeutic agents. We too demonstrated 
elevated anti-apoptotic proteins in COX-2 expressing LNCaP cells (Figure 5.11), 
although we did not assess Mcl-l levels. However, Bcl-2 elevation in our LNCaP 
cells is partly PI3K dependent but COX-2 enzymatically independent, which differs 
from the Lin et al. (2001) above study, which showed Mcl-l to be linked to PI3K 
signalling via COX-2.
What effect could this elevated P-Akt in LNCaP-COX-2 cells be having? We know 
the effect is slight because parental LNCaP cells, being PTEN mutant, have elevated 
P-Akt levels anyway. MDM2, the protein which targets p53 for degradation, is a 
downstream effector of PI3K signalling (Figure 6.1). Because p53 and p27^ ^^  ^
induction is reduced in LNCaP-COX-2 cells which have elevated P-Akt (Figures 5.6 
and 5.7, respectively), the possibility exists that P-Akt is directly responsible for this. 
Other possible explanations for the COX-2 and P-Akt mediated resistance to
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carboplatin by LNCaP-COX-2 include reduced caspase-9 processing, reduced Bad 
activity and reduced induction of p27^^^  ^via the forkhead transcription factors.
Both PI3K and COX-2 inhibition reduce P-Akt levels
We showed in Chapter 4 that celecoxib was not able to sensitise LNCaP-COX-2 to 
carboplatin. However, both celecoxib and wortmannin exposure inhibited PI3K 
signalling, as evidenced by reduction in P-Akt*®^ "^ ^^  levels. This suggests that COX-2 
inhibition and PI3K inhibition mediate a reduction in P-Akt via different mechanisms 
and that celecoxib is working also in a PIP3 or PI3K independent manner. Some 
potential taigets of celecoxib will be discussed below. More importantly, because 
PI3K inhibition via celecoxib does not sensitise LNCaP-COX-2 cells, COX-2 must be 
involved in other pathways in addition to PI3K/ Akt signalling.
Numerous studies demonstrate the utility of PI3K inhibitors in either directly causing 
apoptosis in prostate cancer cells (Lin et al. 1999, Chinni & Sarkar 2002) or to 
sensitise cells to other agents.
Several studies also demonstrate an inhibitory effect of celecoxib on PI3K signalling 
and they typically show that reduced or inhibition of P-Akt levels is evidence for this 
effect. Other COX-2 inhibitors do not possess this ability to prevent Akt activation. 
The relative importance of COX-2-dependent and -independent activity of celecoxib 
however is still unclear. Unlike wortmannin or LY294002, the target of celecoxib is 
not thought to be PI3K itself. Rather, PDKl is the enzyme which is cited often as 
having its activity reduced following celecoxib treatment in cancer cells.
Hsu et al. (2000), Johnson et al. (2001), Zhu et al. (2002) all showed the ability of 
celecoxib to inhibit P-Akt production in prostate cancer cells and in addition Kulp et 
al. (2004) demonstrated this was due to inhibition of PDKl activity. P-Akt and PDKl
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inhibition with celecoxib occui's in other cancer cells also, for example colorectal 
(Yamazaki et al. (2002), Wu et al. (2003)) and hepatocarcinoma cells (Leng et al.
(2003)). Song et al. (2002) showed that celecoxib caused dephosphorylation of ERK2 
in addition to Akt.
Bearing in mind that reduced P-Akt is the cited molecular mechanism for celecoxib 
induced apoptosis in the above studies, another potential target of celecoxib could be 
integrin linked kinase (ILK). This kinase has been reported to phosphorylate Akt on 
the ser473 residue, not thr308 in LNCaP cells (Persad et al. (2000), Graff et al. 
(2000)). Thus, it acts in a manner analogous to PDK2. This could allow us to explain 
the differential ability of PI3K inhibition (with wortmannin and LY294002) and 
COX-2 inhibition (with celecoxib) to sensitise LNCaP-COX-2 to carboplatin. 
Whereas PI3K inhibition results in complete inhibition of the PI3K pathway, 
celecoxib appears to prevent generation of P-Akt®^ '^ '^ ^^  only. It does not prevent 
generation of the active Akt ’^’*^^^  ^phospho-molecule (Figure 6.1).
PI3K, but not COX-2, inhibition reduces COX-2 protein
Our data showed that PI3K inhibition resulted in down-regulation of COX-2 protein. 
Other studies also report a similar effect. This should not be suiprising, as PI3K 
activation is known to induce COX-2 in many cell types (Chapter 1.2.4). It should be 
noted that these studies demonstrate reduction in COX-2 via transcriptional 
mechanisms. COX-2 protein synthesis in our transfected cells is not under normal 
physiological control -  its synthesis is driven by a viral promoter and therefore factors 
which affect COX-2 transcription, stability and degradation, both mRNA and protein 
may not be the same.
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Tang et al. (2001) demonstrated significant reduction, but not complete inhibition, of 
COX-2 protein, with LY294002, following ultraviolet B radiation induced COX-2 
induction in human kératinocytes. Kulkami et al. (2001) showed that P13K inhibition 
with LY294002 reduced COX-2 protein induced by EGF in cervical carcinoma cells. 
Bradbury et al. (2004) showed that both P13K and p38 MAPK inhibition, but not 
MEK inhibition caused reduced COX-2 activity but not COX-2 levels. A mechanism 
was not proposed. Thus, because P13K signalling can induce COX-2, P13K inhibition 
can lead to a reduction in COX-2 levels.
Whereas we found that celecoxib treatment increased COX-2 protein levels, other 
groups report either no changes or a reduction in COX-2 levels following celecoxib 
treatment in various tumour models. The significance of these differences in unclear. 
Lai et al. (2003) showed that COX-2 levels were unaffected by celecoxib treatment in 
cholangiocarcinoma cells, and Arico et al. (2002) also found no change in levels 
following celecoxib treatment of colon cancer cells. In contrast, El-Rayes et al. (2004) 
demonstrated a reduction in COX-2 protein and mRNA in pancreatic cancer cells 
after celecoxib treatment combined with gemcitabine. Importantly, Gupta et al. (2004) 
showed that COX-2 protein, mRNA and activity was reduced in the TRAMP mouse 
model following dietary celecoxib over 8  to 24 weeks.
P13K, but not COX-2, inhibition reduces anti-apoptotic proteins 
Our data also showed that P13K inhibition with wortmannin or LY294002 reduced 
Bcl-2 protein, but not survivin or B c1-x l  (data not shown) in LNCaP-COX-2. In 
contrast, celecoxib at sub-cytotoxic doses did not reduce Bcl-2 protein. These same 
effects were also observed in Bcl-2 expressing LNCaP-Neo cells.
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Davies et ah (1999) inhibited PI3K signalling in LNCaP cells by performing PTEN 
transfection and assessing its effects on Bcl-2 transcription and p53 expression. PTEN 
suppressed P-Akt levels, as did wortmannin, but it did not affect Bcl-2 levels. Further, 
Bcl-2 transfection did not affect ability of PTEN to reduce P-Akt. Lin et ah (1999) 
demonstrated apoptosis with wortmannin and LY294002 in LNCaP, but not with 
inhibitors for pp70S6K, ERK or MEK. Apoptosis was attenuated by DHT and EGF 
ligands, suggesting that the survival signal was originating from cell surface or 
nucleai' receptors. Chinni & Saikar (2002) showed that indole-3-carbinol induced 
apoptosis in PC-3 by preventing Akt phosphorylation and EGF was unable to 
phosphorylate PI3K after indole-3-carbinol pre-incubation. There was also down- 
regulation of Bad and B c1-x l , downstream taigets of Akt. Carson et ah (1999) showed 
that serum withdrawal did not cause apoptosis in LNCaP cells and that Akt remained 
in its active, phosphorylated state. LY294002, however, did cause apoptosis in these 
cells. In contrast, DU145 cells, which contain wild type PTEN, phosphorylation only 
occuixed in presence of exogenous IGF-1 or EGF. Davies et ah (2002) assessed the 
effects of PTEN transfection on proliferation, apoptosis and metastasis in PC-3 cells. 
In vivo PTEN had no effect on apoptosis in PC-3 cells injected into mice prostate, but 
proliferation was reduced. PTEN did not prevent tumour formation, however tumour 
growth was reduced and metastasis was significantly prevented.
Thus, both experimental agents (wortmannin and LY294002) and natural compounds 
(e.g. indole-3-carbinol) which inhibit PI3K signalling can have anti-tumour activity, 
in both in vitro and in vivo cancer models, including prostate cancer. PI3K inhibition 
can cause down-regulation in anti-apoptotic proteins such as Bcl-2 and B c1-xl and this 
could be important in mediating these effects.
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Although we did not observe a strong anti-proliferative effect of wortmannin in either 
LNCaP-Neo or LNCaP-COX-2 (data not shown) in the presence of serum, PI3K 
inhibition has been shown to cause apoptosis in LNCaP cells. The reduction in cell 
viability was greater in LNCaP-Neo, although not significantly, as assessed by the 
MTT assay, which may be a reflection of the elevated PI3K activity measured in 
LNCaP-COX-2.
Although celecoxib has been shown to be apoptotic in various cell types (Chapter 4), 
here we are more concerned with its ability or inability to modulate anti-apoptotic 
proteins at sub-cytotoxic, sensitising doses. Other groups generally report no 
reduction in Bcl-2 in particular following celecoxib treatment, at apoptotic doses.
Hsu et al. (2000) showed no involvement of Bcl-2 in celecoxib induced apoptosis in 
PC-3 and LNCaP cells, as enforced expression of Bcl-2 did not affect the viability of 
these prostate cancer cells to celecoxib. Johnson et al. (2001) obtained similar results 
in PC-3 cells with celecoxib, demonstrating Bcl-2 independent apoptosis. Song et al.
(2002) depleted COX-2 protein in PC-3 cells using a tetracycline induced anti-sense 
system and assessed the effects of celecoxib, rofecoxib, DuP-697 and NS398 
mediated apoptosis. They found that COX-2 expression miiTored PGE2 levels. 
However, reduction of COX-2 had no effect on Bcl-2. COX-2 inhibitors induced 
apoptosis whereas COX-2 ablation did not. Yamazaki et al. (2002) assessed the effect 
of 6  different COX-2 inhibitors on COX-2 positive and negative colon 
adenocarcinoma lines by assessing cell proliferation and apoptosis. Only celecoxib 
induced apoptosis, although all 6  diugs inhibited PGE2 production, whilst Bcl- 2  levels 
remained unchanged. Arico et al. (2002) also showed that celecoxib induced 
apoptosis in colon adenocarcinoma cells but Bcl-2 levels were not affected. Wu et al.
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(2003) showed that celecoxib caused apoptosis in cholangiocarcinoma cells, 
independent of Bcl-2 and Bax. PGE2 partially inhibited this but COX-2 depletion by 
anti-sense transfection did not result in decrease in P-Akt suggesting both COX-2 
dependent and independent mechanisms for celecoxib’s mechanism of action. Leng et 
aL (2003) demonstrated that Bcl-2 and Bax levels were unaffected by celecoxib 
treatment of hepatocarcinoma cell lines. In contrast, Liu et aL (1998) showed that 
NS398 induced apoptosis in LNCaP cells, by up-regulating the inactive 
phosphorylated forms of Bcl-2 and down-regulating the active, unphosphorylated 
form.
What is the clinical significance of the findings from the data presented in this 
Chapter? The potential utility of COX-2 inhibitors, in particular* celecoxib, as 
chemopreventive agents or as adjuvants to sensitise tumours to existing therapy was 
discussed in Chapter 4. There, it was emphasised that these agents could cause a 
reduction in cell viability in cell lines or tumours regardless of their COX-2 status, but 
at doses which are at the upper limit of acceptable toxicity. At sub-cytotoxic doses 
celecoxib could not sensitise resistant COX-2 expressing LNCaP cells to carboplatin. 
PI3K inhibition thus appears to be a more attractive target than COX-2 inhibition. 
This is especially true since we demonstrated an enzyme independent effect of COX-2 
on apoptotic resistance. It was also stated that whilst agents such as celecoxib may 
induce apoptosis in epithelial cancer cells via predominantly COX-2 independent 
mechanisms, in vivo their effect on other tumourigenic processes such as angiogenesis 
or metastasis may be COX-2 dependent.
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To summarise, we have reported in this Chapter that stable COX-2 transfection in 
LNCaP activates the PI3K7 Akt cell survival pathway, as evidenced by elevated P- 
Aktser473 |gygjg LNCaP-COX-2 and other pharmacological effects seen from the 
data within this part of the thesis.
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Chapter 7 Gene Microarray Analysis
7.1 Aims
The purpose of performing gene microaiTay analysis of LNCaP-Neo and LNCaP- 
COX-2 cells was to assess which genes, especially those concerned with the cell cycle 
and apoptosis, are differentially expressed in LNCaP cells as a result of stable COX-2 
transfection, using a set of 3000 oligos for cancer related genes.
7.2 Introduction
Gene microaiTay is sometimes refened to as DNA microaiTay or gene array. The 
teims all refer to a technique in which the principle is nucleic acid base pairing of a 
‘probe’ which is attached to a substrate, and a ‘target’ whose nucleic acid identity or 
abundance is being measured. Various platforms can be utilised to measure the 
relative mRNA amounts in a sample. We used spotted cDNA microarrays on a glass 
slide which was hybridised with both the labelled test sample and a labelled reference 
sample.
The technique provides different information from Western blotting, which detects 
protein levels, and offers greater efficiency and diversity than mRNA analysis by 
either RT-PCR or Northern blot analysis. The same information is derived from RT- 
PCR mRNA analysis, however gene microanays allow analysis of thousands of 
genes, whereas separate experiments would be required for RT-PCR, which work on a 
‘one gene for one experiment’ basis. Just as important, using the microanay approach, 
genes which would not ordinarily be considered in a carcinogenesis model may be 
identified and validated. In addition, gene microanay can allow gene function
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interaction to be better understood, although we have not attempted to do this in this 
project.
It would be expected that gene microanay experiments be performed first to identify 
differentially expressed genes between LNCaP-Neo and LNCaP-COX-2 cells. Then, 
based on the data that these experiments generate, the significance of the identified 
genes would be explored further. However, it should be noted that we perfonned gene 
microanay experiments at the end of the project, rather than using gene microanay 
data as a basis to form hypotheses. Therefore, we have not been able to further 
investigate the data presented in this Chapter.
7 .3  R e s u l t s
Using a ‘3000 cancer oligo’ set from Qiagen Inc., a number of genes were identified 
as being expressed significantly differently between LNCaP-Neo and LNCaP-COX-2 
cells. Not all of these genes have cell cycle or apoptosis related functions.
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e le c te d  G en e  T ree  LMC ep n eo  vs c o u
e le c te d  C ondition  T ree , L N Cap n eo  vs c o k 2 condition tree
C o lo ied  by L fo ;a p  n e o  vs c o ü  (D eiault In terp ie ta tion) 
G e n e  L ist g ood  g e n e  list (751)
Figure 7.1 Dendogram of clustering analysis of gene expression variations in the 
prostate cell lines, LNCaP-Neo and LNCaP-COX-2. The condition tree was 
performed using GeneSpring using an unsupervised Spearman correlation, as 
described in Chapter 2.11. The colours representing the gene expression vary from 
green (reduced), yellow (same) and red (increased expression relative to Universal 
Human Referenee).
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The data obtained from this analysis indicating key differentially expressed genes are 
listed in Tables 7.1 (up-regulated in LNCaP-COX-2) and Table 7.2 (down-regulated 
in LNCaP-COX-2).
Gene Accession
number
p-value Function
a-tubulin NM_006082 0.026 Cytoskeletal component
ADP-ribosylation NM_001667 0.0171 OTP binding RAS protein
factor-like 2
Cyclin I NM_006835 0.00992 Cell cycle progression
Cytochrome c-1 NM_001916 0.00842 Respiratory electron transport chain;
apoptosis
Fatty acid synthase NM_004104 0.00829 Fatty acid synthesis
PKC-like 1 NM_002741 0.0123 Rho- and PDKl signalling
Protein tyrosine NM_004103 0,0262 MAPK signalling activation
kinase P
Signal recognition NM_006947 0.0113 Polypeptide membrane translocation
particle
Survivin NM_001168 0.000607 lAP, anti-apoptotic
Table 7.1 Some genes that are up-regulated as a result of COX-2 transfection in 
LNCaP cells. Some genes identified as being significantly differentially expressed 
between LNCaP-Neo and LNCaP-COX-2 are tabulated along with the p-value. The 
aiTays were analysed using Blue Fuse softwaie and the data was exported into 
GeneSpring for the statistical analysis.
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Gene Accession
number
p-value Function
GST-71 NM_000852 0.0127 Detoxification enzyme, anti­
inflammatory
Protein kinase H200008636 0.0418 Tumour suppressor gene
cAMP dependent
regulatory type l a
Protein tyrosine NM_151460 0.0258 T- and B-lymphocyte activation
phosphatase regulation
receptor type C
Table 7.2 Some genes that are down-regulated as a result of COX-2 transfection 
in LNCaP cells. Some genes identified as being significantly differentially expressed 
between LNCaP-Neo and LNCaP-COX-2 are tabulated along with the p-value. The 
aixays were analysed using Blue Fuse software and the data was exported into 
GeneSpring for the statistical analysis.
Table 7.1 and Table 7.2 shows that gene microarray analysis identified a mixture of 
significantly differentially expressed genes, not all of which have direct cell cycle or 
apoptosis involvement.
There are a number of functional classes of genes represented in Tables 7.1 and Table 
7.2. These include anti-oxidants (GST-ti), cell cycle progi’ession (Cyclin I, ARF-2, 
PKC-like 1, protein tyrosine Idnase p) and the anti-apoptotic survivin. Other genes 
differentially expressed between LNCaP-Neo and LNCaP-COX-2 which may 
contribute to tumourigenesis include fatty acid synthase and a-tubulin.
208
Chapter 7 Gene Microarray Analysis
7A  Discussion
Survivin function and protein levels in our transfected LNCaP cells were discussed in 
Chapter 5. Gene microarray data from Table 7.1 would suggest that the elevated 
survivin protein levels were due to the elevated mRNA levels. However, Krysan et al. 
(2004) demonstrated that in NSCLC, COX-2 transfection resulted in increased 
survivin protein via reduced survivin ubiquitination and degradation. It is possible that 
this could also represent a mechanism for COX-2 mediated survivin elevation. Gene 
microaixay experiments did not confirm the elevated Bcl-2 and B c1-Xl  protein 
detected in LNCaP-COX-2 reported in Chapter 5 due to technical difficulties. Thus, 
these two anti-apoptotic markers could have increased protein but not mRNA levels 
due to COX-2 mediated increased protein stability or reduced protein degradation. 
However, it is also possible that LNCaP-COX-2 does have elevated Bcl-2 and B c1-xl  
mRNA compaied to LNCaP-Neo but experimental artefacts prevented the biological 
difference to be detected.
GST-tt belongs to the GST family of enzymes which are involved in detoxification 
reactions (Chapter 1.2). It conjugates many hydrophobic and electrophilic compounds 
with reduced glutathione. GST-tt is a recognised cancer susceptibility gene (reviewed 
by Nelson et al. 2001). We found that GST-tt mRNA levels were lower in LNCaP- 
COX-2 cells compared to LNCaP-Neo, suggesting that COX-2, by an unknown 
mechanism, lowers the levels of this anti-inflammatory enzyme. We can speculate 
that COX-2, being pro-inflammatory itself (Chapter 1.2.5.4), may negatively regulate 
GST-tt, which has an opposing anti-apoptotic function. It has been proposed that 
inactivation of GST family members may serve as an initiating lesion for prostate 
cancer (Chapter 1.1.2). Our data show that COX-2 may be involved in reducing
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cellular GST-tt levels. Furthermore, GST-tt levels have been reported to be lower in 
HGPIN and prostate cancer compared to normal epithelia, and GST-tt gene silencing 
by hypermethylation has been reported (reviewed by Pathak et al. 2005).
The function of cyclin I is not fully understood, but it does show the highest similarity 
with cyclin G. We found that cyclin I mRNA was higher in LNCaP-COX-2 than 
LNCaP-Neo. Nakamura et al. (1995) first isolated cyclin I from a human brain 
derived cDNA library and they showed that it was expressed independently of the cell 
cycle, suggesting that it may not play a typical cyclin role. Landberg et al. (2005) 
found a strong correlation between cyclin I, VEGF and the VEGF receptor, KDR in 
human breast tumours, although no correlation between cyclin I and P-Rb, cyclin E, 
tumour grade or survival was noted. Bolduc et al. (2004) showed that in adipose 
tissue of male mice, DHT caused up-regulation of a number of genes involved in 
energy metabolism, such as fatty acid synthase and putative cell cycle regulators such 
as cyclin I.
Protein tyrosine kinase P, also known as PYK2 or Focal adhesion Idnase 2 (FAK2) is 
thought to play an important role in neuronal activity, but its involvement in prostate 
physiology is not yet established. Van der Horst et al. (2005) demonstrated the 
importance of this kinase in mediating heregulin mediated invasion of glioma cells as 
a result of HER2 and HER3 heterodimerization. Further, MAPK was activated 
following protein tyrosine kinase phosphorylation by HER3. We found that the 
mRNA for this gene was elevated in LNCaP-COX-2 cells (Table 7.1). As COX-2 has 
been implicated in invasion and metastasis (Chapter 1.2.5.5) it is possible that this 
could in part be due to elevation of protein tyrosine kinase p. Avraham et al. (2003) 
also demonstrated the involvement of this family of proteins in mediating VEGF 
induced angiogenesis in human brain endothelial cells. In particular, VEGF
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phosphorylated protein tyrosine kinase p which permitted migration of endothelial 
cells.
The protein encoded by the PKC-like 1 gene belongs to the PKC super family. This 
kinase is activated by Rho family of small G proteins and mediates the Rho-dependent 
signalling pathway. PDKl is reported to phosphorylate this kinase also. PKC-like 1 
mRNA was found to be elevated in LNCaP-COX-2 compared to LNCaP-Neo. 
Prostate tumours have been reported to over-express this protein also. Metzeger et al.
(2003) showed that PKC-like 1 could activate the androgen receptor, independent of 
ligand in prostate cancer cells. This protein thus could be providing an additional 
survival signal, when over-expressed even further via COX-2, in LNCaP cells, 
a-tubulin, upon polymerisation, forms pait of the cytoskeletal system. Its mRNA 
levels were found to be increased in LNCaP-COX-2 cells and has also been reported 
to be increased in paclitaxel resistant breast cancer cells (Baneijee 2002). However, 
the significance of our findings is not known. Similarly, the 72 kDa signal recognition 
particle, one component of the ribo-protein complex which targets proteins to 
membranes, was also up-regulated in LNCaP-COX-2. The relevance of this is not 
known at this stage.
The gene which encodes for fatty acid synthase produces a multifunctional enzyme 
whose main function is to synthesise palmitate from acetyl-CoA and malonyl-CoA 
into long chain fatty acids. The mRNA for fatty acid synthase was found to be 
elevated in LNCaP-COX-2 (Table 7.1). As Van de Sande et al. (2002) showed that 
PI3K inhibition with both LY294002 and PTEN transfection resulted in decreased 
fatty acid synthase mRNA, we can hypothesise that elevated PI3K activity in LNCaP- 
COX-2 may be responsible for this elevated fatty acid synthase mRNA. Further,
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androgens mediate increased fatty acid synthase gene expression (reviewed by 
Swinnen & Verhoeven 1998).
Protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific 
extinguisher 1) is a regulatory subunit of protein kinase A. It is reported to have 
tumour suppressive function. We found that this gene was down-regulated in LNCaP- 
COX-2. In neuroblastoma cells, Constantinesan et al. (2004) demonstrated that this 
protein inhibited MAPK signalling via B-raf. Veuglers et al. (2004) showed that in 
mice haplosufficient for this protein, tumourigenesis was more prevalent. They also 
demonstrated 65% of mutations in this gene in humans with Carney complex, a 
multiple neoplasia syndrome. We do not know at this stage how important reduced 
expression of this protein in LNCaP-COX-2 is in mediating a resistant phenotype in 
these cells.
Cyt c is a multi-subunit enzyme involved in oxidative phosphorylation. Some subunits 
are encoded for by the mitochondiial genome, the others by nuclear DNA. Hermann 
et al. (2003) showed that the ratio of nuclear to mitochondrial cyt c subunits was 
greater in prostate cancer samples compared to normal and pre-malignant samples. 
There was also altered oxidative phosphorylation between normal and prostate tissue 
and they proposed that this could offer a survival advantage in tumourigenesis. 
Although their findings did not refer to the cyt c subunit 1, we found that this subunit 
was elevated in LNCaP-COX-2 (Table 7.1). Subunit 1 is encoded for by 
mitochondrial DNA. How and why COX-2 mediates an elevation of this gene could 
be explored further. The change in cyt c expression levels could relate to an alteration 
in mitochondrial integrity which in turn could influence the mitochondrial pathway of 
apoptosis.
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The function of the ADP-ribosylation factor-like (ARL) group of genes has not been 
fully elucidated. Like the ADP-ribosylation factor (ARP) gene products, they are 
GTP-binding proteins of the RAS super family. These proteins hydrolyse GTP to 
perform a wide range of cellular functions. Bhamipidati et al. (2000) showed that 
ARL2, whose transcript we have found to be elevated in LNCaP-COX-2 (Table 7.1) 
prevented destruction of tubulin and microtubules. This however is unlikely to explain 
why we also found a-tubulin levels to be elevated in LNCaP-COX-2 (Table 7.1) as 
ARL2 mediated preservation of microtubules is mediated through protein-protein 
interaction and not transcriptional events. The relevance of ARL2 up-regulation in 
COX-2 expressing LNCaP cells is therefore not understood yet.
To summarise, the data in this Chapter highlighted some key differences in gene 
expression between COX-2 non- and over-expressing LNCaP cells as detected by 
gene microaixay analysis. This microaixay data presented some opportunities for 
further investigation. This was because genes potentially involved in tumourigenesis 
were identified with this technique. These included genes implicated in inflammation, 
cell cycle progression and apoptosis inhibition. It confirmed some data presented in 
previous Chapters, which used techniques such as Western blotting and flow 
cytometry. For example, elevation of survivin mRNA by microaixay analysis 
coiToborated with elevated survivin protein (Chapter 5). However, further 
experiments via RT-PCR and Western blotting need to be performed because we 
cannot exclude the possibility that the findings in these gene microanay experiments 
represent false positives.
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This Study showed that COX-2 transfection in the LNCaP cell line mediated a 
resistance to the effects of carboplatin in serum and to etoposide in the absence of 
serum, as measured with the MTT assay, and to celecoxib, as measured with the 
Trypan blue assay. The resistance to carboplatin was due to a number of factors. We 
found an attenuation of its cell cycle effects, and there was reduced p53 and p27^^^  ^
induction and elevation of cyclin Bl. We also detected reduced apoptosis, as COX-2 
produced an elevation of anti-apoptotic Bcl-2, B c1-Xl  and survivin proteins. However, 
COX-2 could not mediate a resistance to the endogenous apoptosis inducers Fas and 
TRAIL. Sui-prisingly, celecoxib was not able to sensitise LNCaP-COX-2 to 
carboplatin and PGE2 could not increase the resistance of LNCaP-Neo to this 
chemotherapeutic agent. This suggested that COX-2 was having a protein (COX-2) 
dependent, but catalytic (PGE2) independent effect on LNCaP cells’ sensitivity to 
carboplatin. COX-2 over-expressing LNCaP cells had elevated P-Akt®^ ”^^^  ^ levels and 
PI3K inhibitors were able to partially sensitise these cells to carboplatin, suggesting 
that COX-2 activated not only PI3K/ Akt but also other pro-survival or pro­
proliferation pathways.
Gene microaixay work confirmed the elevated survivin levels in LNCaP-COX-2. It 
also highlighted a number of other genes which aie differentially expressed between 
COX-2 expressing and COX-2 negative cells. These included reduced GST-tt in 
LNCaP-COX-2, and elevated a-tubulin, fatty acid synthase and PKC-like-1 mRNA in 
LNCaP-COX-2. These COX-2 mediated changes may enhance the tumourigenic 
potential of LNCaP cells by a variety of mechanisms including resistance to 
apoptosis, cell cycle progression or promoting inflammation.
215
Chapter 8 Overall Conclusions and Future Work
We had to develop strategies and models to assess the effect of COX-2 on cell 
viability following cytotoxic treatment because our three prostate cancer cell lines, 
PC-3, DU145 and LNCaP did not express COX-2 protein. Even if a variation of 
COX-2 levels was detected between the cells, it would not have been possible to 
accurately coixelate their sensitivity to vaiious cytotoxic agents to their COX-2 levels. 
The reason for this is that these cells lines are genetically very different and their 
sensitivity to cytotoxic agents would be reflected not just by COX-2 but by a number 
of other genetic factors. This was the reason that PMA induction of COX-2 in PC-3, 
which mediated a resistance to etoposide was not pursued further. PMA may have 
been inducing other genes or stabilising other proteins, in addition to COX-2, and 
could therefore not be considered specific for COX-2.
We concentrated our experiments on the LNCaP stable transfectant. This was because 
COX-2 levels in this model remained consistently elevated and COX-2 mediated 
resistance was observed in a number of scenarios. A stable transfectant of other cell 
lines, for example PC-3 and DU 145 could have been attempted. This would be useful 
for several reasons. Firstly, PC-3 and LNCaP have different characteristics to LNCaP 
-  they are androgen insensitive, whereas LNCaP can be either androgen dependent or 
androgen sensitive. Both PC-3 and DU145 are also p53 defective, unlike LNCaP 
which is wild-type for p53. PC-3 does not express p53 at all, whereas DU145 
expresses mutant, non-functional p53. Secondly, no effect of COX-2 was 
demonstrated in the transient PC-3 transfectant, and this may have been due to the 
lower COX-2 levels, or the fact that it is p53 negative.
The differential effects of celecoxib on LNCaP-Neo and LNCaP-COX-2 cells could 
be explored further. Initial experiments utilising the MTT assay showed that the two
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cell lines had similar IC50 values in a 72 hour cytotoxicity assay. However, Trypan 
blue data provided evidence that COX-2 over-expression caused greater cell kill in 
LNCaP-Neo at 80-100 fxM, doses which exceed the IC50. To confirm if COX-2 anti- 
apoptotic effects are catalysis- or prostaglandin-independent, we could have 
transfected prostate cancer cells with a gene encoding a mutant COX-2 protein, 
deficient in catalysis.
We did not measure the amount of DNA damage carboplatin induced in LNCaP-Neo 
or LNCaP-COX-2. We cannot exclude the possibility that COX-2 is affecting 
components of the DNA damage sense machinery in addition to p53. We did not 
assess if DNA repair enzymes were implicated in anyway. This could be looked at in 
the future.
Although both LNCaP-Neo and LNCaP-COX-2 cells did not detect p27^^ ^^  basally, 
LNCaP-COX-2 did express elevated levels of cyclin Bl. We did not assess if this 
cyclin Bl elevation was a direct result of PI3K activity. This could have been 
achieved by measuring the levels of cyclin Bl following wortmannin or LY294002 
treatment of LNCaP-COX-2 cells.
We demonstrated up-regulation of three anti-apoptotic proteins due to COX-2 
transfection, Bcl-2, B c1-xl  and survivin. We do not know if this was this due to 
increased transcription of their genes or due to increased mRNA or protein stability. 
Gene transcription could be assessed by inserting promoter regions of each of the 
genes, linked to p-galactosidase for example, and measuring activity for both LNCaP- 
Neo and LNCaP-COX-2. We could also have checked if celecoxib or PGE2 can 
modulate these gene transcriptional activities; we suspect not because neither 
celecoxib nor PGE2 could modulate the sensitivity of LNCaP-COX-2 and LNCaP-
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Neo respectively to carboplatin. Krysan et al. (2004) showed that COX-2 caused 
survivin stabilisation via reduced ubiquitination in NSCLC cells. We do not know if 
COX-2 in LNCaP is involved in enhanced protein stability or degradation of a variety 
of cellular proteins. This could be explored further.
We could have transfected either Bcl-2, B c1-Xl  or survivin into LNCaP-Neo or 
parental LNCaP cells to verify the importance of each in mediating the resistance to 
apoptosis. Conversely, we could attempted to down-regulate Bcl-2, B c1-x l  or survivin 
in LNCaP-COX-2, using an anti-sense strategy to assess how significant each is in 
mediating resistances to carboplatin, etoposide and celecoxib.
We did not assess caspase activities in LNCaP-Neo or LNCaP-COX-2 cells following 
either carboplatin, etoposide or celecoxib treatment. This would be interesting to 
explore because there is elevated survivin in LNCaP-COX-2 and this should reduce 
caspase-3 and caspase-7 activity. Similai'ly, as LNCaP cells are known to be resistant 
to TRAIL at the mitochondrial level (Chapter 6 ), and factors which prevent 
mitochondrial membrane potential breakdown (Bcl- 2  and B c1-x l) are elevated in 
COX-2 expressing cells, we could have assessed if COX-2 affects the mitochondrial 
pathway, for example by preventing mitochondrial membrane potential breakdown or 
cyt c release.
It is known that NF-kB is anti-apoptotic, with target genes such as cIAPl, cIAP2, 
xIAP, FLICE and B c1-x l . Therefore, it could be investigated if COX-2 is involved in 
NF-KB signalling in some way; for example, activating it by promoting degradation of 
its inliibitory subunit, IkB.
It would also be possible in the future to generate a xenograft model of COX-2 over­
expressing LNCaP cells, for example in athymic, nude mice to confirm if the
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resistance observed in cell lines to carboplatin, etoposide and celecoxib can be 
reproduced in vivo.
Because celecoxib, in a manner similar to PI3K inhibition, causes decreases in P- 
Aktser473  ^ but it is not thought to inhibit PI3K itself, we could have confirmed that 
celecoxib does not attenuate PI3K activity but wortmannin and LY294002 do with a 
specific assay in LNCaP cells. For example, Arico et al. (2002) did have performed 
specific immunoprécipitation kinase assays of PDKl and Akt.
We demonstrated that COX-2 elevates P-Akt®^ *^ ^^  ^in LNCaP. We could have assessed 
if COX-2 depletion, for example with an anti-sense approach, will also lead to 
reduced P-Akt®^®*^ "^ ^^  levels. This would confirm if COX-2 catalytic activity or COX-2 
binding is important in activating Akt. Wu et al. (2003) showed in 
cholangiocarcinoma cells that it did not, but this may not the case in LNCaP prostate 
cancer cells.
MDM2, the protein which targets p53 for degradation, is a downstream effector of 
PI3K signalling (Figure 6.1). Because p53 and p27^ ^^  ^ induction is reduced in 
LNCaP-COX-2 cells which have elevated P-Akt, the possibility exists that P-Akt is 
directly responsible for this. We could have confirmed if reduced p53 induction in 
COX-2 expressing cells was due to elevated activity of MDM2 by assessing its 
phosphorylation status.
The partial reversal of resistance of LNCaP-COX-2 to carboplatin with PI3K 
inhibitors could have been confirmed with the use of a dominant negative foixn of Akt 
in LNCaP-COX-2.
Although no difference in sensitivity between LNCaP-Neo and LNCaP-COX-2 to 
TRAIL and Fas was observed, we could have observed if COX-2 was mediating any
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changes in the levels of molecules involved in these signalling pathways. For 
example, death receptors DR4, DR5 and Fas, decoy receptors DRl and DR2, caspase- 
8  or cFLIP. We can suspect not, but it is another area which could be investigated 
further.
It is known that LY294002 treatment of PC-3 and LNCaP cells causes reduction of 
pro-apoptotic P-Bad (Yang et al, 2003). This is one example of other potential effects 
of wortmannin or LY294002 we could have potentially explored, particularly in 
LNCaP-COX-2. We showed PI3K inhibition with both wortmannin and LY294002 
caused reduction in COX-2 and Bcl-2 protein. However we did not assess if PI3K 
inhibition could alter cellular levels of the other elevated anti-apoptotic and pro- 
proliferative maikers such as B c1-Xl , survivin and cyclin Bl. The INK MAPK 
pathway phosphorylates B c1-Xl , Bcl-2, Bad and p53 to promote cell cycle aixest and 
apoptosis (Sah et al. 2003). What else does PI3K inhibition do particulaiiy in LNCaP- 
COX-2 but also in LNCaP-Neo? This question could be addressed in the future.
ILK has been shown to phosphoiylate Akt on the ser473 residue (Chapter 6 ). Does 
COX-2 increase ILK levels or activity? We could have inhibited ILK 
pharmacologically and deteixnine if this has the same effect as PI3K inhibition on 
sensitising LNCaP-COX-2 to carboplatin.
Because COX-2 has been shown to increase EGFR levels and EGFR activity (Chapter 
1.2.5.1) and that the EGFR can activate the PI3K/ Akt pathway, we could have 
assessed if the elevated P-Akt levels detected in LNCaP cells transfected with COX-2 
were associated with elevated EGFR levels also. This could have been confirmed by 
Western blot or immunohistochemistry.
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Celecoxib and PGE2 were shown in Chapter 4 not to be able to modulate the 
sensitivity of LNCaP cells to carboplatin. This was explained in Chapter 6  where it 
was shown that celecoxib could not reduce Bcl-2 or COX-2 levels, whereas PI3K 
could. In follow up experiments we could treat LNCaP-Neo with PGE2 and LNCaP- 
COX-2 with celecoxib and perform gene microaixay experiments to assess which 
genes are modulated by COX-2 enzymatic activity. For example, is the elevated 
survivin and Bcl-2 reported in LNCaP-COX-2 due to COX-2 enzymatic activity or 
not. Whilst Western blotting and RT-PCR allow changes in protein and mRNA levels 
respectively to be deteixnined, gene microaixay analysis would allow many 
differences in gene expression between LNCaP-Neo and LNCaP-COX- 2  to be 
identified and investigated further.
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Appendix
The tables in this appendix provide data from individual experiments which form the 
basis of the results in the Figures and Tables below. Experimental details aie 
described in the main body of the thesis.
Table 4.1 and Figure 5.12
Etoposide IC50 data (jU.M)
Average SD Individual values
PC-3 18.8875 6.743766963 20, 28, 30, 13, 15, 18,14, 13
DU145 1 .8 0 . 2 1 .8 , 1 .6 , 2 . 0
LNCaP-Neo 2.708823 1.390170324 4.8, 3.0, 1.25, 3.8, 2.5, 3.8, 6.5, 2.5, 1.4, 
3.2, 1.6, 1.5, 1.9, 1.8, 2.5, 1.6, 2.4
LNCaP-COX-2 3.23 1.817843655 2.0, 1.5, 3.2, 3.8, 6.5, 2.5, 1.4, 3.2, 2.0
IC50 values (jiiM)
LNCal -^Neo LNCaP-COX-2
carboplatin & 500 iiM wortmannin carboplatin & 500 nM wortmannin
44 46 1 0 0 73
27 34 97 73.
35 2 0 145 72
50 63 150 90
Average 39 40.75 123 77
SD 10,0995049 18.24600413 28.39013913 8.6794777
SEM 5.04975247 9.123002064 14.19506957 4.3397389
p values 0.006916213 LNCaP-Neo vs LNCaP-COX-2
2-tail, paired 0.032276216 LNCaP-COX-2 control vs wortmannin
Table 4.2
Carboplatin IC50 data (/tM)
Average SD Individual IC50 values
PC-3-Neo 85.33333 18.17507 100, 65, 91
PC-3-COX-2 84.0 6 . 0 90, 78, 84
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Figure 4.2
VP-16, 3 day, serum free
Appendix
LNCaP-Neo 0.5 1 2 5 10 20 50 100 Date IC50
84.078 79.913 61.102 53.174 56.231 46.758 40.41 34.296 03/07/2003 16
84.542 66.619 41.598 51.445 34.542 34.358 29.13 23.264 07/07/2003 35
84.656 82.438 72.554 64.313 76.127 63.68 45.44 37.603 12/07/2003 38
88.513 78.426 74.186 54.178 51.296 48.746 42.15 33.837 07/08/2003 15
average
STDEV 2.059063 7.018187 15.01572 5.801205 17.12018 1 2 0 3 )4 2  7 .(^ 4 1 7  6.2211: 
1,029532 3.509093 7.507858 2.900602 8.560088 6.010208 3.541208 3.110567
LNCaP-COX-2 0.5 1 2 5 10 20 50 100 Date IC50
104.33 89.501 68.044 66.839 67.47 56.168 47.59 44.923 03/07/2003 36
92.94 85.432 78.714 72.972 68.151 63.936 50.896 39.094 07/07/2003 52
92.11 83.906 69.176 66.825 67.225 56.821 48.568 40.315 12/07/2003 43
92.245 85.459 71.844 65.618 59.802 59.953 54.158 43 86 07/08/2003
28/06/2003
69
55
3 5 .4 0 K i5 86.0745
5.96027 2.396869 3.551894 2.
1.4601162.980135 2.392954 1.6610021.198434 1.96313 1.775947
2.7 
1.39279
UBI
5.612486
p-value 0.106628 
2 tail, paired
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Figure 4.3
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VP-16, 6 day, serum free 
LNCaP-Neo 0.5 1 2 5 10 20 50 100 Date 1050
73.21 60.85 52.48 41.741 37.018 36.005 34.4 41.04 10/06/2003 2
80.933 72.515 57.671 46.694 39.812 34.551 26.39 20.02 11/09/2003 3.6
86.684 77.522 57.582 41.066 32.779 28.246 20.873 16.049 27/10/2003 2.9
74.093 58.253 52.588 37.54 24.576 24.625 24.174 22.285 1100603 2.4
average
STDEV
SEM
LNCaP-COX-2
' d T g f  56.% Ô2r4f.7a)^-63:W ë26 doleII  . . . . . . . . . . . . . . . . . . . . . .  I m *  H  i n n m  u i i i n  i l
3.163483 4.610995 1.470356 1.884913 3.321229 2.67399 2.879364 5.548887
78.73
8.326966
0.5
102.8
92.984
95.665
1
90.359
80.894
82.803
2
68.522
67.871
72.352
5
55.25
58.164
55.665
10
49.462
56.371
52.537
20
37.907
49.122
42.238
50
33.561
35.287
33.069
100 
23.448 
29.758 
14 449
0.344903
Date 1050
16/10/2003 10
09/09/2003 19
16/10/2003 13
16/10/2003 10
average-fflEHSL—.——-™-
SEM
T a b i e  4 .3
'9 7 im 7 - : # a 5 S 3 -* 6 8 1 6 7  56^167- ^  ' ' 4 M »  % :9 7 ^ -m i^ i6 ^
.3.461441 5.655723 1 164808 >.693759! 
2.929257 2.889864 1.397857 0.910086 1.998464 3.265333 0.672502 4 441994
.4.242641
2.12132
p-value 0.01056746 
2 tail, paired
Celecoxib IC50 data (jtiM)
Average SD Individual values
PC-3 75.1 7.94397 70, 79.4, 67, 84
PC-3-Neo 72.6 9.889388 72, 80, 75, 56, 80, 72.6
PC-3-COX-2 67.2 9.121403 54, 62, 76, 74, 70, 67.2
DU145 74.9 7.6799832 74, 74,58, 80, 72,81,79,81
LNCaP-Neo
LNCaP-COX-2
Sulindac IC50 data (/xM)
PC-3 232.33333 48.003472 250,269,178
DU145 410.0 81.853528 340,500, 390
LNCaP-Neo 235.0 76.019734 158, 237,310
LNCaP-COX-2 233.75 75.649961 290, 150, 190, 305
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C e l e c o x i b  t r y p a n  b l u e  d a t a
L N C a P - N e o L N C a P - C O X - 2
A v e r a g e I n d i v i d u a l
v a l u e s
S E M A v e r a g e I n d i v i d u a l
v a l u e s
S E M p - v a l u e
0
9 9 . 6
100, 98.8, 
1 0 0 0 . 4 9 9 . 7 3 3 3 3
99.8, 100, 
99.4 0 . 1 7 6 3 8 3 0 . 8 2 9 7 4 9
1 0
1 0 0
1 0 0 ,  1 0 0 ,  
1 0 0 0 9 8 . 8 6 6 6 7
9 8 . 5 ,
98.9, 99.2 0 . 2 0 2 7 5 9 0 . 0 3 0 5 4 8
40
86.1
78.7,
93.5, 86.1 4 . 2 7 2 3 9 1 9 9 9 6 . 1
95.5,
96.7, 96.1 0 . 3 4 6 4 1 0 . 1 3 5 4 4 3
60
8 3 . 4 6 6 6 6 6 7
65.2,
99.6, 85.6 9 . 9 8 7 5 4 7 8 9 6 . 3 6 6 6 7
95.0,
98.9, 95.2 1 . 2 6 7 9 8 2 0 . 2 8 6 5 1 6
80
6 5 . 9 3 3 3 3 3 3
57.2,
59.6, 81.0 7 . 5 6 5 1 2 4 6 6 9 2 . 7
85.7,
97.2, 95.2 3 . 5 4 7 2 9 9 0 . 0 5 9 0 6
1 0 0
1 8 . 4 3 3 3 3 3 3
33.0, 6.5, 
15.8 7 . 7 6 2 3 7 3 6 3 3 9 . 2
51.9,
26.5, 39.2 7 . 3 3 2 3 4 8 0 . 0 0 4 2 2 7
Tabie 4.4
Zero ECS control IC50 data (/xM)
Average SD Individual values
Celecoxib 31.825 3.888766 33,31,27, 36.3
Sulindac 128.575 62.60928 112, 126,213, 63
Etoposide 44.975 14.87781 50, 28.8, 63.1,38
100 nM PMA data (/xM)
Celecoxib 34.475 1.284199 35, 33.8, 36, 33.1
Sulindac 128.95 57.71201 112, 105,213, 85
Etoposide 76.775 19.03022 100, 53.7,79.4, 74
Figure 4.5
[ P G E 2 ]  (jtxM)
0.1 0.2 0.5 1.0 2.0 5.0 10.0 20.0
110 108.6 106.7 100.6 114.7 127 110 120
104.4 103.4 114.7 110 103.9 96.6 119.7 103.2
98.7 100.9 100.8 100.7 103.2 87.9 93.0 92.4
A v e r a g e 104.367 104.30 107.4 103.767 107.27 103.83 107.57 105.20
S D 5.65007 3.9281 6.9764 5.39846 6.4469 20.529 13.5153 13.908
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Figure 4.6
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[Celecoxib] ijxM)
1 2 5 10 20
88.1 97.7 96.5 100.4 90.8
106.4 102.9 91.7 90.4 70.1
95.1 99.8 94.9 95.0 99.8
Average 96.5333 100.1333 94.36667 95.26667 87.3
SD 9.23381 2.615997 2.44404 5.00533 15.4496
Figure 5.3
% of cells (± SD)
Gi S G2M
LNCaP-Neo Control
Carboplatin
51.8 (3.3)
36.9 (6.5)
26.6 (2.4) 
53.9 (5.5)
21.6 (3.9) 
9.2 (4.4)
LNCaP-COX-2 Control
Carboplatin
61.5(7.7) 
45.6 (10.2)
23.4 (3.9) 
39.0 (8.8)
14.1 (3.0) 
14.8 (2.9)
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